
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Metal-organic frameworks activate the cGAS-STING pathway for cancer immunotherapy - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="15253D7C8AF26B13053D7C0019A3D0FE.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="nanobio">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12369232/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Journal of Nanobiotechnology">
<meta name="citation_title" content="Metal-organic frameworks activate the cGAS-STING pathway for cancer immunotherapy">
<meta name="citation_author" content="Shuxuan Zhu">
<meta name="citation_author_institution" content="Translational Medicine Center, Beijing Chest Hospital, Beijing Tuberculosis and Thoracic Tumor Research Institute, Capital Medical University, Beijing, 101149 China">
<meta name="citation_author" content="Wenfei Xu">
<meta name="citation_author_institution" content="Translational Medicine Center, Beijing Chest Hospital, Beijing Tuberculosis and Thoracic Tumor Research Institute, Capital Medical University, Beijing, 101149 China">
<meta name="citation_author" content="Hongxia Li">
<meta name="citation_author_institution" content="Department of Medical Oncology, Beijing Chest Hospital, Beijing Tuberculosis and Thoracic Tumor Research Institute, Capital Medical University, Beijing, 101149 China">
<meta name="citation_author" content="Zhaogang Sun">
<meta name="citation_author_institution" content="Translational Medicine Center, Beijing Chest Hospital, Beijing Tuberculosis and Thoracic Tumor Research Institute, Capital Medical University, Beijing, 101149 China">
<meta name="citation_author" content="Ying Zhu">
<meta name="citation_author_institution" content="The Fourteenth Retired Veteran Cadre’s Sanatorium of Fengtai District, Beijing, 100076 China">
<meta name="citation_author" content="Wenjing Liu">
<meta name="citation_author_institution" content="Translational Medicine Center, Beijing Chest Hospital, Beijing Tuberculosis and Thoracic Tumor Research Institute, Capital Medical University, Beijing, 101149 China">
<meta name="citation_author" content="Hongqian Chu">
<meta name="citation_author_institution" content="Translational Medicine Center, Beijing Chest Hospital, Beijing Tuberculosis and Thoracic Tumor Research Institute, Capital Medical University, Beijing, 101149 China">
<meta name="citation_publication_date" content="2025 Aug 21">
<meta name="citation_volume" content="23">
<meta name="citation_firstpage" content="578">
<meta name="citation_doi" content="10.1186/s12951-025-03669-4">
<meta name="citation_pmid" content="40841898">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12369232/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12369232/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12369232/pdf/12951_2025_Article_3669.pdf">
<meta name="description" content="Despite the major breakthroughs in immunotherapy, a substantial number of cancer patients continue to confront problems such as low response rates, which restrict the overall effectiveness of existing treatments. There is an urgent necessity to ...">
<meta name="og:title" content="Metal-organic frameworks activate the cGAS-STING pathway for cancer immunotherapy">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Despite the major breakthroughs in immunotherapy, a substantial number of cancer patients continue to confront problems such as low response rates, which restrict the overall effectiveness of existing treatments. There is an urgent necessity to ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12369232/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12369232">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1186/s12951-025-03669-4"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/12951_2025_Article_3669.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12369232%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12369232/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12369232/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12369232/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-nanobio.png" alt="Journal of Nanobiotechnology logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Journal of Nanobiotechnology" title="Link to Journal of Nanobiotechnology" shape="default" href="https://jnanobiotechnology.biomedcentral.com/" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">J Nanobiotechnology</button></div>. 2025 Aug 21;23:578. doi: <a href="https://doi.org/10.1186/s12951-025-03669-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1186/s12951-025-03669-4</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22J%20Nanobiotechnology%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22J%20Nanobiotechnology%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22J%20Nanobiotechnology%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22J%20Nanobiotechnology%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Metal-organic frameworks activate the cGAS-STING pathway for cancer immunotherapy</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhu%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Shuxuan Zhu</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Shuxuan Zhu</span></h3>
<div class="p">
<sup>1</sup>Translational Medicine Center, Beijing Chest Hospital, Beijing Tuberculosis and Thoracic Tumor Research Institute, Capital Medical University, Beijing, 101149 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhu%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Shuxuan Zhu</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Xu%20W%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Wenfei Xu</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Wenfei Xu</span></h3>
<div class="p">
<sup>1</sup>Translational Medicine Center, Beijing Chest Hospital, Beijing Tuberculosis and Thoracic Tumor Research Institute, Capital Medical University, Beijing, 101149 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Xu%20W%22%5BAuthor%5D" class="usa-link"><span class="name western">Wenfei Xu</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Li%20H%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Hongxia Li</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Hongxia Li</span></h3>
<div class="p">
<sup>2</sup>Department of Medical Oncology, Beijing Chest Hospital, Beijing Tuberculosis and Thoracic Tumor Research Institute, Capital Medical University, Beijing, 101149 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Li%20H%22%5BAuthor%5D" class="usa-link"><span class="name western">Hongxia Li</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sun%20Z%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Zhaogang Sun</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Zhaogang Sun</span></h3>
<div class="p">
<sup>1</sup>Translational Medicine Center, Beijing Chest Hospital, Beijing Tuberculosis and Thoracic Tumor Research Institute, Capital Medical University, Beijing, 101149 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sun%20Z%22%5BAuthor%5D" class="usa-link"><span class="name western">Zhaogang Sun</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhu%20Y%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Ying Zhu</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Ying Zhu</span></h3>
<div class="p">
<sup>3</sup>The Fourteenth Retired Veteran Cadre’s Sanatorium of Fengtai District, Beijing, 100076 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhu%20Y%22%5BAuthor%5D" class="usa-link"><span class="name western">Ying Zhu</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Liu%20W%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Wenjing Liu</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Wenjing Liu</span></h3>
<div class="p">
<sup>1</sup>Translational Medicine Center, Beijing Chest Hospital, Beijing Tuberculosis and Thoracic Tumor Research Institute, Capital Medical University, Beijing, 101149 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Liu%20W%22%5BAuthor%5D" class="usa-link"><span class="name western">Wenjing Liu</span></a>
</div>
</div>
<sup>1,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chu%20H%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Hongqian Chu</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Hongqian Chu</span></h3>
<div class="p">
<sup>1</sup>Translational Medicine Center, Beijing Chest Hospital, Beijing Tuberculosis and Thoracic Tumor Research Institute, Capital Medical University, Beijing, 101149 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chu%20H%22%5BAuthor%5D" class="usa-link"><span class="name western">Hongqian Chu</span></a>
</div>
</div>
<sup>1,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="Aff1">
<sup>1</sup>Translational Medicine Center, Beijing Chest Hospital, Beijing Tuberculosis and Thoracic Tumor Research Institute, Capital Medical University, Beijing, 101149 China </div>
<div id="Aff2">
<sup>2</sup>Department of Medical Oncology, Beijing Chest Hospital, Beijing Tuberculosis and Thoracic Tumor Research Institute, Capital Medical University, Beijing, 101149 China </div>
<div id="Aff3">
<sup>3</sup>The Fourteenth Retired Veteran Cadre’s Sanatorium of Fengtai District, Beijing, 100076 China </div>
<div class="author-notes p"><div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div></div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2025 Apr 29; Accepted 2025 Aug 11; Collection date 2025.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© The Author(s) 2025</div>
<p><strong>Open Access</strong> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <a href="https://creativecommons.org/licenses/by-nc-nd/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by-nc-nd/4.0/</a>.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12369232  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40841898/" class="usa-link">40841898</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="Abs1"><h2>Abstract</h2>
<p id="Par1">Despite the major breakthroughs in immunotherapy, a substantial number of cancer patients continue to confront problems such as low response rates, which restrict the overall effectiveness of existing treatments. There is an urgent necessity to combine advanced biomedical advancements with conventional therapies to improve treatment results. The activation of the cyclic GMP-AMP synthase (cGAS) and stimulator of interferon genes (STING) pathway has become a viable technique to elicit innate immune responses against tumors, attracting significant interest as a novel target in cancer therapy. However, STING agonists face significant challenges in clinical application due to complications related to transport efficiency, degradation, and bioavailability. Recent breakthroughs in nanotechnology have facilitated the invention of metal-organic frameworks (MOFs) as adaptable platforms for cancer immunotherapy, utilizing their distinctive characteristics, including large surface area, adjustable porosity, and improved permeability. This review systematically investigates current advancements in the usage of MOFs for altering the cGAS-STING pathway, highlighting their promise as adaptable platforms for agonist administration or direct activation in tumor immunotherapy. Additionally, this review focuses on the use of MOFs as carriers or agonists, integrated with multimodal strategies to potentiate anticancer immune responses via the cGAS-STING pathway. The discussion concludes with an examination of the challenges and future directions for MOFs in boosting immunotherapy through the stimulation of the cGAS-STING pathway.</p>
<section id="sec1"><h3 class="pmc_sec_title">Graphical abstract</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12369232_12951_2025_3669_Figa_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6765/12369232/ab34da777f9b/12951_2025_3669_Figa_HTML.jpg" loading="lazy" id="MO10" height="670" width="669" alt="graphic file with name 12951_2025_3669_Figa_HTML.jpg"></a></p></section><section id="kwd-group1" lang="en" class="kwd-group"><p><strong>Keywords:</strong> Metal-organic frameworks, CGAS-STING, Cancer immunotherapy</p></section></section><section id="Sec1"><h2 class="pmc_sec_title">Introduction</h2>
<p id="Par88">Cancer immunotherapy is currently regarded as a groundbreaking advancement in cancer treatment by awakening and strengthening the immune system to sustainably control previously incurable and extremely aggressive malignancies [<a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>–<a href="#CR3" class="usa-link" aria-describedby="CR3">3</a>]. To date, various cancer immunotherapy approaches have been investigated [<a href="#CR4" class="usa-link" aria-describedby="CR4">4</a>], primarily including immune checkpoint blockade therapy (ICB) and the adoptive transfer of engineered immune cells (ACT) [<a href="#CR5" class="usa-link" aria-describedby="CR5">5</a>]. Moreover, other strategies, such as monoclonal antibodies (mAbs) [<a href="#CR6" class="usa-link" aria-describedby="CR6">6</a>, <a href="#CR7" class="usa-link" aria-describedby="CR7">7</a>], small molecule drugs [<a href="#CR8" class="usa-link" aria-describedby="CR8">8</a>, <a href="#CR9" class="usa-link" aria-describedby="CR9">9</a>], cytokine therapy [<a href="#CR10" class="usa-link" aria-describedby="CR10">10</a>–<a href="#CR14" class="usa-link" aria-describedby="CR14">14</a>], oncolytic viruses [<a href="#CR15" class="usa-link" aria-describedby="CR15">15</a>–<a href="#CR17" class="usa-link" aria-describedby="CR17">17</a>], and cancer vaccines [<a href="#CR18" class="usa-link" aria-describedby="CR18">18</a>–<a href="#CR21" class="usa-link" aria-describedby="CR21">21</a>], have also shown promise. Currently, cancer immunotherapy, especially FDA-approved immune checkpoint inhibitors (ICIs) that strengthen adaptive antitumor immunity, has provided substantial advantages for numerous clinical patients [<a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>]. However, the treatment is still limited by the risk of autoimmune side effects [<a href="#CR23" class="usa-link" aria-describedby="CR23">23</a>–<a href="#CR25" class="usa-link" aria-describedby="CR25">25</a>] and the prevalence of resistance in a considerable number of cancers [<a href="#CR26" class="usa-link" aria-describedby="CR26">26</a>–<a href="#CR28" class="usa-link" aria-describedby="CR28">28</a>]. These limitations are mainly attributed to tumor heterogeneity [<a href="#CR29" class="usa-link" aria-describedby="CR29">29</a>], immunosuppressive tumor microenvironment (TIME) [<a href="#CR30" class="usa-link" aria-describedby="CR30">30</a>, <a href="#CR31" class="usa-link" aria-describedby="CR31">31</a>], insufficient production and performance of tumor-specific CD8 + T lymphocytes, limited availability of appropriate neoantigens, compromised processing and presentation of neoantigens, and epigenetic alterations. Collectively, these considerations have led to many obstacles in the clinical translation of immunotherapy. Notably, the efficacy of adaptive antitumor immunity relies heavily on a robust innate immune response [<a href="#CR32" class="usa-link" aria-describedby="CR32">32</a>]. Recent advancements in biomedical research and technological innovation, which have demonstrated significant therapeutic potential, are providing novel avenues for the development of effective cancer therapies. Among these, mounting evidence indicates that targeting the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) signaling pathway has broad prospects in antitumor immunity [<a href="#CR33" class="usa-link" aria-describedby="CR33">33</a>–<a href="#CR37" class="usa-link" aria-describedby="CR37">37</a>].</p>
<p id="Par89">As an innate immune sensor of cytoplasmic DNA [<a href="#CR38" class="usa-link" aria-describedby="CR38">38</a>–<a href="#CR41" class="usa-link" aria-describedby="CR41">41</a>], cGAS can sense the leakage of DNA from cancer cells [<a href="#CR42" class="usa-link" aria-describedby="CR42">42</a>, <a href="#CR43" class="usa-link" aria-describedby="CR43">43</a>], activate the STING pathway via a cascade reaction, promote the expression of type I interferons (IFN-I) [<a href="#CR44" class="usa-link" aria-describedby="CR44">44</a>, <a href="#CR45" class="usa-link" aria-describedby="CR45">45</a>], and initiate innate anticancer immunity [<a href="#CR46" class="usa-link" aria-describedby="CR46">46</a>]. IFN-I notably functions as a conduit between innate and adaptive immunity [<a href="#CR47" class="usa-link" aria-describedby="CR47">47</a>]. Their activities include facilitating dendritic cell maturation and migration, as well as augmenting cytotoxicity delivered by cytotoxic T lymphocytes or natural killer cells, protecting effector cells from apoptosis, and inhibiting the expression of vascular endothelial growth factor (VEGF) and thereby imposing a suppressive influence on tumor angiogenesis [<a href="#CR48" class="usa-link" aria-describedby="CR48">48</a>]. Consequently, activation of the cGAS-STING pathway can transform immunologically inert “cold” tumors into active “hot” tumors through IFN-I secretion and lymphocyte infiltration [<a href="#CR49" class="usa-link" aria-describedby="CR49">49</a>–<a href="#CR52" class="usa-link" aria-describedby="CR52">52</a>]. This change boosts the antitumor immune response within the TME and improves the effectiveness of existing immunotherapy. Given these processes, targeting the cGAS-STING pathway is a viable route for cancer immunotherapy [<a href="#CR53" class="usa-link" aria-describedby="CR53">53</a>]. Specifically, due to the potent immunostimulatory capacity of the STING signaling pathway, agonists targeting this pathway are identified as promising therapeutic agents, either as standalone treatments or in combination with other therapeutic strategies.</p>
<p id="Par90">Numerous STING agonists, encompassing cyclic dinucleotides (CDNs) and non-CDNs, have been created and extensively assessed in preclinical and clinical investigations [<a href="#CR54" class="usa-link" aria-describedby="CR54">54</a>, <a href="#CR55" class="usa-link" aria-describedby="CR55">55</a>]. Despite their promising therapeutic potential, these agonists are confronted with significant challenges, including instability and low internalization efficiency [<a href="#CR56" class="usa-link" aria-describedby="CR56">56</a>, <a href="#CR57" class="usa-link" aria-describedby="CR57">57</a>]. To address these constraints, considerable efforts have been dedicated to the advancement of nanotherapeutic techniques aimed at activating the cGAS-STING signaling pathway [<a href="#CR52" class="usa-link" aria-describedby="CR52">52</a>, <a href="#CR58" class="usa-link" aria-describedby="CR58">58</a>]. Notably, nanomaterial-mediated activation of this pathway has been demonstrated to robustly enhance tumor-specific immune responses and elicit potent antitumor activity [<a href="#CR59" class="usa-link" aria-describedby="CR59">59</a>, <a href="#CR60" class="usa-link" aria-describedby="CR60">60</a>]. Among these nanomaterials, metal-organic frameworks (MOFs) have attracted significant attention due to their distinctive structural features, including high surface areas, customizable pores, and efficient drug-loading capacity, in addition to their excellent biocompatibility [<a href="#CR61" class="usa-link" aria-describedby="CR61">61</a>–<a href="#CR63" class="usa-link" aria-describedby="CR63">63</a>]. However, the potential of MOFs in cGAS-STING pathway modulation remains underexplored, particularly concerning their dual role as agonist carriers or direct agonists [<a href="#CR64" class="usa-link" aria-describedby="CR64">64</a>, <a href="#CR65" class="usa-link" aria-describedby="CR65">65</a>]. To address this gap, this review comprehensively summarizes recent advances in MOFs-based strategies for enhancing immune stimulation and improving cancer immunotherapy outcomes. Specifically, we highlight the application of MOFs as either delivery vehicles or direct agonists, synergistically integrated with multimodal therapies (e.g., radiotherapy (RT), photodynamic therapy (PDT), photothermal therapy (PTT), and sonodynamic therapy (SDT)), to amplify antitumor immune responses via modulation of the cGAS-STING pathway (Fig. <a href="#Fig1" class="usa-link">1</a>). Finally, the challenges and prospects of MOFs-based approaches in tumor immunotherapy are discussed.</p>
<figure class="fig xbox font-sm" id="Fig1"><h3 class="obj_head">Fig. 1.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12369232_12951_2025_3669_Fig1_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6765/12369232/c16b5b386f07/12951_2025_3669_Fig1_HTML.jpg" loading="lazy" id="d33e822" height="799" width="797" alt="Fig. 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Schematic illustration of metal-organic frameworks (MOFs) as delivery vehicles or agonists to enhance cancer immunotherapy by augmenting the cGAS-STING pathway and integrating multiple therapeutic approaches. (Created with BioRender.com)</p></figcaption></figure></section><section id="Sec2"><h2 class="pmc_sec_title">Mechanism of cGAS-STING and IFN-I in antitumor immunity</h2>
<p id="Par92">In cancer immunotherapy, increasing data suggest that IFN-I secreted after stimulation of the cGAS-STING signaling pathway significantly inhibits tumor development [<a href="#CR66" class="usa-link" aria-describedby="CR66">66</a>–<a href="#CR69" class="usa-link" aria-describedby="CR69">69</a>]. To understand the underlying mechanisms, this section offers an overview of the structural and functional features of cGAS and STING proteins. It delineates the activation of this important signaling pathway, which leads in the generation of IFN-I and the beginning of antitumor immune responses (Fig. <a href="#Fig2" class="usa-link">2</a>).</p>
<figure class="fig xbox font-sm" id="Fig2"><h3 class="obj_head">Fig. 2.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12369232_12951_2025_3669_Fig2_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6765/12369232/21c86a0496f6/12951_2025_3669_Fig2_HTML.jpg" loading="lazy" id="d33e961" height="469" width="669" alt="Fig. 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Overview of cGAS and STING protein architecture and functionality, and the cGAS-STING signalling cascade. (Created with BioRender.com)</p></figcaption></figure><section id="Sec3"><h3 class="pmc_sec_title">Structure and function of cGAS</h3>
<p id="Par93">cGAS, the principal cytosolic DNA sensor, identifies cytoplasmic DNA in a sequence-independent yet length-dependent fashion (&gt; 40 base pairs) across various cell types [<a href="#CR70" class="usa-link" aria-describedby="CR70">70</a>–<a href="#CR72" class="usa-link" aria-describedby="CR72">72</a>]. Structurally, human cGAS (hcGAS) comprises 522 amino acids, with a non-conserved N-terminal domain and a conserved C-terminal nucleotidyltransferase (NTase) domain named Mab21 [<a href="#CR73" class="usa-link" aria-describedby="CR73">73</a>]. The N-terminal domain is crucial for sustaining high enzymatic activity and essential for DNA binding, as it contains specific conserved polar amino acid residues, such as serine (Ser) and threonine (Thr). In contrast, the Mab21 domain exhibits a bilobed architecture with two positively charged surfaces that engage with the sugar-phosphate backbone of DNA [<a href="#CR46" class="usa-link" aria-describedby="CR46">46</a>, <a href="#CR74" class="usa-link" aria-describedby="CR74">74</a>]. Upon dsDNA binding, cGAS forms a 2:2 DNA/cGAS complex, wherein dimerization induces catalytic pocket rearrangement and allosteric activation [<a href="#CR70" class="usa-link" aria-describedby="CR70">70</a>, <a href="#CR75" class="usa-link" aria-describedby="CR75">75</a>]. This structural transformation enables cGAS to catalyze the substrates guanosine triphosphate (GTP) and adenosine triphosphate (ATP) into 2’,3’-cyclic-GMP-AMP (cGAMP), which was a natural ligand of STING protein [<a href="#CR76" class="usa-link" aria-describedby="CR76">76</a>]. Key catalytic residues (E225, D227, D319) coordinate Mg<sup>2+</sup> ions to facilitate cGAMP synthesis, while a zinc finger motif (H390, C396, C397, C404) stabilizes B-type dsDNA recognition [<a href="#CR77" class="usa-link" aria-describedby="CR77">77</a>]. Notably, hcGAS exhibits heightened DNA length sensitivity compared to murine homologs, primarily mediated by Lys187 and Leu195 in the protein spine [<a href="#CR78" class="usa-link" aria-describedby="CR78">78</a>, <a href="#CR79" class="usa-link" aria-describedby="CR79">79</a>].</p></section></section><section id="Sec4"><h2 class="pmc_sec_title">Structure and function of STING</h2>
<p id="Par94">STING, a pattern recognition receptor (PRR), is a transmembrane protein localized to the endoplasmic reticulum (ER) and functions as a sensor for cyclic dinucleotides [<a href="#CR80" class="usa-link" aria-describedby="CR80">80</a>]. Structurally, human STING (hSTING) comprises 379 amino acids, with an N-terminal transmembrane domain and a globular C-terminal domain (CTD) [<a href="#CR81" class="usa-link" aria-describedby="CR81">81</a>]. The N-terminal domain contains four transmembrane regions (TM1-4) that anchor STING to the ER membrane. Notably, STING exists as a constitutive dimer, adopting a domain-swapped architecture where TM1 from one subunit pairs with TM2-4 from the other, forming two layers: a central layer (TM2 and TM4) surrounded by peripheral helices (TM1 and TM3) [<a href="#CR82" class="usa-link" aria-describedby="CR82">82</a>]. Among these helices, TM2, the longest and most tilted relative to the membrane plane, plays a critical role in stabilizing the dimeric structure [<a href="#CR81" class="usa-link" aria-describedby="CR81">81</a>]. CTD is exposed in the cytoplasm and contains the ligand-binding domain (LBD) and the C-terminal tail (CTT). LBD includes four α helices (LBDα1 ~ α4) and 5 β pleated sheets (LBDβ1 ~ β5), while the linker between TM4 and LBDα1 forms a right-handed crossover, positioning the TM and LBD of each subunit on opposite sides of the dimer [<a href="#CR83" class="usa-link" aria-describedby="CR83">83</a>]. This inter-domain interaction, mediated by a surface groove formed by TM2-TM3, the connecting helix, and LBD, is a conserved structural feature essential for protein stability and function [<a href="#CR81" class="usa-link" aria-describedby="CR81">81</a>]. Finally, the CTT contains a TANK-binding kinase 1 (TBK1)-binding motif (TBM) and an interferon regulatory factor 3 (IRF3)-binding motif, which are critical for downstream signaling [<a href="#CR46" class="usa-link" aria-describedby="CR46">46</a>].</p></section><section id="Sec5"><h2 class="pmc_sec_title">Activation of cGAS-STING produces IFN-I</h2>
<p id="Par95">The interaction of cGAMP with STING triggers a conformational change that activates downstream signaling cascades involving TBK1 and IRF3, ultimately leading to IFN-I production [<a href="#CR84" class="usa-link" aria-describedby="CR84">84</a>]. The precise procedure is outlined as follows: Initially, the binding of cGAMP to LBD induces the cytoplasmic part of STING, including the linker, LBD and CTT, to rotate 180° relative to the TM so that the right-handed cross of the linker is untied, and the LBD of the same STING subunit returns to the same side of the TM to form a shoulder-to-shoulder STING dimer [<a href="#CR82" class="usa-link" aria-describedby="CR82">82</a>]. Secondly, cGAMP binding causes LBDα2 and LBDα3 to tilt downward, separating the LBDα2-α3 loops between dimers and eliminating steric clashes [<a href="#CR81" class="usa-link" aria-describedby="CR81">81</a>]. In addition, these conformational changes also trigger CTT release, exposing the STING polymerization interface and enabling parallel dimer assembly into polymers stabilized by disulfide bonds (e.g., Cys148) [<a href="#CR82" class="usa-link" aria-describedby="CR82">82</a>]. Within these polymers, STING dimers recruit TBK1 through high-affinity interactions at the dimer interface, promoting TBK1 trans-autophosphorylation. Notably, only a subset of CTTs within the STING polymer recruit TBK1, while Ser366 on adjacent CTTs is phosphorylated by TBK1, forming the 363LXIS366 motif essential for IRF3 binding [<a href="#CR74" class="usa-link" aria-describedby="CR74">74</a>]. Subsequent IRF3 phosphorylation by TBK1 facilitates its dimerization, nuclear translocation, and transcriptional activation of IFN-I genes, particularly IFN-β [<a href="#CR85" class="usa-link" aria-describedby="CR85">85</a>]. In parallel to the IRF3 pathway, STING activates NF-κB signaling through IκB kinase interaction, leading to pro-inflammatory cytokine expression, particularly IFN-α and IFN-β [<a href="#CR86" class="usa-link" aria-describedby="CR86">86</a>].</p></section><section id="Sec6"><h2 class="pmc_sec_title">The role of IFN-I in cancer immunotherapy</h2>
<p id="Par96">IFN-I is crucial for innate immunity and tumor immunosurveillance [<a href="#CR87" class="usa-link" aria-describedby="CR87">87</a>]. Mechanistically, IFN-I enhances tumor-associated antigen presentation by DCs, facilitating the stimulation and proliferation of tumor-specific T cells and bridging innate and adaptive immunity against malignancies [<a href="#CR88" class="usa-link" aria-describedby="CR88">88</a>]. The antitumor effects of IFN-I are mediated through multiple pathways. First, IFN-I directly inhibits tumor cell proliferation and metastasis by activating intracellular signaling cascades. For example, FAM210B suppresses lung adenocarcinoma (LUAD) cell proliferation and migration by upregulating IFN-α/β expression and activating the STAT1/IRF9/IFIT3 pathway [<a href="#CR89" class="usa-link" aria-describedby="CR89">89</a>]. Second, IFN-I play a pivotal role in ICI therapy. As demonstrated by Zhu et al., endogenous IFN-I signaling in tumor cells is crucial for inhibiting CD47-SIRPα, as it reprograms tumor metabolism and enhances immune cell infiltration and activity [<a href="#CR90" class="usa-link" aria-describedby="CR90">90</a>]. Third, IFN-I modulate tumor cell behaviour by promoting ATP release, which enhances immune cell activation and antitumor responses [<a href="#CR90" class="usa-link" aria-describedby="CR90">90</a>]. Additionally, IFN-γ amplifies the IFN-I response network by upregulating IRF7, promoting Th17-to-Th1 cell conversion and improving antitumor function [<a href="#CR91" class="usa-link" aria-describedby="CR91">91</a>]. In summary, IFN-I exerts potent antitumor effects through diverse mechanisms, and harnessing IFN-I production via the cGAS-STING pathway constitutes a viable approach to augment the efficacy of immunotherapy.</p></section><section id="Sec7"><h2 class="pmc_sec_title">Agonists of the cGAS-STING pathway in cancer immunotherapy</h2>
<p id="Par98">With the deepening understanding of STING and its signaling mechanisms, the cGAS-STING pathway has become a crucial target in cancer immunotherapy, driving extensive studies to discover and develop STING agonists. Based on their chemical structures and mechanisms of action, STING agonists can be categorized into five classes: CDNs and their derivatives, small molecule agonists, metal ion agonists, endogenous DNA agonists, and MOFs-based agonists. In this section, we systematically summarize and discuss these five categories of agonists, as shown in Fig. <a href="#Fig3" class="usa-link">3</a>.</p>
<figure class="fig xbox font-sm" id="Fig3"><h3 class="obj_head">Fig. 3.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12369232_12951_2025_3669_Fig3_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6765/12369232/08c911c9c8d1/12951_2025_3669_Fig3_HTML.jpg" loading="lazy" id="d33e1098" height="473" width="669" alt="Fig. 3"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Classification and mechanisms of agonists that activate the cGAS-STING pathway. (Created with BioRender.com)</p></figcaption></figure><section id="Sec8"><h3 class="pmc_sec_title">CDNs and its derivatives</h3>
<p id="Par99">CDNs, recognized as the most extensively researched STING agonists, are natural ligands synthesized by cGAS in reaction to cytosolic DNA [<a href="#CR92" class="usa-link" aria-describedby="CR92">92</a>]. These molecules, defined by a cyclic structure of two nucleotide units, are essential in the initiation of innate immune responses [<a href="#CR93" class="usa-link" aria-describedby="CR93">93</a>]. The primary endogenous CDN, 2’3’-cGAMP, is synthesized by cGAS in reaction to the presence of double-stranded DNA from damaged or infected cells [<a href="#CR94" class="usa-link" aria-describedby="CR94">94</a>]. CDNs contain cyclic diguanosine monophosphate (c-di-GMP), cyclic diadenosine monophosphate (c-di-AMP), bacterial 3′,3′-cGAMP, and mammalian 2′,3′-cGAMP [<a href="#CR95" class="usa-link" aria-describedby="CR95">95</a>]. Endogenous CDNs encounter notable limitations stemming from their hydrophilic and negatively charged characteristics, which impede cellular internalization [<a href="#CR96" class="usa-link" aria-describedby="CR96">96</a>, <a href="#CR97" class="usa-link" aria-describedby="CR97">97</a>]. Additionally, their vulnerability to degradation by exonucleotide pyrophosphatase/phosphodiesterase (ENPP1) leads to a diminished serum half-life and decreased efficacy [<a href="#CR98" class="usa-link" aria-describedby="CR98">98</a>]. Chemical modifications have been employed on CDNs to address these challenges, focusing on the phosphodiester linkage, 2′/3′-OH groups, ribose, and nucleotides [<a href="#CR99" class="usa-link" aria-describedby="CR99">99</a>]. The modifications have enhanced pharmacokinetic profiles, leading to the advancement of several analogs into clinical trials. ADU-S100, a synthetic phosphorothioate CDN, shows markedly greater activity compared to 2′,3′-cGAMP and exhibits strong antitumor and antimetastatic properties [<a href="#CR98" class="usa-link" aria-describedby="CR98">98</a>]. Furthermore, SB11285 has demonstrated efficacy through intravenous, intraperitoneal, and intratumoral administration. Cyclic adenosine-inosine monophosphate (cAIMP) represents an innovation that includes ribose substitution, internucleotide modification, and phosphate alteration [<a href="#CR100" class="usa-link" aria-describedby="CR100">100</a>]. Fluorine-substituted analogs exhibit enhanced stability and activity [<a href="#CR101" class="usa-link" aria-describedby="CR101">101</a>]. Despite these advancements, CDN-based agonists are predominantly delivered through intratumoral injection in clinical trials, which restricts their applicability to a wider variety of tumors.</p></section><section id="Sec9"><h3 class="pmc_sec_title">Small molecule agonists</h3>
<p id="Par100">Small molecule STING agonists represent a promising class of synthetic compounds designed to activate the STING pathway with superior pharmacological properties compared to natural CDNs. These low molecular weight compounds directly bind to STING, inducing conformational changes that trigger downstream signaling cascades. Early examples, such as flavone acetic acid (FAA) [<a href="#CR102" class="usa-link" aria-describedby="CR102">102</a>], 5,6-dimethylxanthenone-4-acetic acid (DMXAA) [<a href="#CR103" class="usa-link" aria-describedby="CR103">103</a>], and 10-carboxymethyl-9-acridanone (CMA) [<a href="#CR104" class="usa-link" aria-describedby="CR104">104</a>], demonstrated antitumor activity by activating the NF-κB pathway and inducing IFN-I production. However, these agonists selectively bound murine STING (mSTING) but not hSTING, leading to clinical trial failures. A significant breakthrough came with the discovery of ABZI analogs, the first non-nucleotide STING agonists capable of activating both mSTING and hSTING [<a href="#CR105" class="usa-link" aria-describedby="CR105">105</a>]. Among these, dimeric aminobenzimidazole (diABZI) exhibited 18-fold greater potency than cGAMP, robust antitumor activity, and complete tumor regression in murine colon cancer models [<a href="#CR106" class="usa-link" aria-describedby="CR106">106</a>]. Further advancements include orally available MSA-2 [<a href="#CR55" class="usa-link" aria-describedby="CR55">55</a>, <a href="#CR107" class="usa-link" aria-describedby="CR107">107</a>], which selectively targets tumor tissues and enhances anti-PD-1 efficacy, and SR-717 [<a href="#CR108" class="usa-link" aria-describedby="CR108">108</a>], an intraperitoneal agonist with broad species and allele specificity that activates CD8<sup>+</sup> T cells, NK cells, and DCs while upregulating PD-L1 expression. Additionally, novel agonists such as DSDP, BNBC, G10, and the photoactivatable caged-diBSP01 have shown potential in preclinical studies [<a href="#CR109" class="usa-link" aria-describedby="CR109">109</a>, <a href="#CR110" class="usa-link" aria-describedby="CR110">110</a>]. Despite these advances, the therapeutic efficacy of small molecule STING agonists remains limited by insufficient targeting and intracellular stability, resulting in suboptimal pharmacokinetic profiles.</p></section><section id="Sec10"><h3 class="pmc_sec_title">Metal ion agonists</h3>
<p id="Par101">Transition metal ions, particularly manganese (Mn<sup>2+</sup>), have emerged as a novel class of STING agonists with significant immunomodulatory potential [<a href="#CR111" class="usa-link" aria-describedby="CR111">111</a>]. These ions enhance antigen presentation by antigen-presenting cells (APCs), promote the maturation of CD4<sup>+</sup> and CD8<sup>+</sup> T cells, and amplify adaptive immune responses. Mechanistically, Mn<sup>2+</sup> directly activates cGAS even without exogenous double-stranded DNA, resulting in the synthesis of 2′,3′-cGAMP and subsequent generation of IFN-I. Additionally, Mn<sup>2+</sup> catalyzes the conversion of hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) to hydroxyl radicals (•OH), a highly reactive oxygen species (ROS) that further potentiates cGAS-STING signaling [<a href="#CR112" class="usa-link" aria-describedby="CR112">112</a>]. These dual mechanisms enable Mn<sup>2+</sup> to induce innate immune responses independently of infection. Furthermore, Mn<sup>2+</sup> facilitates the development of APCs, such as DCs, bridging innate and adaptive immunity. This immunostimulatory capability positions Mn<sup>2+</sup> as a promising therapeutic agent for infections and tumors.</p></section><section id="Sec11"><h3 class="pmc_sec_title">Endogenous DNA agonists</h3>
<p id="Par102">Endogenous DNA agonists are natural activators of the cGAS-STING pathway, relying on intracellular DNA to initiate immune responses [<a href="#CR113" class="usa-link" aria-describedby="CR113">113</a>]. These agonists include DNA fragments from apoptotic or necrotic tumor cells and mitochondrial DNA (mtDNA) that leak into the cytosol during cellular stress. In cancer therapy, interventions like radiation and chemotherapy induce DNA damage and cell death [<a href="#CR114" class="usa-link" aria-describedby="CR114">114</a>], releasing tumor-derived DNA that potently stimulates the cGAS-STING pathway, triggering IFN-I and pro-inflammatory cytokine secretion. Similarly, mtDNA, structurally akin to bacterial DNA, activates cGAS upon cytosolic release [<a href="#CR115" class="usa-link" aria-describedby="CR115">115</a>]. These mechanisms link tumor cell death to antitumor immunity, highlighting their critical role in cancer immunotherapy. Despite their potential, endogenous DNA agonists face challenges. Their advantages include natural pathway activation without exogenous agents and tumor-specificity when generated during tumor cell death, minimizing off-target effects. However, their reliance on therapeutic interventions limits standalone utility, and excessive cGAS-STING activation can lead to chronic inflammation or autoimmune disorders. To optimize their therapeutic application, strategies like combining radiation therapy with STING agonists or immune checkpoint inhibitors are being explored to enhance antitumor immunity while mitigating adverse effects. Overall, endogenous DNA agonists represent a potent and natural means of activating the cGAS-STING pathway, with ongoing research focused on refining their use in cancer immunotherapy.</p></section></section><section id="Sec12"><h2 class="pmc_sec_title">MOFs activate cGAS-STING pathway for enhanced cancer immunotherapy</h2>
<p id="Par104">Nanoparticles serve as a versatile platform for STING-targeted cancer immunotherapy, functioning either by delivering STING agonists or by mimicking cytosolic DNA to act as agonists independently [<a href="#CR65" class="usa-link" aria-describedby="CR65">65</a>, <a href="#CR116" class="usa-link" aria-describedby="CR116">116</a>]. It has been reported that metal-based nanoparticles are one type of nanoparticles often used to activate the cGAS-STING pathway [<a href="#CR117" class="usa-link" aria-describedby="CR117">117</a>, <a href="#CR118" class="usa-link" aria-describedby="CR118">118</a>]. Among these, manganese-, calcium-, zinc-, platinum-, iron-, lanthanide-based nanoparticles have achieved remarkable advancements in STING pathway activation. However, most of these metal-based nanoparticles are inorganic materials with generally poor biocompatibility and degradability. After entering the systemic circulation, they are prone to cause a series of adverse reactions without trigger the expected immune response [<a href="#CR119" class="usa-link" aria-describedby="CR119">119</a>, <a href="#CR120" class="usa-link" aria-describedby="CR120">120</a>]. These drawbacks necessitate the development of alternative metal-based systems with improved biocompatibility. To overcome these limitations, researchers have designed a series of metal-based nanoparticles based on stable organic ligands to enhance therapeutic efficacy while mitigating toxicity [<a href="#CR37" class="usa-link" aria-describedby="CR37">37</a>, <a href="#CR121" class="usa-link" aria-describedby="CR121">121</a>]. MOFs, formed by coordination between metal ions/clusters and multidentate organic ligands, are particularly representative. Compared to metal-based nanomaterials, MOFs offer advantages including simplicity of fabrication, adjustable surface functionality, controllable release activated by tumor-specific stimuli, including acidic pH or enzymatic activity, and superior biocompatibility [<a href="#CR122" class="usa-link" aria-describedby="CR122">122</a>, <a href="#CR123" class="usa-link" aria-describedby="CR123">123</a>]. MOFs are not only able to be designed to precisely deliver CDNs like 2’3’-cGAMP or small molecule agonists to tumor locations due to the tunable porosity but also to be utilize metal components to act directly on the cGAS-STING pathway. MOFs loaded with both ions and agonists can also be designed to achieve cascade activation of the cGAS-STING pathway, improving activation efficiency [<a href="#CR124" class="usa-link" aria-describedby="CR124">124</a>]. Unlike conventional metal-based nanoparticles, MOFs mitigate issues such as low bioavailability and systemic toxicity due to their organic ligand-mediated degradability and controlled release properties. Challenges persist, including, the potential immunogenicity of specific organic ligands, and the necessity for a thorough assessment of long-term toxicity and biodegradability. Despite these limitations, MOFs show significant potential for enhancing STING-targeted cancer immunotherapy. Current research aims to enhance the design, specificity, and safety of MOFs for clinical applications, establishing them as a prominent platform for future advancements in this area.</p>
<p id="Par105">This section reviews the recent achievements of developing MOFs for cGAS-STING pathway activation and their applications in cancer immunotherapy. Some accomplishments of employing MOFs for cGAS-TING activation are presented in Table <a href="#Tab1" class="usa-link">1</a> and will be elaborated upon in the subsequent paragraph. To better understand the application of MOFs in this field, we categorize them based on their composition and function as follows:</p>
<section class="tw xbox font-sm" id="Tab1"><h3 class="obj_head">Table 1.</h3>
<div class="caption p"><p>Summary of reported MOFs for cGAS-STING activation. The systematic chemical nomenclature and corresponding abbreviations for the compounds presented in the table are as follows: 5,15-di(p-benzoato) porphyrin (H<sub>2</sub>DBP), 2-Methylimidazole (2-MIM), tetrahydroxy-1,4-benzoquinone (THBQ), 4-tert-Butylbenzoic acid (TCPP), 1,3,5-benzenetricarboxylic acid (H<sub>3</sub>BTC), 2,3,6,7,10,11-hexahydroxytriphenylene (HHTP), 2-aminoterephthalic acid (2-ATA), Dithiodiacetic acid (DTDA), triethylamine (TEA)</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Type</th>
<th align="left" colspan="1" rowspan="1">MOFs structure</th>
<th align="left" colspan="1" rowspan="1">STING agonists</th>
<th align="left" colspan="1" rowspan="1">Therapeutic modalities</th>
<th align="left" colspan="1" rowspan="1">Ref.</th>
</tr></thead>
<tbody>
<tr>
<td align="left" rowspan="5" colspan="1">Immunotherapy</td>
<td align="left" colspan="1" rowspan="1">Mn_squaric acid</td>
<td align="left" colspan="1" rowspan="1">Mn</td>
<td align="left" colspan="1" rowspan="1">Metalloimmunotherapy</td>
<td align="left" colspan="1" rowspan="1"> [<a href="#CR125" class="usa-link" aria-describedby="CR125">125</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Zr༏Mn-TCPP</td>
<td align="left" colspan="1" rowspan="1">Mn</td>
<td align="left" colspan="1" rowspan="1">Immunotherapy</td>
<td align="left" colspan="1" rowspan="1"> [<a href="#CR126" class="usa-link" aria-describedby="CR126">126</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Zr_fumaric acid</td>
<td align="left" colspan="1" rowspan="1">MOF-801 + SR-717</td>
<td align="left" colspan="1" rowspan="1">Immunotherapy</td>
<td align="left" colspan="1" rowspan="1"> [<a href="#CR127" class="usa-link" aria-describedby="CR127">127</a>, <a href="#CR128" class="usa-link" aria-describedby="CR128">128</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Mn_AQ4N/SR-717/TEA</td>
<td align="left" colspan="1" rowspan="1">Mn + SR-717</td>
<td align="left" colspan="1" rowspan="1">ICD + Immunotherapy</td>
<td align="left" colspan="1" rowspan="1"> [<a href="#CR129" class="usa-link" aria-describedby="CR129">129</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Zn_2-ICA</td>
<td align="left" colspan="1" rowspan="1">DNAzyme induced mtDNA + Zn + Mn</td>
<td align="left" colspan="1" rowspan="1">Immunotherapy</td>
<td align="left" colspan="1" rowspan="1"> [<a href="#CR130" class="usa-link" aria-describedby="CR130">130</a>]</td>
</tr>
<tr>
<td align="left" rowspan="2" colspan="1">Combination with Chemotherapeutics</td>
<td align="left" colspan="1" rowspan="1">Mn_2-MI</td>
<td align="left" colspan="1" rowspan="1">PPI induced nDNA་Mn</td>
<td align="left" colspan="1" rowspan="1">Chemotherapy་Immunotherapy</td>
<td align="left" colspan="1" rowspan="1"> [<a href="#CR131" class="usa-link" aria-describedby="CR131">131</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Mn_DHTP</td>
<td align="left" colspan="1" rowspan="1">PTX induced nDNA་Mn</td>
<td align="left" colspan="1" rowspan="1">Chemotherapy + Immunotherapy</td>
<td align="left" colspan="1" rowspan="1"> [<a href="#CR132" class="usa-link" aria-describedby="CR132">132</a>]</td>
</tr>
<tr>
<td align="left" rowspan="4" colspan="1">Combination with Radiotherapy</td>
<td align="left" colspan="1" rowspan="1">Hf_HCBB</td>
<td align="left" colspan="1" rowspan="1">ROS induced mtDNA་MSA-2</td>
<td align="left" colspan="1" rowspan="1">RT-RDT + Immunotherapy</td>
<td align="left" colspan="1" rowspan="1"> [<a href="#CR133" class="usa-link" aria-describedby="CR133">133</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Hf_H<sub>2</sub>DBP</td>
<td align="left" colspan="1" rowspan="1">ROS induced mtDNA་ GA</td>
<td align="left" colspan="1" rowspan="1">RT-RDT + Immunotherapy</td>
<td align="left" colspan="1" rowspan="1"> [<a href="#CR134" class="usa-link" aria-describedby="CR134">134</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Ru༏Mn_popCOOH</td>
<td align="left" colspan="1" rowspan="1">ROS induced mtDNA་Mn</td>
<td align="left" colspan="1" rowspan="1">RT-RDT + Immunotherapy</td>
<td align="left" colspan="1" rowspan="1"> [<a href="#CR135" class="usa-link" aria-describedby="CR135">135</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Hf_TCPP</td>
<td align="left" colspan="1" rowspan="1">ROS induced mtDNA</td>
<td align="left" colspan="1" rowspan="1">RT-RDT</td>
<td align="left" colspan="1" rowspan="1"> [<a href="#CR136" class="usa-link" aria-describedby="CR136">136</a>]</td>
</tr>
<tr>
<td align="left" rowspan="2" colspan="1">Combination with Photodynamic Therappy/Photothermal Therapy</td>
<td align="left" colspan="1" rowspan="1">Fe_THBQ</td>
<td align="left" colspan="1" rowspan="1">ROS induced mtDNA་SR-717</td>
<td align="left" colspan="1" rowspan="1">PDT + PTT་Immunotherapy</td>
<td align="left" colspan="1" rowspan="1"> [<a href="#CR137" class="usa-link" aria-describedby="CR137">137</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Mn_TCPP</td>
<td align="left" colspan="1" rowspan="1">ROS induced mtDNA་Mn</td>
<td align="left" colspan="1" rowspan="1">PDT་Immunotherapy</td>
<td align="left" colspan="1" rowspan="1"> [<a href="#CR138" class="usa-link" aria-describedby="CR138">138</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Combination with Sono-Dynamic Therapy</td>
<td align="left" colspan="1" rowspan="1">Co_TCPP</td>
<td align="left" colspan="1" rowspan="1">ROS induced mtDNA + Co</td>
<td align="left" colspan="1" rowspan="1">SDT + Immunotherapy</td>
<td align="left" colspan="1" rowspan="1"> [<a href="#CR139" class="usa-link" aria-describedby="CR139">139</a>]</td>
</tr>
<tr>
<td align="left" rowspan="3" colspan="1">Combination with Cuproptosis and Ferroptosis</td>
<td align="left" colspan="1" rowspan="1">Cu_2-MIM</td>
<td align="left" colspan="1" rowspan="1">Cuproptosis/PPI induced mtDNA/nDNA</td>
<td align="left" colspan="1" rowspan="1">Cuproptosis + Immunotherapy</td>
<td align="left" colspan="1" rowspan="1"> [<a href="#CR140" class="usa-link" aria-describedby="CR140">140</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Fe_2-ATA</td>
<td align="left" colspan="1" rowspan="1">DHA/Fe induced mtDNA</td>
<td align="left" colspan="1" rowspan="1">Ferroptosis + Immunotherapy</td>
<td align="left" colspan="1" rowspan="1"> [<a href="#CR141" class="usa-link" aria-describedby="CR141">141</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Cu-HHTP</td>
<td align="left" colspan="1" rowspan="1">ROS induced mtDNA + MSA-2</td>
<td align="left" colspan="1" rowspan="1">Cuproptosis + Ferroptosis + Immunotherapy</td>
<td align="left" colspan="1" rowspan="1"> [<a href="#CR142" class="usa-link" aria-describedby="CR142">142</a>]</td>
</tr>
<tr>
<td align="left" rowspan="7" colspan="1">Combination with multiple treatments</td>
<td align="left" colspan="1" rowspan="1">Mn༏Ga_2-MI</td>
<td align="left" colspan="1" rowspan="1">ROS induced mtDNA་Mn</td>
<td align="left" colspan="1" rowspan="1">Microwave Hyperthermia + Chemotherapy + Immunotherapy</td>
<td align="left" colspan="1" rowspan="1"> [<a href="#CR143" class="usa-link" aria-describedby="CR143">143</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Zr/Ta_TCPP</td>
<td align="left" colspan="1" rowspan="1">ROS induced mtDNA་SR-717</td>
<td align="left" colspan="1" rowspan="1">PDT/RT-RDT + Immunotherapy</td>
<td align="left" colspan="1" rowspan="1"> [<a href="#CR144" class="usa-link" aria-describedby="CR144">144</a>, <a href="#CR145" class="usa-link" aria-describedby="CR145">145</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Fe_DTDA</td>
<td align="left" colspan="1" rowspan="1">Mn</td>
<td align="left" colspan="1" rowspan="1">PTT + CDT + Immunotherapy</td>
<td align="left" colspan="1" rowspan="1"> [<a href="#CR146" class="usa-link" aria-describedby="CR146">146</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Ti/Mn_NH<sub>2</sub>-H<sub>2</sub>BDC</td>
<td align="left" colspan="1" rowspan="1">SDT/CDT induced nDNA་Mn</td>
<td align="left" colspan="1" rowspan="1">SDT + CDT + Immunotherapy</td>
<td align="left" colspan="1" rowspan="1"> [<a href="#CR147" class="usa-link" aria-describedby="CR147">147</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Cu/Zn_2-MI</td>
<td align="left" colspan="1" rowspan="1">ROS/A4NQ induced mtDNA/nDNA + Zn + Mn</td>
<td align="left" colspan="1" rowspan="1">PDT + Cuproptosis + Ferroptosis + Immunotherapy</td>
<td align="left" colspan="1" rowspan="1"> [<a href="#CR124" class="usa-link" aria-describedby="CR124">124</a>, <a href="#CR148" class="usa-link" aria-describedby="CR148">148</a>–<a href="#CR157" class="usa-link" aria-describedby="CR157">157</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Fe_H<sub>3</sub>BTC</td>
<td align="left" colspan="1" rowspan="1">CDDP and Ferroptosis induced mtDNA + Mn</td>
<td align="left" colspan="1" rowspan="1">Chemotherapy + Ferroptosis + Immunotherapy</td>
<td align="left" colspan="1" rowspan="1"> [<a href="#CR158" class="usa-link" aria-describedby="CR158">158</a>]</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Cu_MTO</td>
<td align="left" colspan="1" rowspan="1">MTO/Cu induced nDNA/mtDNA</td>
<td align="left" colspan="1" rowspan="1">Chemotherapy + Cuproptosis + immunotherapy</td>
<td align="left" colspan="1" rowspan="1"> [<a href="#CR159" class="usa-link" aria-describedby="CR159">159</a>]</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section><section id="Sec13"><h3 class="pmc_sec_title">MOFs as a carrier for delivering STING agonists</h3>
<p id="Par107">MOFs are efficient carriers for delivering STING agonists to tumor sites, ensuring sustained immune activation. They can be modified through synthetic modification [<a href="#CR129" class="usa-link" aria-describedby="CR129">129</a>, <a href="#CR133" class="usa-link" aria-describedby="CR133">133</a>, <a href="#CR134" class="usa-link" aria-describedby="CR134">134</a>] or pore-filling strategies [<a href="#CR144" class="usa-link" aria-describedby="CR144">144</a>], mitigating drug degradation risk. When considering the type of STING agonist to be loaded, the agonists of CDNs and its derivatives are characterized by their relatively large size and susceptibility to enzymatic degradation. Although artificially modified, their application is mainly achieved by intratumoral administration. Therefore, the current design concept is that when MOF is used as a carrier for STING agonists, the main type of STING agonists delivered is small molecule agonists. Small molecule agonists are small in size and are mainly loaded into the pores of MOFs by pore-filling and artificial modification. For example, Liu et al.‘s team constructed a multifunctional immunological nanomedicine (MOF-CpG-DMXAA) by introducing cytosine-phosphate-guanine oligonucleotides (CpG ODNs) and 5,6-dimethylxanthone-4-acetic acid (DMXAA) into MOF-801 (Fig. <a href="#Fig4" class="usa-link">4</a>a) [<a href="#CR127" class="usa-link" aria-describedby="CR127">127</a>]. This nanomedicine enhances the antitumor immune effect in HCC by activating the STING pathway (Fig. <a href="#Fig4" class="usa-link">4</a>b), reprogramming TAMs, maturing DCs, and destroying tumor blood vessels. However, the ultra-small 4.8 Å pore size of MOF-801 limits its ability to deliver larger biomolecules. To address this limitation, researchers have developed mesoporous MOFs with optimized particle sizes and appropriate stability [<a href="#CR160" class="usa-link" aria-describedby="CR160">160</a>–<a href="#CR162" class="usa-link" aria-describedby="CR162">162</a>]. For example, Professor Ding’s team synthesized HM801 with mesoporous structure using a soft template method, enabling the delivery of the STING agonist MSA-2 and the SARS-CoV-2 Delta variant RBD antigen. This approach enhanced both humoral and cellular immune responses, improving vaccine efficacy (Fig. <a href="#Fig4" class="usa-link">4</a>c) [<a href="#CR128" class="usa-link" aria-describedby="CR128">128</a>]. Despite these advancements, challenges remain in the use of MOFs as STING agonist carriers. The preparation of agonist-loaded MOFs often involves complex synthesis steps, including post-synthetic modification and loading processes. Additionally, maintaining the stability and activity of agonists during loading requires optimized conditions. Furthermore, drug release efficiency can be constrained by the pore structure of MOFs and the physiological environment. Certain MOFs may also exhibit gradual degradation under physiological conditions, raising concerns about long-term biological toxicity. Hence, designing MOFs structures that can function as agonists represents a potentially effective approach to overcoming the aforementioned limitations.</p>
<figure class="fig xbox font-sm" id="Fig4"><h4 class="obj_head">Fig. 4.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12369232_12951_2025_3669_Fig4_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6765/12369232/cb39e53645fb/12951_2025_3669_Fig4_HTML.jpg" loading="lazy" id="d33e1588" height="257" width="669" alt="Fig. 4"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>MOFs as carriers for delivering STING agonists. (<strong>a</strong>) Schematic illustration of the preparation of MOF-CpG-DMXAA. Encapsulating MOF-801 with CpG ODNs and the angiogenesis inhibitor DMXAA through coordinate bonds synthesized MOF-CpG-DMXAA. (<strong>b</strong>) In BMDCs, MOF-CpG-DMXAA upregulated the expression of key signaling molecules including p-STING, STING, cGAS, and NF-κB-p65. i: Control, ii: MOF-801, iii: CpG, iv: DMXAA, v: MOF-CpG, vi: MOF-DMXAA, vii: MOF-CpG-DMXAA [<a href="#CR127" class="usa-link" aria-describedby="CR127">127</a>]. Copyright 2023, Wiley-VCH. (<strong>c</strong>) Preparation strategy of R@M@HM801 and its role in initiating STING signaling cascade for antitumor immunity potentiation [<a href="#CR128" class="usa-link" aria-describedby="CR128">128</a>]. Copyright 2024, Elsevier B.V</p></figcaption></figure></section><section id="Sec14"><h3 class="pmc_sec_title">Metal components in MOFs as STING agonists</h3>
<p id="Par109">MOFs can not only load agonists benefitting due to their flexibility in structure and porosity but also directly operate as agonists. A key feature of these MOFs-based agonists is their predominant composition, Zn<sup>2+</sup> [<a href="#CR148" class="usa-link" aria-describedby="CR148">148</a>, <a href="#CR163" class="usa-link" aria-describedby="CR163">163</a>, <a href="#CR164" class="usa-link" aria-describedby="CR164">164</a>] and Mn<sup>2+</sup> [<a href="#CR125" class="usa-link" aria-describedby="CR125">125</a>, <a href="#CR131" class="usa-link" aria-describedby="CR131">131</a>, <a href="#CR135" class="usa-link" aria-describedby="CR135">135</a>, <a href="#CR138" class="usa-link" aria-describedby="CR138">138</a>, <a href="#CR142" class="usa-link" aria-describedby="CR142">142</a>]. Additionally, a subset of cobalt (Co)-based MOFs have also been shown to exhibit STING agonist activity [<a href="#CR139" class="usa-link" aria-describedby="CR139">139</a>]. Notably, MOFs incorporating copper (Cu) or iron (Fe) ions can stimulate mtDNA production for STING activation. Moreover, MOFs can be engineered with photosensitive ligands [<a href="#CR165" class="usa-link" aria-describedby="CR165">165</a>–<a href="#CR169" class="usa-link" aria-describedby="CR169">169</a>] or high-Z elements (such as hafnium) to enhance the ROS [<a href="#CR170" class="usa-link" aria-describedby="CR170">170</a>–<a href="#CR173" class="usa-link" aria-describedby="CR173">173</a>]. The persistent oxidatively generated damage to mtDNA induced by ROS results in mtDNA release, subsequently triggering the activation of the cGAS-STING signaling pathway [<a href="#CR174" class="usa-link" aria-describedby="CR174">174</a>–<a href="#CR177" class="usa-link" aria-describedby="CR177">177</a>]. In this section, we summarize and discuss studies utilizing MOFs as direct or indirect agonists to activate the cGAS-STING pathway, highlighting their diverse mechanisms and therapeutic applications. For example, Prof. Jinzhi Du’s team developed an eco-friendly method to synthesize immunostimulatory Mn<sup>2+</sup>-MOFs (ISAMn-MOFs) for cancer metalloimmunotherapy (Fig. <a href="#Fig5" class="usa-link">5</a>a) [<a href="#CR125" class="usa-link" aria-describedby="CR125">125</a>]. The unique structure of these MOFs facilitates the rapid release of Mn<sup>2+</sup> ions, effectively increasing intracellular Mn<sup>2+</sup> concentrations. This enhancement activates the STING pathway, thereby improving antitumor immune responses. Mn-based MOFs face challenges in structural stability due to Mn valence changes and require extensive safety evaluations, particularly for long-term use. In contrast, Zn-based MOFs exhibit superior chemical and thermal stability. As an essential trace element with lower toxicity, Zn-based MOFs demonstrate excellent safety for biomedical applications, as supported by statistical data in Table <a href="#Tab1" class="usa-link">1</a>. Furthermore, comparative studies have shown that Zn<sup>2+</sup> exhibits unique dual functionality among various metal ions, simultaneously promoting cGAS protein phase separation and enhancing its enzymatic catalytic activity [<a href="#CR178" class="usa-link" aria-describedby="CR178">178</a>]. Furthermore, Zn<sup>2+</sup> induces intracellular ROS accumulation, causing mitochondrial damage and subsequent mtDNA release [<a href="#CR164" class="usa-link" aria-describedby="CR164">164</a>, <a href="#CR179" class="usa-link" aria-describedby="CR179">179</a>]. While individual metal ions have been demonstrated to activate the cGAS-STING signaling pathway, their therapeutic potential in immunotherapy remains constrained when administered as monotherapy [<a href="#CR151" class="usa-link" aria-describedby="CR151">151</a>]. To address these issues, Zheng et al. constructed multifunctional ZIF-8@MnO<sub>2</sub> nanoparticles to facilitate the degradation of MUTP53 and enhance the cGAS stimulation pathway through dual metal ions (Fig. <a href="#Fig5" class="usa-link">5</a>b) [<a href="#CR63" class="usa-link" aria-describedby="CR63">63</a>]. The ZIF-8@MnO<sub>2</sub> nanocomposite demonstrates dual functionality in cancer therapy, releasing Zn<sup>2+</sup> and Mn<sup>2+</sup> to induce oxidative stress and mtDNA leakage. Zn<sup>2+</sup> promotes proteasomal degradation of p53 mutants, alleviating their inhibition on cGAS-STING, while Mn<sup>2+</sup> enhances cGAS sensitivity to dsDNA. Both in vitro and in vivo studies confirm its efficacy in activating the cGAS-STING pathway and combing with PD-L1 blockade, significantly inhibiting breast cancer progression and metastasis. Despite their promising therapeutic potential, MOFs face several critical limitations that hinder their clinical translation, including suboptimal biocompatibility, potential immunogenicity, rapid systemic clearance, inefficient cellular internalization, uncontrolled drug release kinetics, and inadequate target specificity. This can be improved by surface modification [<a href="#CR152" class="usa-link" aria-describedby="CR152">152</a>, <a href="#CR156" class="usa-link" aria-describedby="CR156">156</a>]. Liu and colleagues engineered a biomimetic nanoplatform through sequential fabrication processes: initially developing RBCM-ZM@TD by encapsulating DNAzymes within Mn-ZIF-90 nanoparticles and coating them with red blood cell membranes (RBCM) to prolong systemic circulation (Fig. <a href="#Fig5" class="usa-link">5</a>c). Subsequently, they constructed Vir-ZM@TD by functionalizing the surface with RGD and HA2 peptides, creating a herpes virus-mimetic nanostructure. This innovative design mimics the mtDNA stress typically induced by herpes virus infection, triggering the cGAS-STING pathway-mediated innate immune response and demonstrating potent antitumor efficacy [<a href="#CR130" class="usa-link" aria-describedby="CR130">130</a>].</p>
<figure class="fig xbox font-sm" id="Fig5"><h4 class="obj_head">Fig. 5.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12369232_12951_2025_3669_Fig5_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6765/12369232/2dbf85e2122f/12951_2025_3669_Fig5_HTML.jpg" loading="lazy" id="d33e1738" height="376" width="669" alt="Fig. 5"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig5/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>MOFs as agonists of STING. (<strong>a</strong>) Preparation strategy of ISAMn-MOF [<a href="#CR125" class="usa-link" aria-describedby="CR125">125</a>]. Copyright 2023, American Chemical Society. (<strong>b</strong>) Preparation strategy of the synthesis of ZIF-8@MnO2 and therapeutic strategy of degrading pan-mutant mutp53 proteins for activating cGAS-STING pathway [<a href="#CR63" class="usa-link" aria-describedby="CR63">63</a>]. Copyright 2024, Wiley-VCH GmbH. (<strong>c</strong>) Preparation strategy of Vir-ZM@TD and therapeutic strategy of Vir-ZM@TD that potentiate anti-tumor innate immunity [<a href="#CR130" class="usa-link" aria-describedby="CR130">130</a>]. Copyright 2022, Wiley‐VCH GmbH</p></figcaption></figure></section><section id="Sec15"><h3 class="pmc_sec_title">Multifunctional MOFs activate cGAS-TING to improve immunotherapy</h3>
<p id="Par111">The activation of cGAS-STING is acknowledged as an auspicious immunotherapeutic approach to elicit innate antitumor immune responses. Nevertheless, it is insufficient in activating the cGAS-STING pathway due to numerous immunosuppressive cells entering the TME, which undermines antitumor immunity. The multifunctional architecture of MOFs facilitates the concurrent integration of STING agonists, hence providing targeted and individualized cancer immunotherapy.</p>
<section id="Sec16"><h4 class="pmc_sec_title">Combination with chemotherapeutics</h4>
<p id="Par112">Increasing evidence shows that certain chemotherapeutics, such as paclitaxel (PTX), oxaliplatin (OX), and doxorubicin (DOX), can induce immunogenic cell death (ICD) to lead to a pro-inflammatory and immunogenic TME. Consequently, it is essential to formulate creative methods to enhance the tumor immunosuppressive microenvironment (TIME). and enhance the efficacy of ICB. And MOFs can utilize their metal ions to directly activate the cGAS-STING pathway while generating ·OH to enhance the effect of DNA damage. Notably, the ·OH produced by MOFs not only directly caused cell death, but also effectively and synergistically amplified the effect of chemotherapy-induced ICD. Multiple approaches synergistically amplified the activation of the cGAS-STING pathway and thus enhanced the effects of immunization. For example, Wang et al. developed a manganese (Mn²⁺)-based MOF nanosystem (PEG-MnMOF@PTX) (Fig. <a href="#Fig6" class="usa-link">6</a>a) [<a href="#CR132" class="usa-link" aria-describedby="CR132">132</a>]. The nanosystem can release Mn<sup>2+</sup> under acidic conditions to directly resolve the cGAS-STING pathway while generating ·OH and promoting H<sub>2</sub>O<sub>2</sub> to generate O<sub>2</sub> in situ. The released PTX normalizes tumor blood vessels and improves microenvironmental immunosuppression. In addition, ·OH combined with the released PTX induce ICD of tumor cells. The combination of multiple pathways has increased the efficacy of immunotherapy. Cells treated with PEG-MnMOF@PTX showed significant cytotoxicity, inducing apoptosis up to 43.1% (Fig. <a href="#Fig6" class="usa-link">6</a>b). In the in vitro CT26 tumor model, PEG-MnMOF@PTX significantly inhibited tumor growth, with a tumor inhibition rate (TGI) of up to 68.2% (Fig. <a href="#Fig6" class="usa-link">6</a>c). When PEG-MnMOF@PTX was combined with the PD-L1 immune checkpoint blocker, the antitumor effect was significantly enhanced, and the 40-day survival rate increased from 40 to 80% (Fig. <a href="#Fig6" class="usa-link">6</a>d). In the systematic safety evaluation, PEG-MnMOF@PTX showed good biosafety in vivo. The research demonstrates the PEG-MnMOF@PTX nanosystem not only exhibits significant effects in antitumor and immune activation, but its good in vivo safety also provides important support for its future clinical application.</p>
<figure class="fig xbox font-sm" id="Fig6"><h5 class="obj_head">Fig. 6.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12369232_12951_2025_3669_Fig6_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6765/12369232/b58c991fd710/12951_2025_3669_Fig6_HTML.jpg" loading="lazy" id="d33e1796" height="346" width="669" alt="Fig. 6"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig6/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Combination with Chemotherapeutics. (<strong>a</strong>) Preparation strategy of PEG-MnMOF@PTX and functional principle of TME-adapted PEG-MnMOF@PTX for coordinated chemo-immunotherapy via STING pathway activation. (<strong>b</strong>) The cytotoxicity of PEG-MnMOF, PTX, PEG-MnMOF@PTX on CT26 cells. (<strong>c</strong>) Efficacy of antitumor immune response in vivo: tumor growth inhibition (TGI) of mice treated for 16 days. G1: PBS, G2: PEG-MnMOF, G3: PTX, and G4: PEG-MnMOF@PTX. (<strong>d</strong>) Enhanced antitumor efficacy of PEG-MnMOF@PTX coadministered with ICB therapy in vivo: survival rate of tumor-bearing murine models under differential treatments. G1: PBS, G2: αPD-L1, G3: PEG-MnMOF@PTX, and G4: PEG-MnMOF@PTX + αPD-L1 [<a href="#CR132" class="usa-link" aria-describedby="CR132">132</a>]. Copyright 2024, Mingxiao Fang et al</p></figcaption></figure></section><section id="Sec17"><h4 class="pmc_sec_title">Combination with radiotherapy</h4>
<p id="Par114">RT is a crucial cancer treatment in the clinic, which directly damages the DNA of tumor cells with high-energy rays to induce apoptosis or necrosis. DNA fragments can bind to cGAS and activate STING. In addition, RT induction can also cause in situ ICD, which can be demonstrated by the surface exposure of calreticulin (CRT) and high-mobility group 1 (HMGB-1). This process can also release tumor antigens and damage-associated molecular patterns (DAMPs), TAAs, which can further stimulate immune cells. However, RT faces clinical limitations such as side effects, radioresistance, and inability to target metastatic lesions. Over the past thirty years, considerable efforts have been dedicated to identifying non-chemotherapy radiosensitizers to enhance the effectiveness of radiotherapy while minimizing severe side effects. Although preclinical studies demonstrate their potential to improve radiotherapy-induced cell death, non-chemotherapy radiosensitizers have yet to receive approval for clinical application from the US Food and Drug Administration [<a href="#CR180" class="usa-link" aria-describedby="CR180">180</a>]. The absence of clinical success has been ascribed to the fact that existing radiosensitizers enhance DNA double-strand breaks but are insufficient to overcome the immunosuppressive TME. Considering the constraints of current radiosensitizers, developing new sensitizers or combining them with other therapies may be an effective strategy to address current limitations. MOFs have been shown to not only act as highly effective radiosensitizers to significantly amplify RT-induced DNA damage, but can also load STING agonists through their porous structures or coordination effects, thereby enhancing antitumor immune responses [<a href="#CR134" class="usa-link" aria-describedby="CR134">134</a>]. For example, Lin et al. designed a hafnium (Hf)-based MOF nanomaterial loaded with MSA-2, called MOF/MSA-2 (Fig. <a href="#Fig7" class="usa-link">7</a>a) [<a href="#CR133" class="usa-link" aria-describedby="CR133">133</a>]. MOF/MSA-2 enhances the DNA damage effect of radiotherapy through its high Z characteristic Hf and achieves facilitates prolonged the STING pathway by loading MSA-2. MOF/MSA-2, in conjunction with low-dose radiation, markedly suppressed tumor proliferation and stimulated the tumor immune microenvironment. Additionally, incorporating anti-PD-L1 antibodies can efficiently manage distant metastatic lesions and elicit a systemic anticancer immune response (Fig. <a href="#Fig7" class="usa-link">7</a>b-c). Radiotherapy (RT) frequently encounters failures due to tumor tissue hypoxia, inflammation, adverse effects, and radioresistance. Heterojunction-based radiosensitizers garner significant attention for their lower excitation energy and exceptional catalytic activity compared to conventional transition metal radiosensitizers. MOFs-based heterojunctions are also utilized in biomedicine for cancer treatment, drug transport and release, and imaging, benefiting from their high surface area, uniform and adjustable pore structure, controllable chemical properties, and the variety of metal/ligand subunits. Notably, Hf and thorium (Th) secondary building units have been demonstrated to absorb X-rays to excite ruthenium (Ru) or iridium (Ir)-based photosensitizers in nanoscale MOFs, thereby enhancing free radical generation and facilitating improved RT-RDT. Lu et al. first constructed a bimetallic Mn-MOF by introducing Mn²⁺ into the ruthenium complex and finally introduced gold nanorods (AuNRs) into the system to construct a heterostructured radiosensitizer Au@Mn-MOF (Fig. <a href="#Fig7" class="usa-link">7</a>d) [<a href="#CR135" class="usa-link" aria-describedby="CR135">135</a>]. Au@Mn-MOF can react to the tumor’s acidic milieu and release the ruthenium complex and Mn²⁺ in a controlled manner. Furthermore, to eradicate immunosuppression in NK cell therapy and augment the efficacy of immunotherapy, the incorporation of AuNRs can absorb high-energy X-rays and transfer energy to Mn-MOF, thereby enhancing radiodynamic therapy and activating NK cell-mediated immunotherapy via the cGAS-STING pathway, resulting in an increased apoptosis rate of MDA-MB-231 breast cancer cells to 67.11% (Fig. <a href="#Fig7" class="usa-link">7</a>e). In the nude mouse breast cancer model, the tumor growth inhibition rate (TGI) of the combined treatment group reached 86.31%, and the survival rate within 42 days reached 83.3% (Fig. <a href="#Fig7" class="usa-link">7</a>f). Au@Mn-MOF not only showed good antitumor effects in in vitro and in vivo models but also had good biocompatibility and in vivo distribution characteristics. This study provides new ideas for designing new biofunctionalized MOFs materials and developing combined tumor treatment strategies. Indeed, RT can induce immune activation while simultaneously leading to various immunosuppressive issues, rendering it a double-edged sword in tumor immunomodulation [<a href="#CR181" class="usa-link" aria-describedby="CR181">181</a>]. Chen et al. found that RT significantly triggered autophagy in HCC cells, which in turn restricted the activation of ICD and CGAS stimulation, making the combined treatment effect limited [<a href="#CR136" class="usa-link" aria-describedby="CR136">136</a>].</p>
<figure class="fig xbox font-sm" id="Fig7"><h5 class="obj_head">Fig. 7.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12369232_12951_2025_3669_Fig7_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6765/12369232/ffe8d20e596d/12951_2025_3669_Fig7_HTML.jpg" loading="lazy" id="d33e1876" height="818" width="669" alt="Fig. 7"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig7/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Combination with Radiotherapy. (<strong>a</strong>) Synthetic strategy of MOF/MSA-2. (<strong>b</strong>) and (<strong>c</strong>) Effect of combination of MOF/MSA-2 Plus RT with αPD-L1 in vivo: b) Tumor volume of primary tumors and c) Tumor volume of distant tumors [<a href="#CR133" class="usa-link" aria-describedby="CR133">133</a>]. Copyright 2024, Mingxiao Fang et al. (<strong>d</strong>) Synthetic strategy of Au@Mn-MOF and its role in enhancing radiodynamic/immunotherapy. (<strong>e</strong>) and (<strong>f</strong>) Efficacy of antitumor immune response of Au@Mn-MOF in vivo: <strong>e</strong>) tumor size of nude mice after treated with Au@Mn-MOF, combined with X-ray or NK cells. <strong>f</strong>) Survival curves of mice with differential therapeutic interventions for 42 consecutive days. ⅰ. control, ⅱ. NK cells, ⅲ. Au@Mn-MOF, ⅳ. X-Ray, ⅴ. NK cells + MOF, ⅵ. NK cells + X-Ray, ⅶ. Au@Mn-MOF + X-Ray, ⅷ. Au@Mn-MOF + NK cells + X-Ray [<a href="#CR135" class="usa-link" aria-describedby="CR135">135</a>]. Copyright 2023, Wiley-VCH GmbH</p></figcaption></figure></section><section id="Sec18"><h4 class="pmc_sec_title">Combination with photodynamic therapy/photothermal therapy</h4>
<p id="Par116">PDT refers to a non-invasive treatment method in which photosensitizers (PS) produce ROS under specific wavelength light conditions, which kill tumor cells. It is usually used as a supplementary means of tumor treatment. In recent years, PDT has shown remarkable results in regulating the immune system, primarily innate and adaptive immunity. On the one hand, PDT-induced local tumor tissue damage can trigger an acute inflammatory response, a direct pathway to clearing damaged tissue and restoring homeostasis. On the other hand, PDT can effectively stimulate the innate immune response and activate the adaptive immunological response through the ICD mechanism and cGAS-STING activation mechanism, thereby forming long-term immune memory. This process depends on a series of DAMPs released after PDT-induced tumor cell damage, which acts as “danger signals” to promote the recruitment and activation of APCs. STING activation, when combined with other treatment techniques, has been shown to reverse the TIME, enhancing the efficacy of immunotherapy synergistically. Integrating PDT and STING may be advantageous for augmenting immunotherapeutic efficacy [<a href="#CR61" class="usa-link" aria-describedby="CR61">61</a>, <a href="#CR168" class="usa-link" aria-describedby="CR168">168</a>]. It is noteworthy that MOFs enable a more effective synergistic enhancement of tumor immunotherapy by concurrently combining PDT and STING activation. Specifically, MOFs potentiate the activation of the cGAS-STING pathway either intrinsically or through the delivery of agonists, while simultaneously promoting PDT-induced DNA damage by targeting ROS generation. As most photosensitizers are highly conjugated molecules that tend to aggregate in aqueous media, PS-based MOFs have been extensively used to overcome solubility limitations [<a href="#CR182" class="usa-link" aria-describedby="CR182">182</a>].</p>
<p id="Par117">Ge et al. developed an oxidation-responsive PolyMOF nanoparticle named SR@PMOF (Fig. <a href="#Fig8" class="usa-link">8</a>a) [<a href="#CR144" class="usa-link" aria-describedby="CR144">144</a>]. SR@PMOF can co-deliver a STING agonist, SR-717, and a photosensitizer, TCPP. After intravenous injection, SR@PMOF nanoparticles accumulate at the tumor site. Upon light irradiation at the tumor location, the photosensitizer TCPP generates singlet oxygen (<sup>1</sup>O<sub>2</sub>), which induces tumor cell apoptosis. This process releases fragmented DNA and tumor-associated antigens, activating the immune system. Simultaneously, the structure of SR@PMOF nanoparticles contains thiol bonds that can be disrupted by <sup>1</sup>O<sub>2</sub>, leading to the rapid release of SR-717. The released SR-717 activates the STING pathway, augmenting the immunological response and reversing the TIME. This synergistic effect promotes antitumor immune responses. Experimental findings indicate that SR@PMOF nanoparticles significantly impede the proliferation of both primary and metastatic cancers (Fig. <a href="#Fig8" class="usa-link">8</a>b-c), demonstrating the promising potential for clinical applications. Meanwhile, SR@PMOF showed a favorable safety profile both in vivo and in vitro.</p>
<figure class="fig xbox font-sm" id="Fig8"><h5 class="obj_head">Fig. 8.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12369232_12951_2025_3669_Fig8_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6765/12369232/75d85c2b8970/12951_2025_3669_Fig8_HTML.jpg" loading="lazy" id="d33e2049" height="495" width="669" alt="Fig. 8"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig8/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Combination with photodynamic therapy/photothermal therapy. (<strong>a</strong>) Synthetic strategy of SR@PMOF. (<strong>b</strong>) and (<strong>c</strong>) Antitumor efficacy of SR@PMOF: tumor volume of b) primary and c) distance tumors after differential therapeutic interventions [<a href="#CR144" class="usa-link" aria-describedby="CR144">144</a>]. Copyright 2023, American Chemical Society. (<strong>d</strong>) Synthetic strategy for DZ@A7 and its role in activating the STING pathway to achieve combined photodynamic and metalloimmunotherapy [<a href="#CR163" class="usa-link" aria-describedby="CR163">163</a>]. Copyright 2024, Wiley-VCH GmbH. (<strong>e</strong>) Synthetic strategy of Fe-THBQ/SR as NIR-II PDT and NIR-II Mild-PTT Agent, inducing Ferroptosis, STING Activation, and vasculature normalization [<a href="#CR137" class="usa-link" aria-describedby="CR137">137</a>]. Copyright 2024, The Author(s). (<strong>f</strong>) Synthetic strategy of SR@PMOF. (<strong>g</strong>) and (<strong>h</strong>) Antitumor efficacy of BC@Z-M in vivo: g) tumor growth curve of mice with differential therapeutic interventions. h) survival curves of 4T1 mice with differential therapeutic interventions [<a href="#CR148" class="usa-link" aria-describedby="CR148">148</a>]. Copyright 2024, The Author(s)</p></figcaption></figure><p id="Par118">Notwithstanding promising advancements, photodynamic immunotherapy continues to exhibit a low response rate. Subsequent research indicated inadequate clinical efficacy was primarily due to low immunogenicity and TIME. Research demonstrates that PS generates ROS within the cell nucleus, and the resultant damaged DNA fragments discharged into the cytoplasm can more effectively activate innate immunity via the cGAS-STING pathway [<a href="#CR183" class="usa-link" aria-describedby="CR183">183</a>]. Therefore, Shi et al. advocated for using effective nuclear DNA damage and release to enhance photodynamic immunotherapy by stimulating an innate immune response [<a href="#CR138" class="usa-link" aria-describedby="CR138">138</a>]. Studies have shown that glutathione (GSH), a metabolite of glutamine, confers antioxidant properties to cancer cells, thereby limiting the effectiveness of PDT [<a href="#CR184" class="usa-link" aria-describedby="CR184">184</a>]. Therefore, interrupting glucose and glutamine metabolism simultaneously to hinder the energy intake of cancer cells is beneficial for reversing the immunosuppressive TME and damaging tumor cells. To this end, Li et al. proposed the “internal failure and external aggression” strategy. Specifically, they constructed a functional immunomodulator denoted as ReSZ(FB). ReSZ(FB) induced mitochondrial damage through PDT to release mtDNA, which coordinated with Zn<sup>2+</sup> from Zn-MOF to activate the cGAS-STING pathway while fastening and reprogramming TME, enhancing the immune response and achieved internal and external synergistic antitumor effects [<a href="#CR153" class="usa-link" aria-describedby="CR153">153</a>].</p>
<p id="Par119">However, uncontrolled leakage or excessive exposure of agonists may result in inadvertent activation of non-target cells. To address this problem, Ren et al. developed a MOF-based nanocontroller, designated DZ@A7, which employs tumor microenvironment/near-infrared (NIR) light-triggered decomposition for localized tumor-specific STING activation and photodynamic metalloimmunotherapy (Fig. <a href="#Fig8" class="usa-link">8</a>d) [<a href="#CR163" class="usa-link" aria-describedby="CR163">163</a>]. Precisely, the DZ@A7 nano agonist comprises a polydopamine-modified zeolitic imidazolate framework-8 (ZIF-8) concurrently with the photosensitizer IR780 and the hypoxia drug aquinone dihydrochloride (AQ4N). Mitochondrial-targeted ROS generation via near-infrared irradiation can cause oxidative harm to cancer cells, exacerbated by polydopamine-induced reduction of intracellular GSH. Furthermore, this phenomenon markedly facilitates the release of mtDNA, which is known to activate the cGAS-STING signaling pathway. Subsequently, hypoxia-responsive drugs can increase the accumulation of damaged cytoplasmic DNA by inhibiting the repair of ncDNA, thereby further strengthening the STING pathway. In addition, the overloading of nutrient metal ions (e.g., Mn<sup>2+</sup>, Zn<sup>2+</sup>, Ca<sup>2+</sup>) in cancer cells might further raise cGAS enzyme activity and synergistically amplify STING activation. This tumor-specific STING activation and photodynamic-metal immunotherapy significantly enhanced the immune response and antitumor effect. This tumor-specific STING activation and photodynamic-metal immunotherapy significantly enhanced the immune response, with a tumor inhibition rate of 79.77%. It also does not affect the safety and biocompatibility of DZ@A7.</p>
<p id="Par120">Despite its numerous advantages, photodynamic therapy (PDT) is constrained by the restricted penetration depth of short-wavelength visible light in tissues, rendering it appropriate solely for surface cancers. These limitations have affected its clinical application and therapeutic effect to a certain extent. To tackle this difficulty, photosensitizers activated by light in the near-infrared spectrum (&gt; 700 nm), particularly within the second near-infrared region (NIR-II, 1000–1700 nm), have been created [<a href="#CR185" class="usa-link" aria-describedby="CR185">185</a>, <a href="#CR186" class="usa-link" aria-describedby="CR186">186</a>]. In comparison to light in the first near-infrared window (NIR-I, 700–900 nm), the longer-wavelength NIR-II light reduces the degree of tissue scattering, promises deeper tissue penetration, reduces phototoxicity, and permits a greater maximum allowable power [<a href="#CR187" class="usa-link" aria-describedby="CR187">187</a>, <a href="#CR188" class="usa-link" aria-describedby="CR188">188</a>]. However, the hypoxic characteristics within tumor cells significantly reduce the efficiency of photosensitizers in generating reactive oxygen species, thereby weakening the cytotoxicity of PDT [<a href="#CR189" class="usa-link" aria-describedby="CR189">189</a>–<a href="#CR191" class="usa-link" aria-describedby="CR191">191</a>].</p>
<p id="Par121">Recent research indicate that PDT and PTT can complement each other to achieve excellent antitumor effects [<a href="#CR192" class="usa-link" aria-describedby="CR192">192</a>]. On the one hand, the hyperthermia effect of PTT can improve intracellular delivery of PS and increase oxygen perfusion, thereby promoting PDT efficacy [<a href="#CR193" class="usa-link" aria-describedby="CR193">193</a>]. On the other hand, PDT-generated ROS can attack the heat shock proteins (HSPs), thus negating the self-protection effect of tumor cells and improving PTT efficacy [<a href="#CR194" class="usa-link" aria-describedby="CR194">194</a>]. However, due to the commonly mismatched absorption spectra of agents, current combined photodynamic and photothermal therapy strategies primarily rely on different lasers or multiple functional components. This reliance can compromise therapeutic efficacy, cause energy inefficiency, prolong treatment time, and increase operational complexity [<a href="#CR195" class="usa-link" aria-describedby="CR195">195</a>, <a href="#CR196" class="usa-link" aria-describedby="CR196">196</a>]. Consequently, it is significant to create single-component materials capable of being irradiated by a singular NIR-II laser to concurrently facilitate PDT and PTT, thereby improving both therapeutic effectiveness and clinical applicability.</p>
<p id="Par122">PDT is an oxygen-reliant process, and the hypoxic environment of the TME often limits its therapeutic effectiveness. This hypoxia is primarily caused by malformed and dysfunctional tumor vasculature. Tumor vasculature is characterized by its tortuous, disorganized, and leaky nature with decreased pericyte coverage. These vascular abnormalities exacerbate TME hypoxia, posing a significant obstacle to PDT. Thus, vasculature normalization has emerged as a prospective strategy to mitigate hypoxia and enhance PDT efficiency. Beyond its established roles in coordinating the innate immune response and facilitating adaptive immunity activation, recent studies highlight the potential of the STING pathway activation to promote vascular normalization, alleviate hypoxia, and improve T lymphocyte infiltration. Combining STING activation with PDT is a promising strategy based on these insights to produce synergistic antitumor effects and improve therapeutic outcomes.</p>
<p id="Par123">Because of the above scientific issues, Zhao et al. developed an SR-717 (a STING agonist) loaded iron-tetrahydroxy-1,4-benzoquinone (Fe-THBQ) MOF, specified as Fe-THBQ/SR (Fig. <a href="#Fig8" class="usa-link">8</a>e) [<a href="#CR137" class="usa-link" aria-describedby="CR137">137</a>]. The platform introduced a PS that can be activated by NIR-II, which solved the problem of limited light penetration of traditional photosensitizers. By integrating NIR-II PDT, NIR-II PTT, ferroptosis induction and STING activation, the antitumor effect was significantly enhanced, and the TME was improved. The platform achieved multiple therapeutic effects under single NIR-II laser irradiation, with the advantages of simple operation, high precision and few side effects, providing a new strategy for cancer treatment. In 4T1 breast cancer and B16-F10 melanoma murine models, Fe-THBQ/SR + NIR-II laser irradiation significantly inhibited tumor growth, with tumor inhibition rates reaching 92.9% and 100%, respectively. PDT and PTT are promising for activating ICD and cGAS-STING pathways, but challenges remain. Organic molecules offer structure, biocompatibility, and adjustable functionality, but insufficient potency and severe photodegradation hinder strong immune activation. The development of intelligent organic photosensitizers with high efficacy and on-demand activated photoimmunotherapy properties is needed. Qi et al., using the innovatively designed hypoxia-activated probe called BN-O and vascular disruptor CA4P in Zn-MOF body and further disguised with M1-like macrophage membrane, formed a multifunctional nanoplatform named BC@ZM [<a href="#CR148" class="usa-link" aria-describedby="CR148">148</a>] (Fig. <a href="#Fig8" class="usa-link">8</a>f). This platform responds to the hypoxic environment, realizes the opening of NIR-II fluorescence and photoacoustic signals, triggers photodynamic and photothermal effects, activates the STING pathway, and enhances the immune response. BC@Z-M, in conjunction with 730 nm laser irradiation, markedly suppressed the proliferation of primary tumors and showed an inhibitory effect on unirradiated distant tumors (85% inhibition rate) (Fig. <a href="#Fig8" class="usa-link">8</a>g), showing strong immune activation and remote effects. The survival rate of mice treated with BC@Z-M + L was significantly improved within 40 days (Fig. <a href="#Fig8" class="usa-link">8</a>h), and they showed good antitumor immune memory in tumor rechallenge experiments. BC@Z-M also showed good biocompatibility as well as safety by histological analysis of organs and examination of blood. Although NIR-II PDT has shown great potential in tumor treatment, light intensity attenuation is still significant in deep tissues. In addition, NIR-II photosensitizers still face many challenges in terms of material stability, TME adaptability, imaging and treatment synergy, and clinical application bottlenecks. Future research needs to further optimize the material system, improve targeting, and deeply explore the synergistic mechanism of multimodal treatment to promote the clinical application of NIR-II PDT.</p></section><section id="Sec19"><h4 class="pmc_sec_title">Combination with Sono-Dynamic therapy</h4>
<p id="Par125">Sonodynamic therapy (SDT) utilizes sonosensitizers (SS) and high-intensity focused ultrasound (US) for targeted tumor ablation [<a href="#CR197" class="usa-link" aria-describedby="CR197">197</a>]. Due to the high penetrative power of ultrasonic radiation, SDT can target deep-seated tumors. It is reported that intense SDT-induced damage can trigger tumor immunogenic cell death (ICD) to elicit systemic immune responses against primary, metastatic, and recurrent tumors. However, GSH overexpression in the TME creates a reductive milieu that protects tumor cells from ROS-induced oxidative damage. T-cell insufficiency within the tumor impedes immune responses. Therefore, SDT-driven production of ROS cannot completely eradicate tumors, highlighting the need for rationally designed SS that can modulate the TME and activate antitumor immune responses. Utilizing SS and SDT to directly modulate the activation of cGAS-STING and the subsequent antitumor immune response could be a potential strategy. Conventional organic sonosensitizers, such as porphyrins and their derivatives, are mostly hydrophobic compounds that aggregate easily and have dose-dependent toxic effects. Thus, the introduction of MOFs significantly expands the dynamics of the SDT field and provides more promising SS materials. Nonetheless, SDT-induced ICD primarily targets the destruction of specific tumor cells and exerts a limited regulatory influence on the immune system, potentially resulting in inadequate therapeutic efficacy in instances of multiple tumor lesions. Combining MOFs with the STING activation function with SDT is expected to solve this dilemma. Importantly, the rationale for utilizing MOF-based systems to amplify immunotherapeutic efficacy through SDT synergy involves two key mechanisms: (i) amplifying ultrasound-triggered ROS generation to exacerbate mtDNA/nDNA damage, and (ii) releasing metal ions that synergize with the damaged DNA to potentiate cGAS-STING activation. For example, in order to achieve better SDT immunotherapy effects, Yang et al. combined the mitochondrial targeting ligand triphenylphosphine (TPP) with cobalt-based metal-organic framework (CoTCPP) nanosheets to form TPP@CoTCPP nanoagonists (Fig. <a href="#Fig9" class="usa-link">9</a>a) [<a href="#CR139" class="usa-link" aria-describedby="CR139">139</a>]. Ultrasound stimulation induced ROS production by TPP@CoTCPP, resulting in mitochondrial damage that caused mtDNA to leak into the cytoplasm, thereby activating the cGAS-STING pathway. This transformation converted the TIME into an immunogenic target for immune cells. Cobalt ions, serving as the metal node of the metal-organic framework, enhance STING activity in a cGAMP-dependent manner following their dissociation from the TPP@CoTCPP nanosheet. Consequently, this initiated a cascade of immune responses, primarily involving dendritic cell and CD8<sup>+</sup> T cell infiltration, facilitating effective immunotherapy against local tumor burden and distant metastasis. However, GSH overexpression in TME creates a reductive milieu that protects tumor cells from ROS-induced oxidative damage like in PDT. To this end, Feng’s team developed a new Z-type heterojunction structure (MnxOy/(A/R)TiO₂, MTO for short) by adjusting the heteroatom doping concentration and interface formation in MOFs (Fig. <a href="#Fig9" class="usa-link">9</a>b) [<a href="#CR147" class="usa-link" aria-describedby="CR147">147</a>]. MTO directly kills tumor cells through SDT and Chemodynamic therapy (CDT) and enhances the antitumor effect by activating the immune response. In conjunction with ICB therapy, MTO can induce long-term immunological memory and successfully suppress tumor recurrence and metastasis. In 4T1 breast cancer cells, MTO-0.9 showed significant cytotoxicity under ultrasound irradiation, with a half inhibitory concentration (IC<sub>50</sub>) of approximately 20 µg/mL. In a bilateral tumor model, MTO-0.9 combined with ultrasound irradiation and ICB therapy inhibited the primary tumor and significantly inhibited the growth of distant tumors. In healthy mice, MTO-0.9 showed good biocompatibility and did not cause significant weight loss or tissue damage. This multifunctional nanoplatform provides a new strategy for cancer treatment.</p>
<figure class="fig xbox font-sm" id="Fig9"><h5 class="obj_head">Fig. 9.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12369232_12951_2025_3669_Fig9_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6765/12369232/80f0e74e0ebc/12951_2025_3669_Fig9_HTML.jpg" loading="lazy" id="d33e2096" height="351" width="669" alt="Fig. 9"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig9/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Combination with sono-dynamic therapy. (<strong>a</strong>) Synthetic strategy of TPP@CoTCPP and mechanism of the sonodynamic-ionicimmunotherapy mechanism [<a href="#CR139" class="usa-link" aria-describedby="CR139">139</a>]. Copyright 2023, Elsevier Ltd. (<strong>b</strong>) Synthetic strategy of MnxOy/(A/R)TiO2 (MTO) and Its antitumor Effects as a Multifunctional Sonosensitizer for Self-Enhancing Synergistic Therapy [<a href="#CR147" class="usa-link" aria-describedby="CR147">147</a>]. Copyright 2025, American Chemical Society</p></figcaption></figure></section><section id="Sec20"><h4 class="pmc_sec_title">Combination with Cuproptosis and ferroptosis</h4>
<p id="Par127">Recent studies reveal that cancer cells urgently require metal ions for proliferation and progression, prompting them to reshape their metabolic network to maintain higher intracellular metal ion levels. Therefore, new therapies targeting metal ion metabolism, such as ferroptosis inducers and cuproptosis inducers, have shown broad prospects in the field of cancer treatment. Both cuproptosis and ferroptosis are accompanied by mitochondrial damage, releasing a large amount of mtDNA, and activating innate immunity through the cGAS-STING pathway [<a href="#CR58" class="usa-link" aria-describedby="CR58">58</a>, <a href="#CR198" class="usa-link" aria-describedby="CR198">198</a>–<a href="#CR202" class="usa-link" aria-describedby="CR202">202</a>]. Fe-MOFs and Cu-MOFs in MOFs are excellent inducers of ferroptosis and cuproptosis and can also induce strong innate immunity through synergistic cGAS-STING agonists.</p>
<p id="Par128">Li et al. developed Fe-MOF (MIL-101) using FeCl<sub>3</sub> and aminobenzoic acid, loaded with artesunate (DHA) to reprogram TAMs and enhance antitumor immunity (Fig. <a href="#Fig10" class="usa-link">10</a>a) [<a href="#CR141" class="usa-link" aria-describedby="CR141">141</a>]. Through the synergistic activation of ferroptosis and DNA damage signaling pathways, the cGAS-STING pathway was activated (Fig. <a href="#Fig10" class="usa-link">10</a>b), promoting the polarization of TAMs to the M1 phenotype and achieving effective immunotherapy for lung cancer (Fig. <a href="#Fig10" class="usa-link">10</a>c). However, extracellular vesicles secreted by tumor cells can induce abnormal TAM polarization, shifting M1 to M2-like TAMs and creating a TME, ultimately leading to poor immune responses [<a href="#CR203" class="usa-link" aria-describedby="CR203">203</a>, <a href="#CR204" class="usa-link" aria-describedby="CR204">204</a>]. To address this challenge, Huang et al. developed a nanometal-organic framework (MTO-Cu) by coordinating the chemotherapeutic agent mitoxantrone (MTO) with copper ions, incorporating the macropinocytosis and exosome secretion inhibitor amiloride (AMI), and surface-modifying it with chondroitin sulfate (CS) to create the CS/MTO-Cu@AMI nano adjuvant (Fig. <a href="#Fig10" class="usa-link">10</a>d) [<a href="#CR159" class="usa-link" aria-describedby="CR159">159</a>]. This nanoadjuvant induces cuproptosis-related mitochondrial malfunction, resulting in the depletion of energy necessary for macropinocytosis and exosome release, whereas AMI directly obstructs these processes. Moreover, the damaged dsDNA produced after CS/MTO-Cu@AMI therapy activates the cGAS-STING pathway, augmenting antitumor immunity.</p>
<figure class="fig xbox font-sm" id="Fig10"><h5 class="obj_head">Fig. 10.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12369232_12951_2025_3669_Fig10_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6765/12369232/b4b0f116cac2/12951_2025_3669_Fig10_HTML.jpg" loading="lazy" id="d33e2205" height="729" width="669" alt="Fig. 10"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig10/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Combination with cuproptosis and ferroptosis. (<strong>a</strong>) Synthetic strategy of DHA@MIL-101 and Mechanistic illustration of DHA@MIL-101 in inducing M1 polarization of TAM via ferroptosis-mediated cGAS/STING pathway activation. (<strong>b</strong>) Efficacy of DHA@MIL-101 activate cGAS/STING pathway. (<strong>c</strong>) Antitumor efficacy of DHA@MIL-101 in vivo: Tumor growth curve of mice after differential therapeutic interventions [<a href="#CR141" class="usa-link" aria-describedby="CR141">141</a>]. Copyright 2023, Wiley-VCH GmbH. (<strong>d</strong>) Synthetic strategy of CS/MTO-Cu@AMI and its role in inducing cuproptosis and simultaneously stimulating the innate immune defenses against tumor [<a href="#CR159" class="usa-link" aria-describedby="CR159">159</a>]. Copyright 2023, Wiley‐VCH GmbH. (<strong>e</strong>) Multidimensional immunomodulatory strategy of F@D-CHTP SN-MF: Graphical representation of dual-pathway-driven (ferroptosis and cuproptosis) STING activation coupled with vascular normalization for amplified antitumor immunity [<a href="#CR142" class="usa-link" aria-describedby="CR142">142</a>]. Copyright 2024, Elsevier Inc</p></figcaption></figure><p id="Par129">Single metal therapy may not achieve satisfactory antitumor effects. Synergistic induction of cuproptosis and ferroptosis can overcome the limited efficacy of independent treatments [<a href="#CR205" class="usa-link" aria-describedby="CR205">205</a>, <a href="#CR206" class="usa-link" aria-describedby="CR206">206</a>]. Because studies have shown that in addition to promoting GSH depletion to produce ·OH [<a href="#CR207" class="usa-link" aria-describedby="CR207">207</a>–<a href="#CR209" class="usa-link" aria-describedby="CR209">209</a>], Cu²⁺ can also inhibit the formation of iron-sulfur clusters, increase the suicidal uptake of Fe²⁺ by malignant tumors, and thus induce severe ferroptosis [<a href="#CR210" class="usa-link" aria-describedby="CR210">210</a>, <a href="#CR211" class="usa-link" aria-describedby="CR211">211</a>]. Therefore, the ROS storm caused by ferroptosis and copper death in tumor cells leads to many double-stranded DNA breaks. Combined with agonists such as Zn<sup>2+</sup> or Mn<sup>2+</sup>, it can better stimulate cGAS-STING. However, the ultimate goal of immune activation is to infiltrate effector T cells. Regrettably, aberrant and dysfunctional tumor vasculature obstructs the infiltration and efficacy of effector T cells. Following the research mentioned above, Zhao et al. engineered a defective copper-based MOFs single-site nanozyme (F@D-CHTP SN) co-encapsulated with MSA-2 and furiquintinib, an inhibitor of the vascular endothelial growth factor receptor (VEGFR) (Fig. <a href="#Fig10" class="usa-link">10</a>e) [<a href="#CR142" class="usa-link" aria-describedby="CR142">142</a>]. The conjugated organic ligands and prominently exposed unsaturated Cu-O2 single-atom sites confer exceptional reactive oxygen species generation activity to F@D-CHTP SN, which can disturb cellular redox equilibrium, compromise mitochondrial function, and ultimately trigger copper death and ferroptosis, thereby augmenting tumor immunogenicity. Concurrently, intratumoral STING activation and VEGFR inhibition synergistically facilitate tumor vascular normalization, remodel the immunosuppressive milieu, augment T-cell infiltration, and increase tumor suppression. Our research illustrates the viability and substantial synergistic impact of triggering a cascade of augmented immunity by integrating copper-induced cell death and ferroptosis with STING activation and tumor vascular normalization.</p></section><section id="Sec21"><h4 class="pmc_sec_title">Combination with chemodynamic therapy</h4>
<p id="Par131">CDT utilizes Fenton or Fenton-like reactions within the acidic tumor microenvironment to catalytically convert H₂O₂ present in tumor tissues into highly reactive ·OH. These ·OH radicals induce DNA damage. However, the therapeutic efficacy of CDT is often compromised by the limited endogenous H₂O₂ concentration within tumor cells.Combining CDT with immunotherapy offers a strategy to enhance tumor cell killing. CDT-induced DNA damage can directly engage cGAS, thereby activating the cGAS-STING signaling pathway and eliciting antitumor immunity. The rationale for employing MOFs to augment CDT-induced DNA damage encompasses two key aspects: (i) Metal Ion Dual Functionality: Metal ions released during CDT not only mediate the chemodynamic process but also serve as agonists to activate the cGAS-STING pathway, achieving synergistic therapeutic effects. (ii) TME Modulation: MOFs can be engineered to modulate the TME, addressing factors that limit CDT efficiency, such as the elevated GSH levels characteristic of suppressive tumor microenvironments.</p>
<p id="Par132">Li et al. developed an iron-based metal-organic framework (Fe-MOF) to co-deliver therapeutic agents, encapsulated within an outermost layer of manganese dioxide (MnO₂) (Fig. <a href="#Fig11" class="usa-link">11</a>a). Within this system, Fe²⁺/Fe³⁺ ions mediate the chemodynamic effects. The MnO₂ coating serves a dual purpose: (i) It consumes GSH while concurrently generating ·OH radicals, synergistically enhancing the Fe-ion-driven chemodynamic process. (ii) It activates the cGAS-STING signaling pathway The Fe-MOF@MnO₂@PB@HA (FMPH) nanosystem leverages hyaluronic acid (HA) to enhance tumor-targeting capability. The released Prussian (PB) effectively disrupts angiogenesis and impedes cell proliferation. The MnO₂ component functions to deplete GSH and exerts CDT by generating hydroxyl ·OH. PTT synergizes with ·OH to cooperatively induce ICD in tumor cells. Concurrently, the released Mn²⁺ ions both catalyze Fenton-like reactions and directly activate the cGAS-STING signaling pathway. These multimodal mechanisms act synergistically to amplify the efficacy of immunotherapy. Tumor cells treated with FMPH exhibited potent apoptosis (Fig. <a href="#Fig11" class="usa-link">11</a>b). In 4T1 tumor-bearing mouse models, FMPH demonstrated significant antitumor effects. Biocompatibility assessments included an in vitro hemolysis assay and evaluation of the impact of FMPH treatment on major organs in mice in vivo (Fig. <a href="#Fig11" class="usa-link">11</a>c). Collectively, both in vitro and in vivo results confirmed the favorable biocompatibility and safety profile of the FMPH nanosystem [<a href="#CR146" class="usa-link" aria-describedby="CR146">146</a>].</p>
<figure class="fig xbox font-sm" id="Fig11"><h5 class="obj_head">Fig. 11.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12369232_12951_2025_3669_Fig11_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6765/12369232/838372beefe2/12951_2025_3669_Fig11_HTML.jpg" loading="lazy" id="d33e2246" height="309" width="669" alt="Fig. 11"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig11/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Combination with Chemodynamic Therapy. (<strong>a</strong>) Synthetic strategy of FMPH and Mechanistic illustration of cGAS/STING pathway activation. (<strong>b</strong>) Efficacy of FMPH activate cGAS/STING pathway. (<strong>c</strong>) Antitumor efficacy of FMPH in vivo: Tumor growth curve of mice after differential therapeutic interventions [<a href="#CR146" class="usa-link" aria-describedby="CR146">146</a>]. Copyright 2025, American Chemical Society</p></figcaption></figure></section></section></section><section id="Sec22"><h2 class="pmc_sec_title">Conclusions and future perspectives</h2>
<p id="Par134">Immunotherapy has transformed cancer treatment; nonetheless, its effectiveness is constrained in numerous malignancies because of inadequate immunogenicity. The cGAS-STING signaling system, which connects innate and adaptive immunity, has become a prospective therapeutic target in immuno-oncology. Notwithstanding considerable progress in creating STING agonists, problems remain regarding their stability, delivery efficacy, and therapeutic accuracy. MOFs, characterized by their exact nanostructures, adjustable porosity, and biocompatibility, present a promising platform to address these limitations and improve immunotherapy results. In this review, we aimed to comprehensively review the progress of activation of cGAS-STING by MOFs for immunotherapy. We delineate the structure and route mechanisms associated with cGAS-STING-related proteins and categorize the prevalent types of agonists and their modes of action. We focus on outlining the unique advantages of MOFs in activating the cGAS-STING pathway. In contrast to conventional agonists, which have disadvantages such as susceptibility to catabolism and limited activation efficiency, MOFs have advantages in activating the cGAS-STING pathway for immunotherapy: (i) utilizing MOFs as nanocarriers to deliver STING agonists, which enhances the delivery and efficiency of STING agonists; (ii) employing metal components in MOFs as direct STING activators; and (iii) facilitating MOFs-enabled combination therapies that integrate chemotherapy, PDT, PTT, RT-RDT, and CDT with STING activation. In this review, we cross-sectioned the MOFs introduced in this review, and we can classify them into two main categories: (1) the cGAS-STING pathway activated by ions in the MOFs themselves; (2) the various drugs loaded in the MOFs (the loaded drugs can be classified into two categories: chemotherapeutic drugs, photosensitizers, etc., which can activate the cGAS-STING pathway by inducing DNA damage and direct STING agonists.) MOFs, as carriers for loaded drugs, have the advantages of optimized particle sizes and appropriate stability by modifying the surface and changing the synthesis method. Current research mainly emphasizes MOFs as agonist carriers or metal ionbased activators, with inadequate focus on activation processes facilitated by organic ligands or the comprehensive MOF structure.</p>
<p id="Par135">Various mechanisms and strategies to activate the cGAS-STING pathway based on MOFs were elucidated. In addition to simple delivery of ions and STING agonists, most notably MOFs-based delivery systems are used in immunotherapy combining multiple therapeutic treatments. Whether combined with chemotherapy, sonodynamic, photodynamic, or any other therapy, the underlying mechanism is to enhance DNA damage and thus immune activation of the cGAS-STING pathway. However, combination therapeutic approaches offer both promise and obstacles. Although MOFs facilitate the simultaneous delivery of immunological agents, photosensitizers, and diagnostic probes, this combinatorial strategy necessitates meticulous attention to the mechanisms of action: (i) possible antagonistic interactions among therapeutic components; (ii) intricate formulation procedures; and (iii) the potential for excessive immune activation. Consequently, the formulation of combination therapies must be informed by a comprehensive comprehension of the molecular interactions among various treatment modalities, guaranteeing synergistic rather than antagonistic outcomes. Future research should develop more focused mechanistic studies of combination therapies that equilibrate therapeutic efficacy with immune regulation while ensuring robust safety profiles via thorough preclinical evaluation.</p>
<p id="Par136">A review of MOFs systems capable of activating the cGAS-STING pathway showed that MOFs systems have shown promising results in the preclinical stage. Although promising, there are still many hurdles to overcome to cross over to the clinical stage:</p>
<p id="Par137">1) Intricate formulation procedures. The preparation of functionalized MOFs usually involves complex synthetic steps. To achieve clinical applications, it is necessary to ensure that the materials can be produced easily in large quantities and maintain functional stability.</p>
<p id="Par138">2) Safety. The in vivo safety and compatibility of MOFs for clinical use needs to be more validated than simple experimental studies in the preclinical stage. Toxicity and biocompatibility of MOFs are still the major influencing factors for the lack of large-scale clinical use. Therefore, in the future, we need to focus more on systematically examining the pharmacokinetics and biodistribution of MOFs modules to enhance their therapeutic index and safety profile.</p>
<p id="Par139">3) In-depth study of the mechanism: As a chemically synthesized nanomaterial, the mechanism of action of MOFs in vivo and the morphology of their action in vivo still need to be further investigated. Currently, the study is superficial, and in the future, researchers need to focus on exploring the in-depth mechanism of its action, so as to provide a more powerful scientific basis for the application of MOFs in clinical translation.</p>
<p id="Par140">In summary, although MOFs-mediated cGAS-STING activation signifies a promising advancement in cancer immunotherapy, its practical implementation necessitates overcoming existing constraints via interdisciplinary research, new material development, and comprehensive assessment of therapeutic results. The ongoing progress in this domain offers significant potential for creating more effective and accurate cancer immunotherapies.</p></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgements</h2>
<p>Not applicable.</p></section><section id="glossary1" class="glossary"><h2 class="pmc_sec_title">Abbreviations</h2>
<dl class="def-list">
<dt>cGAS</dt>
<dd><p id="Par2">Cyclic GMP-AMP synthase</p></dd>
<dt>STING</dt>
<dd><p id="Par3">Stimulator of interferon genes</p></dd>
<dt>MOFs</dt>
<dd><p id="Par4">Metal-organic frameworks</p></dd>
<dt>ICB</dt>
<dd><p id="Par5">Immune checkpoint blockade therapy</p></dd>
<dt>ACT</dt>
<dd><p id="Par6">Adoptive Cell Transfer Therapy</p></dd>
<dt>mAbs</dt>
<dd><p id="Par7">Monoclonal antibodies</p></dd>
<dt>ICIs</dt>
<dd><p id="Par8">Immune checkpoint inhibitors</p></dd>
<dt>TIME</dt>
<dd><p id="Par9">Immunosuppressive tumor microenvironment</p></dd>
<dt>IFN-I</dt>
<dd><p id="Par10">Type I interferons</p></dd>
<dt>VEGF</dt>
<dd><p id="Par11">Vascular endothelial growth factor</p></dd>
<dt>CDNs</dt>
<dd><p id="Par12">Cyclic dinucleotides</p></dd>
<dt>RT</dt>
<dd><p id="Par13">Radiotherapy</p></dd>
<dt>PDT</dt>
<dd><p id="Par14">Photodynamic therapy</p></dd>
<dt>PTT</dt>
<dd><p id="Par15">Photothermal therapy</p></dd>
<dt>SDT</dt>
<dd><p id="Par16">Sonodynamic therapy</p></dd>
<dt>hcGAS</dt>
<dd><p id="Par17">Human cGAS</p></dd>
<dt>NTase</dt>
<dd><p id="Par18">Nucleotidyltransferase</p></dd>
<dt>Ser</dt>
<dd><p id="Par19">Serine</p></dd>
<dt>Thr</dt>
<dd><p id="Par20">Threonine</p></dd>
<dt>GTP</dt>
<dd><p id="Par21">Guanosine triphosphate</p></dd>
<dt>ATP</dt>
<dd><p id="Par22">Adenosine triphosphate</p></dd>
<dt>cGAMP</dt>
<dd><p id="Par23">2’,3’-cyclic-GMP-AMP</p></dd>
<dt>PRR</dt>
<dd><p id="Par24">Pattern recognition receptor</p></dd>
<dt>ER</dt>
<dd><p id="Par25">Endoplasmic reticulum</p></dd>
<dt>hSTING</dt>
<dd><p id="Par26">Human STING</p></dd>
<dt>CTD</dt>
<dd><p id="Par27">C-terminal domain</p></dd>
<dt>LBD</dt>
<dd><p id="Par28">Ligand-binding domain</p></dd>
<dt>CTT</dt>
<dd><p id="Par29">C-terminal tail</p></dd>
<dt>TBK1</dt>
<dd><p id="Par30">TANK-binding kinase 1</p></dd>
<dt>IRF3</dt>
<dd><p id="Par31">Interferon regulatory factor 3</p></dd>
<dt>TBM</dt>
<dd><p id="Par32">TANK-binding kinase 1-binding motif</p></dd>
<dt>LUAD</dt>
<dd><p id="Par33">Lung adenocarcinoma</p></dd>
<dt>c-di-GMP</dt>
<dd><p id="Par34">Cyclic diguanosine monophosphate</p></dd>
<dt>c-di-AMP</dt>
<dd><p id="Par35">Cyclic diadenosine monophosphate</p></dd>
<dt>ENPP1</dt>
<dd><p id="Par36">Exonucleotide pyrophosphatase/phosphodiesterase</p></dd>
<dt>cAIMP</dt>
<dd><p id="Par37">Cyclic adenosine-inosine monophosphate</p></dd>
<dt>FAA</dt>
<dd><p id="Par38">Flavone acetic acid</p></dd>
<dt>DMXAA</dt>
<dd><p id="Par39">5,6-dimethylxanthenone-4-acetic acid</p></dd>
<dt>CMA</dt>
<dd><p id="Par40">10-carboxymethyl-9-acridanone</p></dd>
<dt>mSTING</dt>
<dd><p id="Par41">Murine STING</p></dd>
<dt>diABZI</dt>
<dd><p id="Par42">Dimeric aminobenzimidazole</p></dd>
<dt>APCs</dt>
<dd><p id="Par43">Antigen-presenting cells</p></dd>
<dt>H<sub>2</sub>O<sub>2</sub>
</dt>
<dd><p id="Par44">Hydrogen peroxide</p></dd>
<dt>ROS</dt>
<dd><p id="Par45">Reactive oxygen species</p></dd>
<dt>•OH</dt>
<dd><p id="Par46">Hydroxyl radicals</p></dd>
<dt>mtDNA</dt>
<dd><p id="Par47">Mitochondrial DNA</p></dd>
<dt>H2DBP</dt>
<dd><p id="Par48">5,15-di(p-benzoato) porphyrin</p></dd>
<dt>2-MIM</dt>
<dd><p id="Par49">2-Methylimidazole</p></dd>
<dt>THBQ</dt>
<dd><p id="Par50">Tetrahydroxy-1,4-benzoquinone</p></dd>
<dt>TCPP</dt>
<dd><p id="Par51">4-tert-Butylbenzoic acid</p></dd>
<dt>H3BTC</dt>
<dd><p id="Par52">1,3,5-benzenetricarboxylic acid</p></dd>
<dt>2-ATA</dt>
<dd><p id="Par53">2-aminoterephthalic acid</p></dd>
<dt>DTDA</dt>
<dd><p id="Par54">Dithiodiacetic acid</p></dd>
<dt>TEA</dt>
<dd><p id="Par55">Triethylamine</p></dd>
<dt>Co</dt>
<dd><p id="Par56">Cobalt</p></dd>
<dt>Cu</dt>
<dd><p id="Par57">Copper</p></dd>
<dt>Fe</dt>
<dd><p id="Par58">Iron</p></dd>
<dt>RBCM</dt>
<dd><p id="Par59">Red blood cell membranes</p></dd>
<dt>PTX</dt>
<dd><p id="Par60">Paclitaxel</p></dd>
<dt>OX</dt>
<dd><p id="Par61">Oxaliplatin</p></dd>
<dt>DOX</dt>
<dd><p id="Par62">Doxorubicin</p></dd>
<dt>TGI</dt>
<dd><p id="Par63">Tumor growth inhibition</p></dd>
<dt>CRT</dt>
<dd><p id="Par64">Calreticulin</p></dd>
<dt>HMGB-1</dt>
<dd><p id="Par65">High-mobility group 1</p></dd>
<dt>DAMPs</dt>
<dd><p id="Par66">Damage-associated molecular patterns</p></dd>
<dt>Hf</dt>
<dd><p id="Par67">Hafnium</p></dd>
<dt>Th</dt>
<dd><p id="Par68">Thorium</p></dd>
<dt>Ru</dt>
<dd><p id="Par69">Ruthenium</p></dd>
<dt>Ir</dt>
<dd><p id="Par70">Iridium</p></dd>
<dt>PS</dt>
<dd><p id="Par71">Photosensitizers</p></dd>
<dt>
<sup>1</sup>O<sub>2</sub>
</dt>
<dd><p id="Par72">Singlet oxygen</p></dd>
<dt>GSH</dt>
<dd><p id="Par73">Glutathione</p></dd>
<dt>NIR</dt>
<dd><p id="Par74">Near-infrared</p></dd>
<dt>ZIF-8</dt>
<dd><p id="Par75">Zeolitic imidazolate framework-8</p></dd>
<dt>HSPs</dt>
<dd><p id="Par76">Heat shock proteins</p></dd>
<dt>SS</dt>
<dd><p id="Par77">Sonosensitizers</p></dd>
<dt>US</dt>
<dd><p id="Par78">Ultrasound</p></dd>
<dt>ICD</dt>
<dd><p id="Par79">Immunogenic cell death</p></dd>
<dt>CDT</dt>
<dd><p id="Par80">Chemodynamic therapy</p></dd>
<dt>MTO</dt>
<dd><p id="Par81">Mitoxantrone</p></dd>
<dt>AMI</dt>
<dd><p id="Par82">Amiloride</p></dd>
<dt>CS</dt>
<dd><p id="Par83">Chondroitin sulfate</p></dd>
<dt>VEGFR</dt>
<dd><p id="Par84">Vascular endothelial growth factor receptor</p></dd>
<dt>MnO₂</dt>
<dd><p id="Par85">Manganese dioxide</p></dd>
<dt>HA</dt>
<dd><p id="Par86">Hyaluronic acid</p></dd>
<dt>PB</dt>
<dd><p id="Par87">Prussian</p></dd>
</dl></section><section id="notes1"><h2 class="pmc_sec_title">Author contributions</h2>
<p>Conceptualization Z.S., H.C.; writing-original draft preparation, S.Z., W.X., W.L.; writing-review and editing, W.L., Z.S., Y.Z., H.C.; funding acquisition, H.C., All authors have read and agreed to the published version of the manuscript.</p></section><section id="notes2"><h2 class="pmc_sec_title">Funding</h2>
<p>This work was supported by the Capital Medical University Outstanding Young Talents Project (No. B2407).</p></section><section id="notes3"><h2 class="pmc_sec_title">Data availability</h2>
<p>No datasets were generated or analysed during the current study.</p></section><section id="notes4"><h2 class="pmc_sec_title">Declarations</h2>
<section id="FPar1"><h3 class="pmc_sec_title">Ethics approval and consent to participate</h3>
<p id="Par141">Not applicable.</p></section><section id="FPar2"><h3 class="pmc_sec_title">Consent for publication</h3>
<p id="Par142">All authors have provided consent for the manuscript to be published in Journal of Nanobiotechnology.</p></section><section id="FPar3"><h3 class="pmc_sec_title">Competing interests</h3>
<p id="Par143">The authors declare no competing interests.</p></section></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="fn1">
<p><strong>Publisher’s note</strong></p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</div></div></section><section id="_ci93_" lang="en" class="contrib-info"><h2 class="pmc_sec_title">Contributor Information</h2>
<p>Wenjing Liu, Email: liuwenjing@ustc.edu.</p>
<p>Hongqian Chu, Email: chuhongqian@bjxkyy.cn.</p></section><section id="Bib1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="Bib1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="CR1">
<span class="label">1.</span><cite>Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:480–9.
</cite> [<a href="https://doi.org/10.1038/nature10673" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3967235/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22193102/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mellman%20I,%20Coukos%20G,%20Dranoff%20G.%20Cancer%20immunotherapy%20comes%20of%20age.%20Nature.%202011;480:480%E2%80%939." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR2">
<span class="label">2.</span><cite>McNutt M. Cancer Immunotherapy Sci. 2013;342:1432–3.</cite> [<a href="https://scholar.google.com/scholar_lookup?McNutt%20M.%20Cancer%20Immunotherapy%20Sci.%202013;342:1432%E2%80%933." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR3">
<span class="label">3.</span><cite>Sanmamed MF, Chen L. A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell. 2018;175:313–26.
</cite> [<a href="https://doi.org/10.1016/j.cell.2018.09.035" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6538253/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30290139/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sanmamed%20MF,%20Chen%20L.%20A%20paradigm%20shift%20in%20cancer%20immunotherapy:%20from%20enhancement%20to%20normalization.%20Cell.%202018;175:313%E2%80%9326." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR4">
<span class="label">4.</span><cite>Dagher OK, Schwab RD, Brookens SK, Posey AD. Advances in cancer immunotherapies. Cell. 2023;186:1814.
</cite> [<a href="https://doi.org/10.1016/j.cell.2023.02.039" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37059073/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Dagher%20OK,%20Schwab%20RD,%20Brookens%20SK,%20Posey%20AD.%20Advances%20in%20cancer%20immunotherapies.%20Cell.%202023;186:1814." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR5">
<span class="label">5.</span><cite>Liu Ye, Wang Y, Yang Y, Weng L, Wu Q, Zhang J, Zhao P, Fang L, Shi Y, Wang P. Emerging phagocytosis checkpoints in cancer immunotherapy. Signal Transduct Target Ther. 2023;8: 104.
</cite> [<a href="https://doi.org/10.1038/s41392-023-01365-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9990587/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36882399/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Liu%20Ye,%20Wang%20Y,%20Yang%20Y,%20Weng%20L,%20Wu%20Q,%20Zhang%20J,%20Zhao%20P,%20Fang%20L,%20Shi%20Y,%20Wang%20P.%20Emerging%20phagocytosis%20checkpoints%20in%20cancer%20immunotherapy.%20Signal%20Transduct%20Target%20Ther.%202023;8:%20104." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR6">
<span class="label">6.</span><cite>Weiner LM, Dhodapkar MV, Ferrone S. Monoclonal antibodies for cancer immunotherapy. Lancet. 2009;373:1033–40.
</cite> [<a href="https://doi.org/10.1016/S0140-6736(09)60251-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2677705/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19304016/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Weiner%20LM,%20Dhodapkar%20MV,%20Ferrone%20S.%20Monoclonal%20antibodies%20for%20cancer%20immunotherapy.%20Lancet.%202009;373:1033%E2%80%9340." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR7">
<span class="label">7.</span><cite>Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol. 2010;10:317–27.
</cite> [<a href="https://doi.org/10.1038/nri2744" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3508064/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20414205/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Weiner%20LM,%20Surana%20R,%20Wang%20S.%20Monoclonal%20antibodies:%20versatile%20platforms%20for%20cancer%20immunotherapy.%20Nat%20Rev%20Immunol.%202010;10:317%E2%80%9327." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR8">
<span class="label">8.</span><cite>Wu Y, Yang Z, Cheng K, Bi H, Chen J. Small molecule-based immunomodulators for cancer therapy. Acta Pharm Sin B. 2022;12:4287–308.
</cite> [<a href="https://doi.org/10.1016/j.apsb.2022.11.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9764074/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36562003/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wu%20Y,%20Yang%20Z,%20Cheng%20K,%20Bi%20H,%20Chen%20J.%20Small%20molecule-based%20immunomodulators%20for%20cancer%20therapy.%20Acta%20Pharm%20Sin%20B.%202022;12:4287%E2%80%93308." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR9">
<span class="label">9.</span><cite>Offringa R, Kötzner L, Huck B, Urbahns K. The expanding role for small molecules in immuno-oncology. Nat Rev Drug Discov. 2022;21:821–40.
</cite> [<a href="https://doi.org/10.1038/s41573-022-00538-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35982333/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Offringa%20R,%20K%C3%B6tzner%20L,%20Huck%20B,%20Urbahns%20K.%20The%20expanding%20role%20for%20small%20molecules%20in%20immuno-oncology.%20Nat%20Rev%20Drug%20Discov.%202022;21:821%E2%80%9340." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR10">
<span class="label">10.</span><cite>Propper DJ, Balkwill FR. Harnessing cytokines and chemokines for cancer therapy. Nat Rev Clin Oncol. 2022;19:237–53.
</cite> [<a href="https://doi.org/10.1038/s41571-021-00588-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34997230/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Propper%20DJ,%20Balkwill%20FR.%20Harnessing%20cytokines%20and%20chemokines%20for%20cancer%20therapy.%20Nat%20Rev%20Clin%20Oncol.%202022;19:237%E2%80%9353." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR11">
<span class="label">11.</span><cite>Yi M, Li T, Niu M, Zhang H, Wu Y, Wu K, Dai Z. Targeting cytokine and chemokine signaling pathways for cancer therapy. Signal Transduct Target Ther. 2024;9: 176.
</cite> [<a href="https://doi.org/10.1038/s41392-024-01868-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11275440/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39034318/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yi%20M,%20Li%20T,%20Niu%20M,%20Zhang%20H,%20Wu%20Y,%20Wu%20K,%20Dai%20Z.%20Targeting%20cytokine%20and%20chemokine%20signaling%20pathways%20for%20cancer%20therapy.%20Signal%20Transduct%20Target%20Ther.%202024;9:%20176." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR12">
<span class="label">12.</span><cite>Briukhovetska D, Dörr J, Endres S, Libby P, Dinarello CA, Kobold S. Interleukins in cancer: from biology to therapy. Nat Rev Cancer. 2021;21:481–99.
</cite> [<a href="https://doi.org/10.1038/s41568-021-00363-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8173513/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34083781/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Briukhovetska%20D,%20D%C3%B6rr%20J,%20Endres%20S,%20Libby%20P,%20Dinarello%20CA,%20Kobold%20S.%20Interleukins%20in%20cancer:%20from%20biology%20to%20therapy.%20Nat%20Rev%20Cancer.%202021;21:481%E2%80%9399." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR13">
<span class="label">13.</span><cite>Feng B, Bai Z, Zhou X, Zhao Y, Xie Y-Q, Huang X, Liu Y, Enbar T, Li R, Wang Y. The type 2 cytokine Fc–IL-4 revitalizes exhausted CD8<sup>+</sup> T cells against cancer. Nature. 2024;634:712–20.
</cite> [<a href="https://doi.org/10.1038/s41586-024-07962-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11485240/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39322665/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Feng%20B,%20Bai%20Z,%20Zhou%20X,%20Zhao%20Y,%20Xie%20Y-Q,%20Huang%20X,%20Liu%20Y,%20Enbar%20T,%20Li%20R,%20Wang%20Y.%20The%20type%202%20cytokine%20Fc%E2%80%93IL-4%20revitalizes%20exhausted%20CD8+%20T%20cells%20against%20cancer.%20Nature.%202024;634:712%E2%80%9320." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR14">
<span class="label">14.</span><cite>Hernandez R, Põder J, LaPorte KM, Malek TR. Engineering IL-2 for immunotherapy of autoimmunity and cancer. Nat Rev Immunol. 2022;22:614–28.
</cite> [<a href="https://doi.org/10.1038/s41577-022-00680-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35217787/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hernandez%20R,%20P%C3%B5der%20J,%20LaPorte%20KM,%20Malek%20TR.%20Engineering%20IL-2%20for%20immunotherapy%20of%20autoimmunity%20and%20cancer.%20Nat%20Rev%20Immunol.%202022;22:614%E2%80%9328." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR15">
<span class="label">15.</span><cite>Chen Y, Chen X, Bao W, Liu G, Wei W, Ping Y. An oncolytic virus–T cell chimera for cancer immunotherapy. Nat Biotechnol. 2024;42:1876–87.
</cite> [<a href="https://doi.org/10.1038/s41587-023-02118-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38336902/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chen%20Y,%20Chen%20X,%20Bao%20W,%20Liu%20G,%20Wei%20W,%20Ping%20Y.%20An%20oncolytic%20virus%E2%80%93T%20cell%20chimera%20for%20cancer%20immunotherapy.%20Nat%20Biotechnol.%202024;42:1876%E2%80%9387." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR16">
<span class="label">16.</span><cite>Tian Y, Xie D, Yang L. Engineering strategies to enhance oncolytic viruses in cancer immunotherapy. Signal Transduct Target Ther. 2022;7: 117.
</cite> [<a href="https://doi.org/10.1038/s41392-022-00951-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8987060/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35387984/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Tian%20Y,%20Xie%20D,%20Yang%20L.%20Engineering%20strategies%20to%20enhance%20oncolytic%20viruses%20in%20cancer%20immunotherapy.%20Signal%20Transduct%20Target%20Ther.%202022;7:%20117." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR17">
<span class="label">17.</span><cite>Shalhout SZ, Miller DM, Emerick KS, Kaufman HL. Therapy with oncolytic viruses: progress and challenges. Nat Rev Clin Oncol. 2023;20:160–77.
</cite> [<a href="https://doi.org/10.1038/s41571-022-00719-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36631681/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Shalhout%20SZ,%20Miller%20DM,%20Emerick%20KS,%20Kaufman%20HL.%20Therapy%20with%20oncolytic%20viruses:%20progress%20and%20challenges.%20Nat%20Rev%20Clin%20Oncol.%202023;20:160%E2%80%9377." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR18">
<span class="label">18.</span><cite>Lin MJ, Svensson-Arvelund J, Lubitz GS, Marabelle A, Melero I, Brown BD, Brody JD. Cancer vaccines: the next immunotherapy frontier. Nat Cancer. 2022;3:911–26.
</cite> [<a href="https://doi.org/10.1038/s43018-022-00418-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35999309/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lin%20MJ,%20Svensson-Arvelund%20J,%20Lubitz%20GS,%20Marabelle%20A,%20Melero%20I,%20Brown%20BD,%20Brody%20JD.%20Cancer%20vaccines:%20the%20next%20immunotherapy%20frontier.%20Nat%20Cancer.%202022;3:911%E2%80%9326." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR19">
<span class="label">19.</span><cite>Fan T, Zhang M, Yang J, Zhu Z, Cao W, Dong C. Therapeutic cancer vaccines: advancements, challenges, and prospects. Signal Transduct Target Ther. 2023;8: 450.
</cite> [<a href="https://doi.org/10.1038/s41392-023-01674-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10716479/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38086815/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Fan%20T,%20Zhang%20M,%20Yang%20J,%20Zhu%20Z,%20Cao%20W,%20Dong%20C.%20Therapeutic%20cancer%20vaccines:%20advancements,%20challenges,%20and%20prospects.%20Signal%20Transduct%20Target%20Ther.%202023;8:%20450." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR20">
<span class="label">20.</span><cite>Zhang Y, Ma S, Liu X, Xu Y, Zhao J, Si X, Li H, Huang Z, Wang Z, Tang Z. Supramolecular assembled programmable nanomedicine as in situ cancer vaccine for cancer immunotherapy. Adv Mater. 2021;33:2007293.</cite> [<a href="https://doi.org/10.1002/adma.202007293" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33448050/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20Y,%20Ma%20S,%20Liu%20X,%20Xu%20Y,%20Zhao%20J,%20Si%20X,%20Li%20H,%20Huang%20Z,%20Wang%20Z,%20Tang%20Z.%20Supramolecular%20assembled%20programmable%20nanomedicine%20as%20in%20situ%20cancer%20vaccine%20for%20cancer%20immunotherapy.%20Adv%20Mater.%202021;33:2007293." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR21">
<span class="label">21.</span><cite>Bo Y, Wang H. Biomaterial-based in situ cancer vaccines. Adv Mater. 2024;36:2210452.</cite> [<a href="https://doi.org/10.1002/adma.202210452" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10408245/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36649567/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Bo%20Y,%20Wang%20H.%20Biomaterial-based%20in%20situ%20cancer%20vaccines.%20Adv%20Mater.%202024;36:2210452." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR22">
<span class="label">22.</span><cite>Kraehenbuehl L, Weng C-H, Eghbali S, Wolchok JD, Merghoub T. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. Nat Rev Clin Oncol. 2022;19:37–50.
</cite> [<a href="https://doi.org/10.1038/s41571-021-00552-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34580473/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kraehenbuehl%20L,%20Weng%20C-H,%20Eghbali%20S,%20Wolchok%20JD,%20Merghoub%20T.%20Enhancing%20immunotherapy%20in%20cancer%20by%20targeting%20emerging%20immunomodulatory%20pathways.%20Nat%20Rev%20Clin%20Oncol.%202022;19:37%E2%80%9350." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR23">
<span class="label">23.</span><cite>Khan S, Gerber DE. Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: a review. Semin Cancer Biol. 2020;64:93–101.
</cite> [<a href="https://doi.org/10.1016/j.semcancer.2019.06.012" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6980444/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31330185/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Khan%20S,%20Gerber%20DE.%20Autoimmunity,%20checkpoint%20inhibitor%20therapy%20and%20immune-related%20adverse%20events:%20a%20review.%20Semin%20Cancer%20Biol.%202020;64:93%E2%80%93101." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR24">
<span class="label">24.</span><cite>Kennedy LB, Salama AK. A review of cancer immunotherapy toxicity. CA Cancer J Clin. 2020;70:86–104.
</cite> [<a href="https://doi.org/10.3322/caac.21596" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31944278/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kennedy%20LB,%20Salama%20AK.%20A%20review%20of%20cancer%20immunotherapy%20toxicity.%20CA%20Cancer%20J%20Clin.%202020;70:86%E2%80%93104." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR25">
<span class="label">25.</span><cite>Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Chávez A, Keegan N, Khamashta MA, Lambotte O, Mariette X, Prat A, Suárez-Almazor ME. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6:38.
</cite> [<a href="https://doi.org/10.1038/s41572-020-0160-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9728094/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32382051/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ramos-Casals%20M,%20Brahmer%20JR,%20Callahan%20MK,%20Flores-Ch%C3%A1vez%20A,%20Keegan%20N,%20Khamashta%20MA,%20Lambotte%20O,%20Mariette%20X,%20Prat%20A,%20Su%C3%A1rez-Almazor%20ME.%20Immune-related%20adverse%20events%20of%20checkpoint%20inhibitors.%20Nat%20Rev%20Dis%20Primers.%202020;6:38." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR26">
<span class="label">26.</span><cite>Haslam A, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open. 2019;2:e192535.
</cite> [<a href="https://doi.org/10.1001/jamanetworkopen.2019.2535" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6503493/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31050774/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Haslam%20A,%20Prasad%20V.%20Estimation%20of%20the%20percentage%20of%20US%20patients%20with%20cancer%20who%20are%20eligible%20for%20and%20respond%20to%20checkpoint%20inhibitor%20immunotherapy%20drugs.%20JAMA%20Netw%20Open.%202019;2:e192535." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR27">
<span class="label">27.</span><cite>Korman AJ, Garrett-Thomson SC, Lonberg N. The foundations of immune checkpoint Blockade and the Lpilimumab approval decennial. Nat Rev Drug Discov. 2022;21:509–28.
</cite> [<a href="https://doi.org/10.1038/s41573-021-00345-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34937915/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Korman%20AJ,%20Garrett-Thomson%20SC,%20Lonberg%20N.%20The%20foundations%20of%20immune%20checkpoint%20Blockade%20and%20the%20Lpilimumab%20approval%20decennial.%20Nat%20Rev%20Drug%20Discov.%202022;21:509%E2%80%9328." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR28">
<span class="label">28.</span><cite>Jackson CM, Choi J, Lim M. Mechanisms of immunotherapy resistance: Iessons from glioblastoma. Nat Immunol. 2019;20:1100–9.
</cite> [<a href="https://doi.org/10.1038/s41590-019-0433-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31358997/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Jackson%20CM,%20Choi%20J,%20Lim%20M.%20Mechanisms%20of%20immunotherapy%20resistance:%20Iessons%20from%20glioblastoma.%20Nat%20Immunol.%202019;20:1100%E2%80%939." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR29">
<span class="label">29.</span><cite>Vitale I, Shema E, Loi S, Galluzzi L. Intratumoral heterogeneity in cancer progression and response to immunotherapy. Nat Med. 2021;27:212–24.
</cite> [<a href="https://doi.org/10.1038/s41591-021-01233-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33574607/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Vitale%20I,%20Shema%20E,%20Loi%20S,%20Galluzzi%20L.%20Intratumoral%20heterogeneity%20in%20cancer%20progression%20and%20response%20to%20immunotherapy.%20Nat%20Med.%202021;27:212%E2%80%9324." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR30">
<span class="label">30.</span><cite>Phuengkham H, Ren L, Shin IW, Lim YT. Nanoengineered immune niches for reprogramming the immunosuppressive tumor microenvironment and enhancing cancer immunotherapy. Adv Mater. 2019;31:1803322.</cite> [<a href="https://doi.org/10.1002/adma.201803322" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30773696/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Phuengkham%20H,%20Ren%20L,%20Shin%20IW,%20Lim%20YT.%20Nanoengineered%20immune%20niches%20for%20reprogramming%20the%20immunosuppressive%20tumor%20microenvironment%20and%20enhancing%20cancer%20immunotherapy.%20Adv%20Mater.%202019;31:1803322." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR31">
<span class="label">31.</span><cite>Maggiorani D, Le O, Lisi V, Landais S, Moquin-Beaudry G, Lavallée VP, Decaluwe H, Beauséjour C. Senescence drives immunotherapy resistance by inducing an immunosuppressive tumor microenvironment. Nat Commun. 2024;15:2435.
</cite> [<a href="https://doi.org/10.1038/s41467-024-46769-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10948808/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38499573/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Maggiorani%20D,%20Le%20O,%20Lisi%20V,%20Landais%20S,%20Moquin-Beaudry%20G,%20Lavall%C3%A9e%20VP,%20Decaluwe%20H,%20Beaus%C3%A9jour%20C.%20Senescence%20drives%20immunotherapy%20resistance%20by%20inducing%20an%20immunosuppressive%20tumor%20microenvironment.%20Nat%20Commun.%202024;15:2435." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR32">
<span class="label">32.</span><cite>Carpenter S, O’Neill LAJ. From periphery to center stage: 50 years of advancements in innate immunity. Cell. 2024;187:2030–51.
</cite> [<a href="https://doi.org/10.1016/j.cell.2024.03.036" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11060700/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38670064/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Carpenter%20S,%20O%E2%80%99Neill%20LAJ.%20From%20periphery%20to%20center%20stage:%2050%20years%20of%20advancements%20in%20innate%20immunity.%20Cell.%202024;187:2030%E2%80%9351." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR33">
<span class="label">33.</span><cite>Li A, Yi M, Qin S, Song Y, Chu Q, Wu K. Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy. J Hematol Oncol. 2019;12:35.
</cite> [<a href="https://doi.org/10.1186/s13045-019-0721-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6444510/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30935414/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Li%20A,%20Yi%20M,%20Qin%20S,%20Song%20Y,%20Chu%20Q,%20Wu%20K.%20Activating%20cGAS-STING%20pathway%20for%20the%20optimal%20effect%20of%20cancer%20immunotherapy.%20J%20Hematol%20Oncol.%202019;12:35." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR34">
<span class="label">34.</span><cite>Jiang M, Chen P, Wang L, Li W, Chen B, Liu Y, Wang H, Zhao S, Ye L, He Y, Zhou C. cGAS-STING, an important pathway in cancer immunotherapy. J Hematol Oncol. 2020;13:81.
</cite> [<a href="https://doi.org/10.1186/s13045-020-00916-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7310007/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32571374/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Jiang%20M,%20Chen%20P,%20Wang%20L,%20Li%20W,%20Chen%20B,%20Liu%20Y,%20Wang%20H,%20Zhao%20S,%20Ye%20L,%20He%20Y,%20Zhou%20C.%20cGAS-STING,%20an%20important%20pathway%20in%20cancer%20immunotherapy.%20J%20Hematol%20Oncol.%202020;13:81." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR35">
<span class="label">35.</span><cite>Yan H, Lu W, Wang F. The cGAS-STING pathway: a therapeutic target in chromosomally unstable cancers. Signal Transduct Target Ther. 2023;8:45.
</cite> [<a href="https://doi.org/10.1038/s41392-023-01328-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9886966/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36717545/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yan%20H,%20Lu%20W,%20Wang%20F.%20The%20cGAS-STING%20pathway:%20a%20therapeutic%20target%20in%20chromosomally%20unstable%20cancers.%20Signal%20Transduct%20Target%20Ther.%202023;8:45." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR36">
<span class="label">36.</span><cite>Feng D, Kang X, Wang H, He Z, Xu H, Li Y, Fan A, Xu H, Zhang Y, Song J, Hou J, Qi J, Zhang W. Photochemical bomb: precision nuclear targeting to activate cGAS-STING pathway for enhanced bladder cancer immunotherapy. Biomaterials. 2025;318:123126.
</cite> [<a href="https://doi.org/10.1016/j.biomaterials.2025.123126" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39884129/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Feng%20D,%20Kang%20X,%20Wang%20H,%20He%20Z,%20Xu%20H,%20Li%20Y,%20Fan%20A,%20Xu%20H,%20Zhang%20Y,%20Song%20J,%20Hou%20J,%20Qi%20J,%20Zhang%20W.%20Photochemical%20bomb:%20precision%20nuclear%20targeting%20to%20activate%20cGAS-STING%20pathway%20for%20enhanced%20bladder%20cancer%20immunotherapy.%20Biomaterials.%202025;318:123126." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR37">
<span class="label">37.</span><cite>Zhang X, Tang D, Xiao H, Li B, Shang K, Zhao D. Activating the cGAS-STING pathway by manganese-based nanoparticles combined with platinum-based nanoparticles for enhanced ovarian cancer immunotherapy. ACS Nano. 2025;19:4346–65.
</cite> [<a href="https://doi.org/10.1021/acsnano.4c12237" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39846241/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20X,%20Tang%20D,%20Xiao%20H,%20Li%20B,%20Shang%20K,%20Zhao%20D.%20Activating%20the%20cGAS-STING%20pathway%20by%20manganese-based%20nanoparticles%20combined%20with%20platinum-based%20nanoparticles%20for%20enhanced%20ovarian%20cancer%20immunotherapy.%20ACS%20Nano.%202025;19:4346%E2%80%9365." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR38">
<span class="label">38.</span><cite>Chen Q, Sun L, Chen ZJ. Regulation and function of the cGAS–STING pathway of cytosolic DNA sensing. Nat Immunol. 2016;17:1142–9.
</cite> [<a href="https://doi.org/10.1038/ni.3558" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27648547/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chen%20Q,%20Sun%20L,%20Chen%20ZJ.%20Regulation%20and%20function%20of%20the%20cGAS%E2%80%93STING%20pathway%20of%20cytosolic%20DNA%20sensing.%20Nat%20Immunol.%202016;17:1142%E2%80%939." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR39">
<span class="label">39.</span><cite>Yu L, Liu P. Cytosolic DNA sensing by cGAS: eegulation, function, and human diseases. Signal Transduct Target Ther. 2021;6:170.
</cite> [<a href="https://doi.org/10.1038/s41392-021-00554-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8085147/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33927185/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yu%20L,%20Liu%20P.%20Cytosolic%20DNA%20sensing%20by%20cGAS:%20eegulation,%20function,%20and%20human%20diseases.%20Signal%20Transduct%20Target%20Ther.%202021;6:170." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR40">
<span class="label">40.</span><cite>Kwon J, Bakhoum SF. The cytosolic DNA-sensing cGAS–STING pathway in cancer. Cancer Discov. 2020;10:26–39.
</cite> [<a href="https://doi.org/10.1158/2159-8290.CD-19-0761" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7151642/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31852718/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kwon%20J,%20Bakhoum%20SF.%20The%20cytosolic%20DNA-sensing%20cGAS%E2%80%93STING%20pathway%20in%20cancer.%20Cancer%20Discov.%202020;10:26%E2%80%9339." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR41">
<span class="label">41.</span><cite>Motwani M, Pesiridis S, Fitzgerald KA. DNA sensing by the cGAS–STING pathway in health and disease. Nat Rev Genet. 2019;20:657–74.
</cite> [<a href="https://doi.org/10.1038/s41576-019-0151-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31358977/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Motwani%20M,%20Pesiridis%20S,%20Fitzgerald%20KA.%20DNA%20sensing%20by%20the%20cGAS%E2%80%93STING%20pathway%20in%20health%20and%20disease.%20Nat%20Rev%20Genet.%202019;20:657%E2%80%9374." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR42">
<span class="label">42.</span><cite>Dvorkin S, Cambier S, Volkman HE, Stetson DB. New frontiers in the cGAS-STING intracellular DNA-sensing pathway. Immunity. 2024;57:718–30.
</cite> [<a href="https://doi.org/10.1016/j.immuni.2024.02.019" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11013568/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38599167/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Dvorkin%20S,%20Cambier%20S,%20Volkman%20HE,%20Stetson%20DB.%20New%20frontiers%20in%20the%20cGAS-STING%20intracellular%20DNA-sensing%20pathway.%20Immunity.%202024;57:718%E2%80%9330." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR43">
<span class="label">43.</span><cite>Lanng KRB, Lauridsen EL, Jakobsen MR. The balance of STING signaling orchestrates immunity in cancer. Nat Immunol. 2024;25:1144–57.
</cite> [<a href="https://doi.org/10.1038/s41590-024-01872-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38918609/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lanng%20KRB,%20Lauridsen%20EL,%20Jakobsen%20MR.%20The%20balance%20of%20STING%20signaling%20orchestrates%20immunity%20in%20cancer.%20Nat%20Immunol.%202024;25:1144%E2%80%9357." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR44">
<span class="label">44.</span><cite>Ishikawa H, Ma Z, Barber GN. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature. 2009;461:788–92.
</cite> [<a href="https://doi.org/10.1038/nature08476" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4664154/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19776740/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ishikawa%20H,%20Ma%20Z,%20Barber%20GN.%20STING%20regulates%20intracellular%20DNA-mediated,%20type%20I%20interferon-dependent%20innate%20immunity.%20Nature.%202009;461:788%E2%80%9392." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR45">
<span class="label">45.</span><cite>Lam KC, Araya RE, Huang A, Chen Q, Di Modica M, Rodrigues RR, Lopès A, Johnson SB, Schwarz B, Bohrnsen E, Cogdill AP, Bosio CM, Wargo JA, Lee MP, Goldszmid RS. Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment. Cell. 2021;184:5338–56.
</cite> [<a href="https://doi.org/10.1016/j.cell.2021.09.019" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8650838/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34624222/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lam%20KC,%20Araya%20RE,%20Huang%20A,%20Chen%20Q,%20Di%20Modica%20M,%20Rodrigues%20RR,%20Lop%C3%A8s%20A,%20Johnson%20SB,%20Schwarz%20B,%20Bohrnsen%20E,%20Cogdill%20AP,%20Bosio%20CM,%20Wargo%20JA,%20Lee%20MP,%20Goldszmid%20RS.%20Microbiota%20triggers%20STING-type%20I%20IFN-dependent%20monocyte%20reprogramming%20of%20the%20tumor%20microenvironment.%20Cell.%202021;184:5338%E2%80%9356." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR46">
<span class="label">46.</span><cite>Zhang X, Bai X-c, Chen ZJ. Structures and mechanisms in the cGAS-STING innate immunity pathway. Immunity. 2020;53:43–53.
</cite> [<a href="https://doi.org/10.1016/j.immuni.2020.05.013" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32668227/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20X,%20Bai%20X-c,%20Chen%20ZJ.%20Structures%20and%20mechanisms%20in%20the%20cGAS-STING%20innate%20immunity%20pathway.%20Immunity.%202020;53:43%E2%80%9353." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR47">
<span class="label">47.</span><cite>Belardelli F, Ferrantini M. Cytokines as a link between innate and adaptive antitumor immunity. Trends Immunol. 2002;23:201–8.
</cite> [<a href="https://doi.org/10.1016/s1471-4906(02)02195-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11923115/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Belardelli%20F,%20Ferrantini%20M.%20Cytokines%20as%20a%20link%20between%20innate%20and%20adaptive%20antitumor%20immunity.%20Trends%20Immunol.%202002;23:201%E2%80%938." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR48">
<span class="label">48.</span><cite>Ma B, Dela Cruz CS, Hartl D, Kang M-J, Takyar S, Homer RJ, Lee CG, Elias JA. RIG-like helicase innate immunity inhibits vascular endothelial growth factor tissue responses via a type I IFN–dependent mechanism. Am J Respir Crit Care Med. 2011;183:1322–35.
</cite> [<a href="https://doi.org/10.1164/rccm.201008-1276OC" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3114061/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21278304/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ma%20B,%20Dela%20Cruz%20CS,%20Hartl%20D,%20Kang%20M-J,%20Takyar%20S,%20Homer%20RJ,%20Lee%20CG,%20Elias%20JA.%20RIG-like%20helicase%20innate%20immunity%20inhibits%20vascular%20endothelial%20growth%20factor%20tissue%20responses%20via%20a%20type%20I%20IFN%E2%80%93dependent%20mechanism.%20Am%20J%20Respir%20Crit%20Care%20Med.%202011;183:1322%E2%80%9335." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR49">
<span class="label">49.</span><cite>Wu B, Zhang B, Li B, Wu H, Jiang M. Cold and hot tumors: from molecular mechanisms to targeted therapy. Signal Transduct Target Ther. 2024;9: 274.
</cite> [<a href="https://doi.org/10.1038/s41392-024-01979-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11491057/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39420203/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wu%20B,%20Zhang%20B,%20Li%20B,%20Wu%20H,%20Jiang%20M.%20Cold%20and%20hot%20tumors:%20from%20molecular%20mechanisms%20to%20targeted%20therapy.%20Signal%20Transduct%20Target%20Ther.%202024;9:%20274." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR50">
<span class="label">50.</span><cite>Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18:197–218.
</cite> [<a href="https://doi.org/10.1038/s41573-018-0007-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30610226/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Galon%20J,%20Bruni%20D.%20Approaches%20to%20treat%20immune%20hot,%20altered%20and%20cold%20tumours%20with%20combination%20immunotherapies.%20Nat%20Rev%20Drug%20Discov.%202019;18:197%E2%80%93218." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR51">
<span class="label">51.</span><cite>Liu YT, Sun ZJ. Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics. 2021;11:5365–86.
</cite> [<a href="https://doi.org/10.7150/thno.58390" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8039952/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33859752/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Liu%20YT,%20Sun%20ZJ.%20Turning%20cold%20tumors%20into%20hot%20tumors%20by%20improving%20T-cell%20infiltration.%20Theranostics.%202021;11:5365%E2%80%9386." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR52">
<span class="label">52.</span><cite>Ying X, Chen Q, Yang Y, Wu Z, Zeng W, Miao C, Huang Q, Ai K. Nanomedicines Harnessing cGAS-STING pathway: sparking immune revitalization to transform ‘cold’ tumors into ‘hot’ tumors. Mol Cancer. 2024;23:277.
</cite> [<a href="https://doi.org/10.1186/s12943-024-02186-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11664935/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39710707/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ying%20X,%20Chen%20Q,%20Yang%20Y,%20Wu%20Z,%20Zeng%20W,%20Miao%20C,%20Huang%20Q,%20Ai%20K.%20Nanomedicines%20Harnessing%20cGAS-STING%20pathway:%20sparking%20immune%20revitalization%20to%20transform%20%E2%80%98cold%E2%80%99%20tumors%20into%20%E2%80%98hot%E2%80%99%20tumors.%20Mol%20Cancer.%202024;23:277." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR53">
<span class="label">53.</span><cite>Samson N, Ablasser A. The cGAS–STING pathway and cancer. Nat Cancer. 2022;3:1452–63.
</cite> [<a href="https://doi.org/10.1038/s43018-022-00468-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36510011/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Samson%20N,%20Ablasser%20A.%20The%20cGAS%E2%80%93STING%20pathway%20and%20cancer.%20Nat%20Cancer.%202022;3:1452%E2%80%9363." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR54">
<span class="label">54.</span><cite>Kong X, Zuo H, Huang H-D, Zhang Q, Chen J, He C, Hu Y. STING as an emerging therapeutic target for drug discovery: perspectives from the global patent landscape. J Adv Res. 2023;44:119–33.
</cite> [<a href="https://doi.org/10.1016/j.jare.2022.05.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9936525/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35636721/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kong%20X,%20Zuo%20H,%20Huang%20H-D,%20Zhang%20Q,%20Chen%20J,%20He%20C,%20Hu%20Y.%20STING%20as%20an%20emerging%20therapeutic%20target%20for%20drug%20discovery:%20perspectives%20from%20the%20global%20patent%20landscape.%20J%20Adv%20Res.%202023;44:119%E2%80%9333." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR55">
<span class="label">55.</span><cite>Pan B-S, Perera SA, Piesvaux JA, Presland JP, Schroeder GK, Cumming JN, Trotter BW, Altman MD, Buevich AV, Cash B. An orally available non-nucleotide STING agonist with antitumor activity. Science. 2020;369:eaba6098.
</cite> [<a href="https://doi.org/10.1126/science.aba6098" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32820094/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Pan%20B-S,%20Perera%20SA,%20Piesvaux%20JA,%20Presland%20JP,%20Schroeder%20GK,%20Cumming%20JN,%20Trotter%20BW,%20Altman%20MD,%20Buevich%20AV,%20Cash%20B.%20An%20orally%20available%20non-nucleotide%20STING%20agonist%20with%20antitumor%20activity.%20Science.%202020;369:eaba6098." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR56">
<span class="label">56.</span><cite>Yan H, Chen W. The promise and challenges of cyclic dinucleotides as molecular adjuvants for vaccine development. Vaccines. 2021;9:917.
</cite> [<a href="https://doi.org/10.3390/vaccines9080917" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8402453/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34452042/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yan%20H,%20Chen%20W.%20The%20promise%20and%20challenges%20of%20cyclic%20dinucleotides%20as%20molecular%20adjuvants%20for%20vaccine%20development.%20Vaccines.%202021;9:917." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR57">
<span class="label">57.</span><cite>Carozza JA, Cordova AF, Brown JA, AlSaif Y, Böhnert V, Cao X, Mardjuki RE, Skariah G, Fernandez D, Li L. ENPP1’s regulation of extracellular cGAMP is a ubiquitous mechanism of attenuating STING signaling. Proc Natl Acad Sci U S A. 2022;119:e2119189119.
</cite> [<a href="https://doi.org/10.1073/pnas.2119189119" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9173814/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35588451/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Carozza%20JA,%20Cordova%20AF,%20Brown%20JA,%20AlSaif%20Y,%20B%C3%B6hnert%20V,%20Cao%20X,%20Mardjuki%20RE,%20Skariah%20G,%20Fernandez%20D,%20Li%20L.%20ENPP1%E2%80%99s%20regulation%20of%20extracellular%20cGAMP%20is%20a%20ubiquitous%20mechanism%20of%20attenuating%20STING%20signaling.%20Proc%20Natl%20Acad%20Sci%20U%20S%20A.%202022;119:e2119189119." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR58">
<span class="label">58.</span><cite>Liang J-L, Jin X-K, Zhang S-M, Huang Q-X, Ji P, Deng X-C, Cheng S-X, Chen W-H, Zhang X-Z. Specific activation of cGAS-STING pathway by nanotherapeutics-mediated ferroptosis evoked endogenous signaling for boosting systemic tumor immunotherapy. Sci Bull. 2023;68:622–36.</cite> [<a href="https://doi.org/10.1016/j.scib.2023.02.027" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36914548/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Liang%20J-L,%20Jin%20X-K,%20Zhang%20S-M,%20Huang%20Q-X,%20Ji%20P,%20Deng%20X-C,%20Cheng%20S-X,%20Chen%20W-H,%20Zhang%20X-Z.%20Specific%20activation%20of%20cGAS-STING%20pathway%20by%20nanotherapeutics-mediated%20ferroptosis%20evoked%20endogenous%20signaling%20for%20boosting%20systemic%20tumor%20immunotherapy.%20Sci%20Bull.%202023;68:622%E2%80%9336." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR59">
<span class="label">59.</span><cite>Wang Y, Liu Y, Zhang J, Peng Q, Wang X, Xiao X, Shi K. Nanomaterial-mediated modulation of the cGAS-STING signaling pathway for enhanced cancer immunotherapy. Acta Biomater. 2024;176:51–76.
</cite> [<a href="https://doi.org/10.1016/j.actbio.2024.01.008" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38237711/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang%20Y,%20Liu%20Y,%20Zhang%20J,%20Peng%20Q,%20Wang%20X,%20Xiao%20X,%20Shi%20K.%20Nanomaterial-mediated%20modulation%20of%20the%20cGAS-STING%20signaling%20pathway%20for%20enhanced%20cancer%20immunotherapy.%20Acta%20Biomater.%202024;176:51%E2%80%9376." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR60">
<span class="label">60.</span><cite>Tan J, Wang M, Ding B, Lin J. Advanced nanomaterials targeting activation of STING for enhanced cancer immunotherapy. Coord Chem Rev. 2023;493: 215316.</cite> [<a href="https://scholar.google.com/scholar_lookup?Tan%20J,%20Wang%20M,%20Ding%20B,%20Lin%20J.%20Advanced%20nanomaterials%20targeting%20activation%20of%20STING%20for%20enhanced%20cancer%20immunotherapy.%20Coord%20Chem%20Rev.%202023;493:%20215316." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR61">
<span class="label">61.</span><cite>Ni K, Luo T, Nash GT, Lin W. Nanoscale metal–organic frameworks for cancer immunotherapy. Acc Chem Res. 2020;53:1739–48.
</cite> [<a href="https://doi.org/10.1021/acs.accounts.0c00313" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9359629/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32808760/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ni%20K,%20Luo%20T,%20Nash%20GT,%20Lin%20W.%20Nanoscale%20metal%E2%80%93organic%20frameworks%20for%20cancer%20immunotherapy.%20Acc%20Chem%20Res.%202020;53:1739%E2%80%9348." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR62">
<span class="label">62.</span><cite>Kitagawa S. Metal–organic frameworks (MOFs). Chem Soc Rev. 2014;43:5415–8.
</cite> [<a href="https://doi.org/10.1039/c4cs90059f" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25011480/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kitagawa%20S.%20Metal%E2%80%93organic%20frameworks%20(MOFs).%20Chem%20Soc%20Rev.%202014;43:5415%E2%80%938." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR63">
<span class="label">63.</span><cite>Sun L, Gao H, Wang H, Zhou J, Ji X, Jiao Y, Qin X, Ni D, Zheng X. Nanoscale metal–organic frameworks-mediated degradation of mutant p53 proteins and activation of cGAS‐STING pathway for enhanced cancer immunotherapy. Adv Sci. 2024;11: 2307278.</cite> [<a href="https://doi.org/10.1002/advs.202307278" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10966556/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38225693/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sun%20L,%20Gao%20H,%20Wang%20H,%20Zhou%20J,%20Ji%20X,%20Jiao%20Y,%20Qin%20X,%20Ni%20D,%20Zheng%20X.%20Nanoscale%20metal%E2%80%93organic%20frameworks-mediated%20degradation%20of%20mutant%20p53%20proteins%20and%20activation%20of%20cGAS%E2%80%90STING%20pathway%20for%20enhanced%20cancer%20immunotherapy.%20Adv%20Sci.%202024;11:%202307278." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR64">
<span class="label">64.</span><cite>Zhou S, Cheng F, Zhang Y, Su T, Zhu G. Engineering and delivery of cGAS-STING immunomodulators for the immunotherapy of cancer and autoimmune diseases. Acc Chem Res. 2023;56:2933–43.
</cite> [<a href="https://doi.org/10.1021/acs.accounts.3c00394" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10882213/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37802125/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhou%20S,%20Cheng%20F,%20Zhang%20Y,%20Su%20T,%20Zhu%20G.%20Engineering%20and%20delivery%20of%20cGAS-STING%20immunomodulators%20for%20the%20immunotherapy%20of%20cancer%20and%20autoimmune%20diseases.%20Acc%20Chem%20Res.%202023;56:2933%E2%80%9343." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR65">
<span class="label">65.</span><cite>Liang J-L, Jin X-K, Deng X-C, Huang Q-X, Zhang S-M, Chen W-H, Zhang X-Z. Targeting activation of cGAS-STING signaling pathway by engineered biomaterials for enhancing cancer immunotherapy. Mater Today. 2024;78:251–96.</cite> [<a href="https://scholar.google.com/scholar_lookup?Liang%20J-L,%20Jin%20X-K,%20Deng%20X-C,%20Huang%20Q-X,%20Zhang%20S-M,%20Chen%20W-H,%20Zhang%20X-Z.%20Targeting%20activation%20of%20cGAS-STING%20signaling%20pathway%20by%20engineered%20biomaterials%20for%20enhancing%20cancer%20immunotherapy.%20Mater%20Today.%202024;78:251%E2%80%9396." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR66">
<span class="label">66.</span><cite>Si W, Liang H, Bugno J, Xu Q, Ding X, Yang K, Fu Y, Weichselbaum RR, Zhao X, Wang L. <em>Lactobacillus rhamnosus</em> GG induces cGAS/STING- dependent type I interferon and improves response to immune checkpoint blockade. Gut. 2022;71:521–33.
</cite> [<a href="https://doi.org/10.1136/gutjnl-2020-323426" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8710942/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33685966/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Si%20W,%20Liang%20H,%20Bugno%20J,%20Xu%20Q,%20Ding%20X,%20Yang%20K,%20Fu%20Y,%20Weichselbaum%20RR,%20Zhao%20X,%20Wang%20L.%20Lactobacillus%20rhamnosus%20GG%20induces%20cGAS/STING-%20dependent%20type%20I%20interferon%20and%20improves%20response%20to%20immune%20checkpoint%20blockade.%20Gut.%202022;71:521%E2%80%9333." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR67">
<span class="label">67.</span><cite>Zhang Z, Zhang C. Regulation of cGAS–STING signalling and its diversity of cellular outcomes. Nat Rev Immunol. 2025;25:425–44.
</cite> [<a href="https://doi.org/10.1038/s41577-024-01112-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39774812/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20Z,%20Zhang%20C.%20Regulation%20of%20cGAS%E2%80%93STING%20signalling%20and%20its%20diversity%20of%20cellular%20outcomes.%20Nat%20Rev%20Immunol.%202025;25:425%E2%80%9344." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR68">
<span class="label">68.</span><cite>Yuan H, Qiu C, Wang X, Wang P, Yi L, Peng X, Xu X, Huang W, Bai Y, Wei J, Ma J, Wong YK, Fu C, Xiao W, Chen C, Long Y, Li Z, Wang J. Engineering semiconducting polymeric nanoagonists potentiate cGAS-STING pathway activation and elicit long term memory against recurrence in breast cancer. Adv Mater. 2025;37:2406662.</cite> [<a href="https://doi.org/10.1002/adma.202406662" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39629527/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yuan%20H,%20Qiu%20C,%20Wang%20X,%20Wang%20P,%20Yi%20L,%20Peng%20X,%20Xu%20X,%20Huang%20W,%20Bai%20Y,%20Wei%20J,%20Ma%20J,%20Wong%20YK,%20Fu%20C,%20Xiao%20W,%20Chen%20C,%20Long%20Y,%20Li%20Z,%20Wang%20J.%20Engineering%20semiconducting%20polymeric%20nanoagonists%20potentiate%20cGAS-STING%20pathway%20activation%20and%20elicit%20long%20term%20memory%20against%20recurrence%20in%20breast%20cancer.%20Adv%20Mater.%202025;37:2406662." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR69">
<span class="label">69.</span><cite>Zheng J, Mo J, Zhu T, Zhuo W, Yi Y, Hu S, Yin J, Zhang W, Zhou H, Liu Z. Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapy. Mol Cancer. 2020;19:133.
</cite> [<a href="https://doi.org/10.1186/s12943-020-01250-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7450153/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32854711/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zheng%20J,%20Mo%20J,%20Zhu%20T,%20Zhuo%20W,%20Yi%20Y,%20Hu%20S,%20Yin%20J,%20Zhang%20W,%20Zhou%20H,%20Liu%20Z.%20Comprehensive%20elaboration%20of%20the%20cGAS-STING%20signaling%20axis%20in%20cancer%20development%20and%20immunotherapy.%20Mol%20Cancer.%202020;19:133." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR70">
<span class="label">70.</span><cite>Andreeva L, Hiller B, Kostrewa D, Lässig C, de Oliveira Mann CC, Jan Drexler D, Maiser A, Gaidt M, Leonhardt H, Hornung V. Hopfner K-P. cGAS senses long and HMGB/TFAM-bound U-turn DNA by forming protein–DNA ladders. Nature. 2017;549:394–8.
</cite> [<a href="https://doi.org/10.1038/nature23890" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28902841/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Andreeva%20L,%20Hiller%20B,%20Kostrewa%20D,%20L%C3%A4ssig%20C,%20de%20Oliveira%20Mann%20CC,%20Jan%20Drexler%20D,%20Maiser%20A,%20Gaidt%20M,%20Leonhardt%20H,%20Hornung%20V.%20Hopfner%20K-P.%20cGAS%20senses%20long%20and%20HMGB/TFAM-bound%20U-turn%20DNA%20by%20forming%20protein%E2%80%93DNA%20ladders.%20Nature.%202017;549:394%E2%80%938." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR71">
<span class="label">71.</span><cite>O’Neill LAJ. Sensing the dark side of DNA. Science. 2013;339:763–4.
</cite> [<a href="https://doi.org/10.1126/science.1234724" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23413341/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?O%E2%80%99Neill%20LAJ.%20Sensing%20the%20dark%20side%20of%20DNA.%20Science.%202013;339:763%E2%80%934." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR72">
<span class="label">72.</span><cite>Li X, Shu C, Yi G, Chaton Catherine T, Shelton Catherine L, Diao J, Zuo X, Kao CC, Herr Andrew B, Li P. Cyclic GMP-AMP synthase is activated by double-stranded DNA-induced oligomerization. Immunity. 2013;39:1019–31.
</cite> [<a href="https://doi.org/10.1016/j.immuni.2013.10.019" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3886715/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24332030/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Li%20X,%20Shu%20C,%20Yi%20G,%20Chaton%20Catherine%20T,%20Shelton%20Catherine%20L,%20Diao%20J,%20Zuo%20X,%20Kao%20CC,%20Herr%20Andrew%20B,%20Li%20P.%20Cyclic%20GMP-AMP%20synthase%20is%20activated%20by%20double-stranded%20DNA-induced%20oligomerization.%20Immunity.%202013;39:1019%E2%80%9331." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR73">
<span class="label">73.</span><cite>Civril F, Deimling T, de Oliveira Mann CC, Ablasser A, Moldt M, Witte G, Hornung V, Hopfner K-P. Structural mechanism of cytosolic DNA sensing by cGAS. Nature. 2013;498:332–7.
</cite> [<a href="https://doi.org/10.1038/nature12305" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3768140/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23722159/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Civril%20F,%20Deimling%20T,%20de%20Oliveira%20Mann%20CC,%20Ablasser%20A,%20Moldt%20M,%20Witte%20G,%20Hornung%20V,%20Hopfner%20K-P.%20Structural%20mechanism%20of%20cytosolic%20DNA%20sensing%20by%20cGAS.%20Nature.%202013;498:332%E2%80%937." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR74">
<span class="label">74.</span><cite>Zhang C, Shang G, Gui X, Zhang X, Bai X-c, Chen ZJ. Structural basis of STING binding with and phosphorylation by TBK1. Nature. 2019;567:394–8.
</cite> [<a href="https://doi.org/10.1038/s41586-019-1000-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6862768/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30842653/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20C,%20Shang%20G,%20Gui%20X,%20Zhang%20X,%20Bai%20X-c,%20Chen%20ZJ.%20Structural%20basis%20of%20STING%20binding%20with%20and%20phosphorylation%20by%20TBK1.%20Nature.%202019;567:394%E2%80%938." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR75">
<span class="label">75.</span><cite>Ablasser A, Chen ZJ. cGAS in action: expanding roles in immunity and inflammation. Science. 2019;363:eaat8657.
</cite> [<a href="https://doi.org/10.1126/science.aat8657" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30846571/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ablasser%20A,%20Chen%20ZJ.%20cGAS%20in%20action:%20expanding%20roles%20in%20immunity%20and%20inflammation.%20Science.%202019;363:eaat8657." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR76">
<span class="label">76.</span><cite>Gentili M, Kowal J, Tkach M, Satoh T, Lahaye X, Conrad C, Boyron M, Lombard B, Durand S, Kroemer G. Transmission of innate immune signaling by packaging of cGAMP in viral particles. Science. 2015;349:1232–6.
</cite> [<a href="https://doi.org/10.1126/science.aab3628" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26229115/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gentili%20M,%20Kowal%20J,%20Tkach%20M,%20Satoh%20T,%20Lahaye%20X,%20Conrad%20C,%20Boyron%20M,%20Lombard%20B,%20Durand%20S,%20Kroemer%20G.%20Transmission%20of%20innate%20immune%20signaling%20by%20packaging%20of%20cGAMP%20in%20viral%20particles.%20Science.%202015;349:1232%E2%80%936." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR77">
<span class="label">77.</span><cite>Kranzusch PJ, Lee AS-Y, Berger JM, Doudna JA. Structure of human cGAS reveals a conserved family of second-messenger enzymes in innate immunity. Cell Rep. 2013;3:1362–8.
</cite> [<a href="https://doi.org/10.1016/j.celrep.2013.05.008" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3800681/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23707061/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kranzusch%20PJ,%20Lee%20AS-Y,%20Berger%20JM,%20Doudna%20JA.%20Structure%20of%20human%20cGAS%20reveals%20a%20conserved%20family%20of%20second-messenger%20enzymes%20in%20innate%20immunity.%20Cell%20Rep.%202013;3:1362%E2%80%938." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR78">
<span class="label">78.</span><cite>Patel DJ, Yu Y, Xie W. cGAMP-activated cGAS–STING signaling: its bacterial origins and evolutionary adaptation by metazoans. Nat Struct Mol Biol. 2023;30:245–60.
</cite> [<a href="https://doi.org/10.1038/s41594-023-00933-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11749898/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36894694/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Patel%20DJ,%20Yu%20Y,%20Xie%20W.%20cGAMP-activated%20cGAS%E2%80%93STING%20signaling:%20its%20bacterial%20origins%20and%20evolutionary%20adaptation%20by%20metazoans.%20Nat%20Struct%20Mol%20Biol.%202023;30:245%E2%80%9360." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR79">
<span class="label">79.</span><cite>Du J-m, Qian M-j, Yuan T, Chen R-h, He Q-j, Yang B, Ling Q, Zhu H. cGAS and cancer therapy: a double-edged sword. Acta Pharmacol Sin. 2022;43:2202–11.
</cite> [<a href="https://doi.org/10.1038/s41401-021-00839-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9433456/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35042992/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Du%20J-m,%20Qian%20M-j,%20Yuan%20T,%20Chen%20R-h,%20He%20Q-j,%20Yang%20B,%20Ling%20Q,%20Zhu%20H.%20cGAS%20and%20cancer%20therapy:%20a%20double-edged%20sword.%20Acta%20Pharmacol%20Sin.%202022;43:2202%E2%80%9311." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR80">
<span class="label">80.</span><cite>Hopfner K-P, Hornung V. Molecular mechanisms and cellular functions of cGAS–STING signalling. Nat Rev Mol Cell Biol. 2020;21:501–21.
</cite> [<a href="https://doi.org/10.1038/s41580-020-0244-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32424334/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hopfner%20K-P,%20Hornung%20V.%20Molecular%20mechanisms%20and%20cellular%20functions%20of%20cGAS%E2%80%93STING%20signalling.%20Nat%20Rev%20Mol%20Cell%20Biol.%202020;21:501%E2%80%9321." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR81">
<span class="label">81.</span><cite>Shang G, Zhang C, Chen ZJ, Bai X-c, Zhang X. Cryo-EM structures of STING reveal its mechanism of activation by cyclic GMP–AMP. Nature. 2019;567:389–93.
</cite> [<a href="https://doi.org/10.1038/s41586-019-0998-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6859894/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30842659/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Shang%20G,%20Zhang%20C,%20Chen%20ZJ,%20Bai%20X-c,%20Zhang%20X.%20Cryo-EM%20structures%20of%20STING%20reveal%20its%20mechanism%20of%20activation%20by%20cyclic%20GMP%E2%80%93AMP.%20Nature.%202019;567:389%E2%80%9393." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR82">
<span class="label">82.</span><cite>Lu D, Shang G, Li J, Lu Y, Bai X-c, Zhang X. Activation of STING by targeting a pocket in the transmembrane domain. Nature. 2022;604:557–62.
</cite> [<a href="https://doi.org/10.1038/s41586-022-04559-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9098198/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35388221/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lu%20D,%20Shang%20G,%20Li%20J,%20Lu%20Y,%20Bai%20X-c,%20Zhang%20X.%20Activation%20of%20STING%20by%20targeting%20a%20pocket%20in%20the%20transmembrane%20domain.%20Nature.%202022;604:557%E2%80%9362." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR83">
<span class="label">83.</span><cite>Zhang Z, Zhou H, Ouyang X, Dong Y, Sarapultsev A, Luo S, Hu D. Multifaceted functions of STING in human health and disease: from molecular mechanism to targeted strategy. Signal Transduct Target Ther. 2022;7: 394.
</cite> [<a href="https://doi.org/10.1038/s41392-022-01252-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9780328/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36550103/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20Z,%20Zhou%20H,%20Ouyang%20X,%20Dong%20Y,%20Sarapultsev%20A,%20Luo%20S,%20Hu%20D.%20Multifaceted%20functions%20of%20STING%20in%20human%20health%20and%20disease:%20from%20molecular%20mechanism%20to%20targeted%20strategy.%20Signal%20Transduct%20Target%20Ther.%202022;7:%20394." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR84">
<span class="label">84.</span><cite>Lu X, Li X, Li L, Han C, Li S. Advances in the prerequisite and consequence of STING downstream signalosomes. Med Rev. 2024;4(5):435–51.</cite> [<a href="https://doi.org/10.1515/mr-2024-0016" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11495525/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39444795/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lu%20X,%20Li%20X,%20Li%20L,%20Han%20C,%20Li%20S.%20Advances%20in%20the%20prerequisite%20and%20consequence%20of%20STING%20downstream%20signalosomes.%20Med%20Rev.%202024;4(5):435%E2%80%9351." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR85">
<span class="label">85.</span><cite>Shi J-H, Xie X, Sun S-C. TBK1 as a regulator of autoimmunity and antitumor immunity. Cell Mol Immunol. 2018;15:743–5.
</cite> [<a href="https://doi.org/10.1038/cmi.2017.165" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6141483/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29503440/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Shi%20J-H,%20Xie%20X,%20Sun%20S-C.%20TBK1%20as%20a%20regulator%20of%20autoimmunity%20and%20antitumor%20immunity.%20Cell%20Mol%20Immunol.%202018;15:743%E2%80%935." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR86">
<span class="label">86.</span><cite>Chen H, Wang D, Liu J, Chen J, Hu Y, Ni Y. Augmenting antitumor immune effects through the coactivation of cGAS-STING and NF-κB crosstalk in dendritic cells and macrophages by engineered manganese ferrite nanohybrids. ACS Appl Mater Interfaces. 2025;17:13375–90.
</cite> [<a href="https://doi.org/10.1021/acsami.4c18570" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39964151/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chen%20H,%20Wang%20D,%20Liu%20J,%20Chen%20J,%20Hu%20Y,%20Ni%20Y.%20Augmenting%20antitumor%20immune%20effects%20through%20the%20coactivation%20of%20cGAS-STING%20and%20NF-%CE%BAB%20crosstalk%20in%20dendritic%20cells%20and%20macrophages%20by%20engineered%20manganese%20ferrite%20nanohybrids.%20ACS%20Appl%20Mater%20Interfaces.%202025;17:13375%E2%80%9390." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR87">
<span class="label">87.</span><cite>Dunn GP, Bruce AT, Sheehan KC, Shankaran V, Uppaluri R, Bui JD, Diamond MS, Koebel CM, Arthur C, White JM. A critical function for type I interferons in cancer immunoediting. Nat Immunol. 2005;6:722–9.
</cite> [<a href="https://doi.org/10.1038/ni1213" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15951814/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Dunn%20GP,%20Bruce%20AT,%20Sheehan%20KC,%20Shankaran%20V,%20Uppaluri%20R,%20Bui%20JD,%20Diamond%20MS,%20Koebel%20CM,%20Arthur%20C,%20White%20JM.%20A%20critical%20function%20for%20type%20I%20interferons%20in%20cancer%20immunoediting.%20Nat%20Immunol.%202005;6:722%E2%80%939." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR88">
<span class="label">88.</span><cite>Girard M, Law JC, Edilova MI, Watts TH. Type I interferons drive the maturation of human DC3s with a distinct costimulatory profile characterized by high GITRL. Sci Immunol. 2020;5(53): eabe0347.
</cite> [<a href="https://doi.org/10.1126/sciimmunol.abe0347" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33188059/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Girard%20M,%20Law%20JC,%20Edilova%20MI,%20Watts%20TH.%20Type%20I%20interferons%20drive%20the%20maturation%20of%20human%20DC3s%20with%20a%20distinct%20costimulatory%20profile%20characterized%20by%20high%20GITRL.%20Sci%20Immunol.%202020;5(53):%20eabe0347." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR89">
<span class="label">89.</span><cite>Gao X, Huang D, Liu Y, Zhang G, Zheng X, Guan B, Chen A, Wu J, Luo S-M, Liu Z. FAM210B activates STAT1/IRF9/IFIT3 axis by upregulating IFN-α/β expression to impede the progression of lung adenocarcinoma. Cell Death Dis. 2025;16:63.
</cite> [<a href="https://doi.org/10.1038/s41419-025-07375-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11791038/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39900908/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gao%20X,%20Huang%20D,%20Liu%20Y,%20Zhang%20G,%20Zheng%20X,%20Guan%20B,%20Chen%20A,%20Wu%20J,%20Luo%20S-M,%20Liu%20Z.%20FAM210B%20activates%20STAT1/IRF9/IFIT3%20axis%20by%20upregulating%20IFN-%CE%B1/%CE%B2%20expression%20to%20impede%20the%20progression%20of%20lung%20adenocarcinoma.%20Cell%20Death%20Dis.%202025;16:63." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR90">
<span class="label">90.</span><cite>Zhou H, Wang W, Xu H, Liang Y, Ding J, Lv M, Ren B, Peng H, Fu Y-X, Zhu M. Metabolic reprograming mediated by tumor cell-intrinsic type I IFN signaling is required for CD47-SIRPα blockade efficacy. Nat Commun. 2024;15:5759.
</cite> [<a href="https://doi.org/10.1038/s41467-024-50136-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11233683/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38982116/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhou%20H,%20Wang%20W,%20Xu%20H,%20Liang%20Y,%20Ding%20J,%20Lv%20M,%20Ren%20B,%20Peng%20H,%20Fu%20Y-X,%20Zhu%20M.%20Metabolic%20reprograming%20mediated%20by%20tumor%20cell-intrinsic%20type%20I%20IFN%20signaling%20is%20required%20for%20CD47-SIRP%CE%B1%20blockade%20efficacy.%20Nat%20Commun.%202024;15:5759." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR91">
<span class="label">91.</span><cite>Yu X, Du Y, Cai C, Cai B, Zhu M, Xing C, Tan P, Lin M, Wu J, Li J. Inflammasome activation negatively regulates MyD88-IRF7 type I IFN signaling and anti-malaria immunity. Nat Commun. 2018;9:4964.
</cite> [<a href="https://doi.org/10.1038/s41467-018-07384-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6251914/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30470758/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yu%20X,%20Du%20Y,%20Cai%20C,%20Cai%20B,%20Zhu%20M,%20Xing%20C,%20Tan%20P,%20Lin%20M,%20Wu%20J,%20Li%20J.%20Inflammasome%20activation%20negatively%20regulates%20MyD88-IRF7%20type%20I%20IFN%20signaling%20and%20anti-malaria%20immunity.%20Nat%20Commun.%202018;9:4964." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR92">
<span class="label">92.</span><cite>Zhang X, Shi H, Wu J, Zhang X, Sun L, Chen C, Chen ZJ. Cyclic GMP-AMP containing mixed phosphodiester linkages is an endogenous high-affinity ligand for STING. Mol Cell. 2013;51:226–35.
</cite> [<a href="https://doi.org/10.1016/j.molcel.2013.05.022" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3808999/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23747010/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20X,%20Shi%20H,%20Wu%20J,%20Zhang%20X,%20Sun%20L,%20Chen%20C,%20Chen%20ZJ.%20Cyclic%20GMP-AMP%20containing%20mixed%20phosphodiester%20linkages%20is%20an%20endogenous%20high-affinity%20ligand%20for%20STING.%20Mol%20Cell.%202013;51:226%E2%80%9335." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR93">
<span class="label">93.</span><cite>Burdette DL, Monroe KM, Sotelo-Troha K, Iwig JS, Eckert B, Hyodo M, Hayakawa Y, Vance RE. STING is a direct innate immune sensor of cyclic di-GMP. Nature. 2011;478:515–8.
</cite> [<a href="https://doi.org/10.1038/nature10429" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3203314/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21947006/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Burdette%20DL,%20Monroe%20KM,%20Sotelo-Troha%20K,%20Iwig%20JS,%20Eckert%20B,%20Hyodo%20M,%20Hayakawa%20Y,%20Vance%20RE.%20STING%20is%20a%20direct%20innate%20immune%20sensor%20of%20cyclic%20di-GMP.%20Nature.%202011;478:515%E2%80%938." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR94">
<span class="label">94.</span><cite>Morehouse BR, Govande AA, Millman A, Keszei AFA, Lowey B, Ofir G, Shao S, Sorek R, Kranzusch PJ. STING cyclic dinucleotide sensing originated in bacteria. Nature. 2020;586:429–33.
</cite> [<a href="https://doi.org/10.1038/s41586-020-2719-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7572726/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32877915/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Morehouse%20BR,%20Govande%20AA,%20Millman%20A,%20Keszei%20AFA,%20Lowey%20B,%20Ofir%20G,%20Shao%20S,%20Sorek%20R,%20Kranzusch%20PJ.%20STING%20cyclic%20dinucleotide%20sensing%20originated%20in%20bacteria.%20Nature.%202020;586:429%E2%80%9333." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR95">
<span class="label">95.</span><cite>Krasteva PV, Sondermann H. Versatile modes of cellular regulation via cyclic dinucleotides. Nat Chem Biol. 2017;13:350–9.
</cite> [<a href="https://doi.org/10.1038/nchembio.2337" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5773344/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28328921/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Krasteva%20PV,%20Sondermann%20H.%20Versatile%20modes%20of%20cellular%20regulation%20via%20cyclic%20dinucleotides.%20Nat%20Chem%20Biol.%202017;13:350%E2%80%939." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR96">
<span class="label">96.</span><cite>Dane EL, Belessiotis-Richards A, Backlund C, Wang J, Hidaka K, Milling LE, Bhagchandani S, Melo MB, Wu S, Li N. STING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robust anticancer immunity. Nat Mater. 2022;21:710–20.
</cite> [<a href="https://doi.org/10.1038/s41563-022-01251-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9156412/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35606429/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Dane%20EL,%20Belessiotis-Richards%20A,%20Backlund%20C,%20Wang%20J,%20Hidaka%20K,%20Milling%20LE,%20Bhagchandani%20S,%20Melo%20MB,%20Wu%20S,%20Li%20N.%20STING%20agonist%20delivery%20by%20tumour-penetrating%20PEG-lipid%20nanodiscs%20primes%20robust%20anticancer%20immunity.%20Nat%20Mater.%202022;21:710%E2%80%9320." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR97">
<span class="label">97.</span><cite>Lu X, Xia H, Gao W, Pan X, Yan Y, Zhang R, He Y, Wang Y, Chen B, Mei D. A pH-responsive and guanidinium-rich nanoadjuvant efficiently delivers STING agonist for cancer immunotherapy. ACS Nano. 2025;19:6758–70.
</cite> [<a href="https://doi.org/10.1021/acsnano.4c10202" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39933120/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lu%20X,%20Xia%20H,%20Gao%20W,%20Pan%20X,%20Yan%20Y,%20Zhang%20R,%20He%20Y,%20Wang%20Y,%20Chen%20B,%20Mei%20D.%20A%20pH-responsive%20and%20guanidinium-rich%20nanoadjuvant%20efficiently%20delivers%20STING%20agonist%20for%20cancer%20immunotherapy.%20ACS%20Nano.%202025;19:6758%E2%80%9370." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR98">
<span class="label">98.</span><cite>Li L, Yin Q, Kuss P, Maliga Z, Millán JL, Wu H, Mitchison TJ. Hydrolysis of 2’3’-cGAMP by ENPP1 and design of nonhydrolyzable analogs. Nat Chem Biol. 2014;10:1043–8.
</cite> [<a href="https://doi.org/10.1038/nchembio.1661" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4232468/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25344812/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Li%20L,%20Yin%20Q,%20Kuss%20P,%20Maliga%20Z,%20Mill%C3%A1n%20JL,%20Wu%20H,%20Mitchison%20TJ.%20Hydrolysis%20of%202%E2%80%993%E2%80%99-cGAMP%20by%20ENPP1%20and%20design%20of%20nonhydrolyzable%20analogs.%20Nat%20Chem%20Biol.%202014;10:1043%E2%80%938." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR99">
<span class="label">99.</span><cite>Garland KM, Sheehy TL, Wilson JT. Chemical and biomolecular strategies for STING pathway activation in cancer immunotherapy. Chem Rev. 2022;122:5977–6039.
</cite> [<a href="https://doi.org/10.1021/acs.chemrev.1c00750" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8994686/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35107989/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Garland%20KM,%20Sheehy%20TL,%20Wilson%20JT.%20Chemical%20and%20biomolecular%20strategies%20for%20STING%20pathway%20activation%20in%20cancer%20immunotherapy.%20Chem%20Rev.%202022;122:5977%E2%80%936039." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR100">
<span class="label">100.</span><cite>Lioux T, Mauny M-A, Lamoureux A, Bascoul N, Hays M, Vernejoul F, Baudru A-S, Boularan C, Lopes-Vicente J, Qushair G. Design, synthesis, and biological evaluation of novel cyclic adenosine–inosine monophosphate (cAIMP) analogs that activate stimulator of interferon genes (STING). J Med Chem. 2016;59:10253–67.
</cite> [<a href="https://doi.org/10.1021/acs.jmedchem.6b01300" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27783523/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lioux%20T,%20Mauny%20M-A,%20Lamoureux%20A,%20Bascoul%20N,%20Hays%20M,%20Vernejoul%20F,%20Baudru%20A-S,%20Boularan%20C,%20Lopes-Vicente%20J,%20Qushair%20G.%20Design,%20synthesis,%20and%20biological%20evaluation%20of%20novel%20cyclic%20adenosine%E2%80%93inosine%20monophosphate%20(cAIMP)%20analogs%20that%20activate%20stimulator%20of%20interferon%20genes%20(STING).%20J%20Med%20Chem.%202016;59:10253%E2%80%9367." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR101">
<span class="label">101.</span><cite>Yang X, Wu T, Phipps RJ, Toste FD. Advances in catalytic enantioselective fluorination, mono-, di-, and trifluoromethylation, and trifluoromethylthiolation reactions. Chem Rev. 2015;115:826–70.
</cite> [<a href="https://doi.org/10.1021/cr500277b" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4311656/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25337896/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yang%20X,%20Wu%20T,%20Phipps%20RJ,%20Toste%20FD.%20Advances%20in%20catalytic%20enantioselective%20fluorination,%20mono-,%20di-,%20and%20trifluoromethylation,%20and%20trifluoromethylthiolation%20reactions.%20Chem%20Rev.%202015;115:826%E2%80%9370." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR102">
<span class="label">102.</span><cite>Bibby M, Phillips RM, Double J, Pratesi G. Anti-tumour activity of flavone acetic acid (NSC 347512) in mice–influence of immune status. Br J Cancer. 1991;63:57–62.
</cite> [<a href="https://doi.org/10.1038/bjc.1991.12" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC1971643/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/1989665/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Bibby%20M,%20Phillips%20RM,%20Double%20J,%20Pratesi%20G.%20Anti-tumour%20activity%20of%20flavone%20acetic%20acid%20(NSC%20347512)%20in%20mice%E2%80%93influence%20of%20immune%20status.%20Br%20J%20Cancer.%201991;63:57%E2%80%9362." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR103">
<span class="label">103.</span><cite>Prantner D, Perkins DJ, Lai W, Williams MS, Sharma S, Fitzgerald KA, Vogel SN. 5, 6-Dimethylxanthenone-4-acetic acid (DMXAA) activates stimulator of interferon gene (STING)-dependent innate immune pathways and is regulated by mitochondrial membrane potential. J Biol Chem. 2012;287:39776–88.
</cite> [<a href="https://doi.org/10.1074/jbc.M112.382986" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3501038/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23027866/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Prantner%20D,%20Perkins%20DJ,%20Lai%20W,%20Williams%20MS,%20Sharma%20S,%20Fitzgerald%20KA,%20Vogel%20SN.%205,%206-Dimethylxanthenone-4-acetic%20acid%20(DMXAA)%20activates%20stimulator%20of%20interferon%20gene%20(STING)-dependent%20innate%20immune%20pathways%20and%20is%20regulated%20by%20mitochondrial%20membrane%20potential.%20J%20Biol%20Chem.%202012;287:39776%E2%80%9388." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR104">
<span class="label">104.</span><cite>Mu W, Xu G, Li L, Wen J, Xiu Y, Zhao J, Liu T, Wei Z, Luo W, Yang H. Carnosic acid directly targets STING C-terminal tail to improve STING‐mediated inflammatory diseases. Adv Sci. 2025;12:2417686.</cite> [<a href="https://doi.org/10.1002/advs.202417686" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11984877/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39965124/" class="usa-link">PubMed</a>]</li>
<li id="CR105">
<span class="label">105.</span><cite>Chen N-N, Zhang H, Zhu Q-S, Zeng T, Dai W, Zhou Y-L, Xin G-F, Wu B-D, Gong S-J, Jiang Z-Y. Development of orally bioavailable amidobenzimidazole analogues targeting stimulator of interferon gene (STING) receptor. J Med Chem. 2023;66:5584–610.
</cite> [<a href="https://doi.org/10.1021/acs.jmedchem.2c02046" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37027512/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chen%20N-N,%20Zhang%20H,%20Zhu%20Q-S,%20Zeng%20T,%20Dai%20W,%20Zhou%20Y-L,%20Xin%20G-F,%20Wu%20B-D,%20Gong%20S-J,%20Jiang%20Z-Y.%20Development%20of%20orally%20bioavailable%20amidobenzimidazole%20analogues%20targeting%20stimulator%20of%20interferon%20gene%20(STING)%20receptor.%20J%20Med%20Chem.%202023;66:5584%E2%80%93610." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR106">
<span class="label">106.</span><cite>Ramanjulu JM, Pesiridis GS, Yang J, Concha N, Singhaus R, Zhang S-Y, Tran J-L, Moore P, Lehmann S, Eberl HC. Design of amidobenzimidazole STING receptor agonists with systemic activity. Nature. 2018;564:439–43.
</cite> [<a href="https://doi.org/10.1038/s41586-018-0705-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30405246/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ramanjulu%20JM,%20Pesiridis%20GS,%20Yang%20J,%20Concha%20N,%20Singhaus%20R,%20Zhang%20S-Y,%20Tran%20J-L,%20Moore%20P,%20Lehmann%20S,%20Eberl%20HC.%20Design%20of%20amidobenzimidazole%20STING%20receptor%20agonists%20with%20systemic%20activity.%20Nature.%202018;564:439%E2%80%9343." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR107">
<span class="label">107.</span><cite>Liu J, Huang X, Ding J. Identification of MSA-2: an oral antitumor non-nucleotide STING agonist. Signal Transduct Target Ther. 2021;6: 18.
</cite> [<a href="https://doi.org/10.1038/s41392-020-00459-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7804957/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33436539/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Liu%20J,%20Huang%20X,%20Ding%20J.%20Identification%20of%20MSA-2:%20an%20oral%20antitumor%20non-nucleotide%20STING%20agonist.%20Signal%20Transduct%20Target%20Ther.%202021;6:%2018." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR108">
<span class="label">108.</span><cite>Chin EN, Yu C, Vartabedian VF, Jia Y, Kumar M, Gamo AM, Vernier W, Ali SH, Kissai M, Lazar DC. Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic. Science. 2020;369:993–9.
</cite> [<a href="https://doi.org/10.1126/science.abb4255" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32820126/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chin%20EN,%20Yu%20C,%20Vartabedian%20VF,%20Jia%20Y,%20Kumar%20M,%20Gamo%20AM,%20Vernier%20W,%20Ali%20SH,%20Kissai%20M,%20Lazar%20DC.%20Antitumor%20activity%20of%20a%20systemic%20STING-activating%20non-nucleotide%20cGAMP%20mimetic.%20Science.%202020;369:993%E2%80%939." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR109">
<span class="label">109.</span><cite>Jeon MJ, Lee H, Lee J, Baek SY, Lee D, Jo S, Lee J-Y, Kang M, Jung HR, Han SB. Development of potent immune modulators targeting stimulator of interferon genes receptor. J Med Chem. 2022;65(7):5407–32.
</cite> [<a href="https://doi.org/10.1021/acs.jmedchem.1c01795" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35315650/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Jeon%20MJ,%20Lee%20H,%20Lee%20J,%20Baek%20SY,%20Lee%20D,%20Jo%20S,%20Lee%20J-Y,%20Kang%20M,%20Jung%20HR,%20Han%20SB.%20Development%20of%20potent%20immune%20modulators%20targeting%20stimulator%20of%20interferon%20genes%20receptor.%20J%20Med%20Chem.%202022;65(7):5407%E2%80%9332." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR110">
<span class="label">110.</span><cite>Liu D, Yu B, Guan X, Song B, Pan H, Wang R, Feng X, Pan L, Huang H, Wang Z. Discovery of a photoactivatable dimerized STING agonist based on the benzo[b]selenophene scaffold. Chem Sci. 2023;14:4174–82.
</cite> [<a href="https://doi.org/10.1039/d2sc06860e" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10094158/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37063808/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Liu%20D,%20Yu%20B,%20Guan%20X,%20Song%20B,%20Pan%20H,%20Wang%20R,%20Feng%20X,%20Pan%20L,%20Huang%20H,%20Wang%20Z.%20Discovery%20of%20a%20photoactivatable%20dimerized%20STING%20agonist%20based%20on%20the%20benzo%5Bb%5Dselenophene%20scaffold.%20Chem%20Sci.%202023;14:4174%E2%80%9382." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR111">
<span class="label">111.</span><cite>Lei H, Li Q, Li G, Wang T, Lv X, Pei Z, Gao X, Yang N, Gong F, Yang Y. Manganese molybdate nanodots with dual amplification of STING activation for cycle treatment of metalloimmunotherapy. Bioact Mater. 2024;31:53–62.
</cite> [<a href="https://doi.org/10.1016/j.bioactmat.2023.07.026" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10432900/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37601278/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lei%20H,%20Li%20Q,%20Li%20G,%20Wang%20T,%20Lv%20X,%20Pei%20Z,%20Gao%20X,%20Yang%20N,%20Gong%20F,%20Yang%20Y.%20Manganese%20molybdate%20nanodots%20with%20dual%20amplification%20of%20STING%20activation%20for%20cycle%20treatment%20of%20metalloimmunotherapy.%20Bioact%20Mater.%202024;31:53%E2%80%9362." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR112">
<span class="label">112.</span><cite>He Q, Zheng R, Ma J, Zhao L, Shi Y, Qiu J. Responsive manganese-based nanoplatform amplifying cGAS-STING activation for immunotherapy. Biomater Res. 2023;27:29.
</cite> [<a href="https://doi.org/10.1186/s40824-023-00374-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10105937/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37061706/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?He%20Q,%20Zheng%20R,%20Ma%20J,%20Zhao%20L,%20Shi%20Y,%20Qiu%20J.%20Responsive%20manganese-based%20nanoplatform%20amplifying%20cGAS-STING%20activation%20for%20immunotherapy.%20Biomater%20Res.%202023;27:29." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR113">
<span class="label">113.</span><cite>Shae D, Becker KW, Christov P, Yun DS, Lytton-Jean AK, Sevimli S, Ascano M, Kelley M, Johnson DB, Balko JM. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy. Nat Nanotechnol. 2019;14:269–78.
</cite> [<a href="https://doi.org/10.1038/s41565-018-0342-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6402974/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30664751/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Shae%20D,%20Becker%20KW,%20Christov%20P,%20Yun%20DS,%20Lytton-Jean%20AK,%20Sevimli%20S,%20Ascano%20M,%20Kelley%20M,%20Johnson%20DB,%20Balko%20JM.%20Endosomolytic%20polymersomes%20increase%20the%20activity%20of%20cyclic%20dinucleotide%20STING%20agonists%20to%20enhance%20cancer%20immunotherapy.%20Nat%20Nanotechnol.%202019;14:269%E2%80%9378." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR114">
<span class="label">114.</span><cite>Reisländer T, Groelly FJ, Tarsounas M. DNA damage and cancer immunotherapy: a STING in the tale. Mol Cell. 2020;80:21–8.
</cite> [<a href="https://doi.org/10.1016/j.molcel.2020.07.026" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32810436/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Reisl%C3%A4nder%20T,%20Groelly%20FJ,%20Tarsounas%20M.%20DNA%20damage%20and%20cancer%20immunotherapy:%20a%20STING%20in%20the%20tale.%20Mol%20Cell.%202020;80:21%E2%80%938." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR115">
<span class="label">115.</span><cite>Newman LE, Shadel GS. Mitochondrial DNA release in innate immune signaling. Annu Rev Biochem. 2023;92:299–332.
</cite> [<a href="https://doi.org/10.1146/annurev-biochem-032620-104401" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11058562/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37001140/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Newman%20LE,%20Shadel%20GS.%20Mitochondrial%20DNA%20release%20in%20innate%20immune%20signaling.%20Annu%20Rev%20Biochem.%202023;92:299%E2%80%93332." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR116">
<span class="label">116.</span><cite>Chen X, Xu Z, Li T, Thakur A, Wen Y, Zhang K, Liu Y, Liang Q, Liu W, Qin J-J. Nanomaterial-encapsulated STING agonists for immune modulation in cancer therapy. Biomark Res. 2024;12:2.
</cite> [<a href="https://doi.org/10.1186/s40364-023-00551-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10773049/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38185685/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chen%20X,%20Xu%20Z,%20Li%20T,%20Thakur%20A,%20Wen%20Y,%20Zhang%20K,%20Liu%20Y,%20Liang%20Q,%20Liu%20W,%20Qin%20J-J.%20Nanomaterial-encapsulated%20STING%20agonists%20for%20immune%20modulation%20in%20cancer%20therapy.%20Biomark%20Res.%202024;12:2." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR117">
<span class="label">117.</span><cite>Tan J, Wang M, Ding B, Ma P, Lin J. Advanced nanomaterials targeting activation of STING for enhanced cancer immunotherapy. Coord Chem Rev. 2023;493: 215316.</cite> [<a href="https://scholar.google.com/scholar_lookup?Tan%20J,%20Wang%20M,%20Ding%20B,%20Ma%20P,%20Lin%20J.%20Advanced%20nanomaterials%20targeting%20activation%20of%20STING%20for%20enhanced%20cancer%20immunotherapy.%20Coord%20Chem%20Rev.%202023;493:%20215316." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR118">
<span class="label">118.</span><cite>Liu C, Guo L, Wang Y, Zhang J, Fu C. Delivering metal ions by nanomaterials: turning metal ions into drug-like cancer theranostic agents. Coord Chem Rev. 2023;494: 215332.</cite> [<a href="https://scholar.google.com/scholar_lookup?Liu%20C,%20Guo%20L,%20Wang%20Y,%20Zhang%20J,%20Fu%20C.%20Delivering%20metal%20ions%20by%20nanomaterials:%20turning%20metal%20ions%20into%20drug-like%20cancer%20theranostic%20agents.%20Coord%20Chem%20Rev.%202023;494:%20215332." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR119">
<span class="label">119.</span><cite>Li X, Liu H, Gao W, Yang Q, Li X, Zhou X, Wang L, Lu Z, Liu J, Luo A, Chen C, Liu Z, Zhao Y. Octadecyl gallate and lipid-modified MnSe<sub>2</sub> nanoparticles enhance radiosensitivity in esophageal squamous cell carcinoma and promote radioprotection in normal tissues. Adv Mater. 2024;36:2311291.</cite> [<a href="https://doi.org/10.1002/adma.202311291" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38408154/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Li%20X,%20Liu%20H,%20Gao%20W,%20Yang%20Q,%20Li%20X,%20Zhou%20X,%20Wang%20L,%20Lu%20Z,%20Liu%20J,%20Luo%20A,%20Chen%20C,%20Liu%20Z,%20Zhao%20Y.%20Octadecyl%20gallate%20and%20lipid-modified%20MnSe2%20nanoparticles%20enhance%20radiosensitivity%20in%20esophageal%20squamous%20cell%20carcinoma%20and%20promote%20radioprotection%20in%20normal%20tissues.%20Adv%20Mater.%202024;36:2311291." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR120">
<span class="label">120.</span><cite>Fu L, Hu Y, Qi C, He T, Jiang S, Jiang C, He J, Qu J, Lin J, Huang P. Biodegradable manganese-doped calcium phosphate nanotheranostics for traceable cascade reaction-enhanced anti-tumor therapy. ACS Nano. 2019;13:13985–94.
</cite> [<a href="https://doi.org/10.1021/acsnano.9b05836" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31833366/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Fu%20L,%20Hu%20Y,%20Qi%20C,%20He%20T,%20Jiang%20S,%20Jiang%20C,%20He%20J,%20Qu%20J,%20Lin%20J,%20Huang%20P.%20Biodegradable%20manganese-doped%20calcium%20phosphate%20nanotheranostics%20for%20traceable%20cascade%20reaction-enhanced%20anti-tumor%20therapy.%20ACS%20Nano.%202019;13:13985%E2%80%9394." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR121">
<span class="label">121.</span><cite>Peng K, Zheng Y, Xia W, Mao Z. Organometallic anti-tumor agents: targeting from biomolecules to dynamic bioprocesses. Chem Soc Rev. 2023;52:2790–832.
</cite> [<a href="https://doi.org/10.1039/d2cs00757f" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37014670/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Peng%20K,%20Zheng%20Y,%20Xia%20W,%20Mao%20Z.%20Organometallic%20anti-tumor%20agents:%20targeting%20from%20biomolecules%20to%20dynamic%20bioprocesses.%20Chem%20Soc%20Rev.%202023;52:2790%E2%80%93832." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR122">
<span class="label">122.</span><cite>Wang Y, Yan J, Wen N, Xiong H, Cai S, He Q, Hu Y, Peng D, Liu Z, Liu Y. Metal-organic frameworks for stimuli-responsive drug delivery. Biomaterials. 2020;230:119619.
</cite> [<a href="https://doi.org/10.1016/j.biomaterials.2019.119619" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31757529/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang%20Y,%20Yan%20J,%20Wen%20N,%20Xiong%20H,%20Cai%20S,%20He%20Q,%20Hu%20Y,%20Peng%20D,%20Liu%20Z,%20Liu%20Y.%20Metal-organic%20frameworks%20for%20stimuli-responsive%20drug%20delivery.%20Biomaterials.%202020;230:119619." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR123">
<span class="label">123.</span><cite>Liu B, Duan H, Sun L, Liu Z, Sun Z, Chu H. Core–shell structured metal–organic frameworks for pH-triggered combination photodynamic/chemotherapy-based cancer treatment. Biomater Res. 2025;29:0138.
</cite> [<a href="https://doi.org/10.34133/bmr.0138" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11751201/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39844866/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Liu%20B,%20Duan%20H,%20Sun%20L,%20Liu%20Z,%20Sun%20Z,%20Chu%20H.%20Core%E2%80%93shell%20structured%20metal%E2%80%93organic%20frameworks%20for%20pH-triggered%20combination%20photodynamic/chemotherapy-based%20cancer%20treatment.%20Biomater%20Res.%202025;29:0138." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR124">
<span class="label">124.</span><cite>Li H, Zhang C, Chen Y, Xu Y, Yao W, Fan W. Biodegradable long-circulating nanoagonists optimize tumor-tropism chemo-metalloimmunotherapy for boosted antitumor immunity by cascade cGAS-STING pathway activation. ACS Nano. 2024;18:23711–26.
</cite> [<a href="https://doi.org/10.1021/acsnano.4c08463" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39148423/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Li%20H,%20Zhang%20C,%20Chen%20Y,%20Xu%20Y,%20Yao%20W,%20Fan%20W.%20Biodegradable%20long-circulating%20nanoagonists%20optimize%20tumor-tropism%20chemo-metalloimmunotherapy%20for%20boosted%20antitumor%20immunity%20by%20cascade%20cGAS-STING%20pathway%20activation.%20ACS%20Nano.%202024;18:23711%E2%80%9326." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR125">
<span class="label">125.</span><cite>Zheng S-J, Yang M, Luo J-Q, Liu R, Song J, Chen Y, Du J-Z. Manganese-based immunostimulatory metal–organic framework activates the cGAS-STING pathway for cancer metalloimmunotherapy. ACS Nano. 2023;17:15905–17.
</cite> [<a href="https://doi.org/10.1021/acsnano.3c03962" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37565626/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zheng%20S-J,%20Yang%20M,%20Luo%20J-Q,%20Liu%20R,%20Song%20J,%20Chen%20Y,%20Du%20J-Z.%20Manganese-based%20immunostimulatory%20metal%E2%80%93organic%20framework%20activates%20the%20cGAS-STING%20pathway%20for%20cancer%20metalloimmunotherapy.%20ACS%20Nano.%202023;17:15905%E2%80%9317." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR126">
<span class="label">126.</span><cite>Liu F, Tan L, Dai Z, Wang Y, Huang L, Zhang Y, Cheng Q, Li X, Liu M-D, Wang L. Manganese-based microcrystals equipped with Ythdf1-targeted biomimetic nanovaccines for reinforced dendritic cell spatiotemporal orchestration. Nano Today. 2024;54:102112.</cite> [<a href="https://scholar.google.com/scholar_lookup?Liu%20F,%20Tan%20L,%20Dai%20Z,%20Wang%20Y,%20Huang%20L,%20Zhang%20Y,%20Cheng%20Q,%20Li%20X,%20Liu%20M-D,%20Wang%20L.%20Manganese-based%20microcrystals%20equipped%20with%20Ythdf1-targeted%20biomimetic%20nanovaccines%20for%20reinforced%20dendritic%20cell%20spatiotemporal%20orchestration.%20Nano%20Today.%202024;54:102112." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR127">
<span class="label">127.</span><cite>Chen X, Tang Q, Wang J, Zhou Y, Li F, Xie Y, Wang X, Du L, Li J, Pu J. A DNA/DMXAA/Metal–organic framework activator of innate immunity for boosting anticancer immunity. Adv Mater. 2023;35:2210440.</cite> [<a href="https://doi.org/10.1002/adma.202210440" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36656162/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chen%20X,%20Tang%20Q,%20Wang%20J,%20Zhou%20Y,%20Li%20F,%20Xie%20Y,%20Wang%20X,%20Du%20L,%20Li%20J,%20Pu%20J.%20A%20DNA/DMXAA/Metal%E2%80%93organic%20framework%20activator%20of%20innate%20immunity%20for%20boosting%20anticancer%20immunity.%20Adv%20Mater.%202023;35:2210440." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR128">
<span class="label">128.</span><cite>Huang C, Zhi X, Ye T, Wang X, Li K, Li Y, Zhang Q, Jiang L, Ding X. Boosting humoral and cellular immunity with enhanced STING activation by hierarchical mesoporous metal-organic framework adjuvants. J Control Release. 2024;370:691–706.
</cite> [<a href="https://doi.org/10.1016/j.jconrel.2024.05.010" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38723671/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Huang%20C,%20Zhi%20X,%20Ye%20T,%20Wang%20X,%20Li%20K,%20Li%20Y,%20Zhang%20Q,%20Jiang%20L,%20Ding%20X.%20Boosting%20humoral%20and%20cellular%20immunity%20with%20enhanced%20STING%20activation%20by%20hierarchical%20mesoporous%20metal-organic%20framework%20adjuvants.%20J%20Control%20Release.%202024;370:691%E2%80%93706." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR129">
<span class="label">129.</span><cite>Zhou Y, Huang X, Wu D, Xie X, Li H, Wang Q, Liao Y, Li H. HIFU postoperative hypoxia enables metal-organic frameworks amplifying Banoxantrone and STING activation for enhanced immunotherapy. Chem Eng J. 2025;505:159704. </cite>
</li>
<li id="CR130">
<span class="label">130.</span><cite>Zhao X, Wang Y, Jiang W, Wang Q, Li J, Wen Z, Li A, Zhang K, Zhang Z, Shi J. Herpesvirus-Mimicking DNAzyme‐Loaded nanoparticles as a mitochondrial DNA stress inducer to activate innate immunity for tumor therapy. Adv Mater. 2022;34:2204585.</cite> [<a href="https://doi.org/10.1002/adma.202204585" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35869026/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhao%20X,%20Wang%20Y,%20Jiang%20W,%20Wang%20Q,%20Li%20J,%20Wen%20Z,%20Li%20A,%20Zhang%20K,%20Zhang%20Z,%20Shi%20J.%20Herpesvirus-Mimicking%20DNAzyme%E2%80%90Loaded%20nanoparticles%20as%20a%20mitochondrial%20DNA%20stress%20inducer%20to%20activate%20innate%20immunity%20for%20tumor%20therapy.%20Adv%20Mater.%202022;34:2204585." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR131">
<span class="label">131.</span><cite>Xu M, Chang Y, Zhu G, Zhu X, Song X, Li J. Transforming cold tumors into hot ones with a metal–organic framework-based biomimetic nanosystem for enhanced immunotherapy. ACS Appl Mater Interfaces. 2023;15:17470–84.
</cite> [<a href="https://doi.org/10.1021/acsami.2c21005" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36995264/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Xu%20M,%20Chang%20Y,%20Zhu%20G,%20Zhu%20X,%20Song%20X,%20Li%20J.%20Transforming%20cold%20tumors%20into%20hot%20ones%20with%20a%20metal%E2%80%93organic%20framework-based%20biomimetic%20nanosystem%20for%20enhanced%20immunotherapy.%20ACS%20Appl%20Mater%20Interfaces.%202023;15:17470%E2%80%9384." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR132">
<span class="label">132.</span><cite>Fang M, Zheng J, Wang J, Zheng C, Leng X, Wen E, Li P, Ran H, Zhang L, Wang Z. Amplifying STING activation and alleviating immunosuppression through a Mn<sup>2+</sup>-based metal-organic framework nanosystem for synergistic cancer therapy. Biomater Res. 2024;28: 0028.
</cite> [<a href="https://doi.org/10.34133/bmr.0028" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11075671/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38715912/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Fang%20M,%20Zheng%20J,%20Wang%20J,%20Zheng%20C,%20Leng%20X,%20Wen%20E,%20Li%20P,%20Ran%20H,%20Zhang%20L,%20Wang%20Z.%20Amplifying%20STING%20activation%20and%20alleviating%20immunosuppression%20through%20a%20Mn2+-based%20metal-organic%20framework%20nanosystem%20for%20synergistic%20cancer%20therapy.%20Biomater%20Res.%202024;28:%200028." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR133">
<span class="label">133.</span><cite>Wang C, Li J, Jiang X, Ma X, Zhen W, Tillman L, Weichselbaum RR, Lin W. Bifunctional metal–organic framework synergistically enhances radiotherapy and activates STING for potent cancer radio-immunotherapy. Angew Chem Int Ed Engl. 2025;64:e202417027.
</cite> [<a href="https://doi.org/10.1002/anie.202417027" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39375150/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang%20C,%20Li%20J,%20Jiang%20X,%20Ma%20X,%20Zhen%20W,%20Tillman%20L,%20Weichselbaum%20RR,%20Lin%20W.%20Bifunctional%20metal%E2%80%93organic%20framework%20synergistically%20enhances%20radiotherapy%20and%20activates%20STING%20for%20potent%20cancer%20radio-immunotherapy.%20Angew%20Chem%20Int%20Ed%20Engl.%202025;64:e202417027." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR134">
<span class="label">134.</span><cite>Luo T, Jiang X, Fan Y, Yuan E, Li J, Tillman L, Lin W. STING agonist-conjugated metal-organic framework induces artificial leukocytoid structures and immune hotspots for systemic antitumor responses. Natl Sci Rev. 2024;11:nwae167. </cite> [<a href="https://doi.org/10.1093/nsr/nwae167" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11182667/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38887543/" class="usa-link">PubMed</a>]</li>
<li id="CR135">
<span class="label">135.</span><cite>Xiong Z, Yang M, Liu P, Tang Z, Yang Y, Zhan M, Chen T, Li X, Lu L. Designing bimetallic metal-organic framework‐based heterojunction radiosensitizer for enhanced radiodynamic therapy and immunotherapy. Adv Funct Mater. 2024;34:2312919.</cite> [<a href="https://scholar.google.com/scholar_lookup?Xiong%20Z,%20Yang%20M,%20Liu%20P,%20Tang%20Z,%20Yang%20Y,%20Zhan%20M,%20Chen%20T,%20Li%20X,%20Lu%20L.%20Designing%20bimetallic%20metal-organic%20framework%E2%80%90based%20heterojunction%20radiosensitizer%20for%20enhanced%20radiodynamic%20therapy%20and%20immunotherapy.%20Adv%20Funct%20Mater.%202024;34:2312919." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR136">
<span class="label">136.</span><cite>Gong Y, Cheng Y, Zeng F, Liu X, Yang Y, Zhang F, Wen C, Yang F, Li H, He Y. A self-gelling hemostatic powder boosting radiotherapy-elicited NK cell immunity to combat postoperative hepatocellular carcinoma relapse. Biomaterials. 2025;317:123068.
</cite> [<a href="https://doi.org/10.1016/j.biomaterials.2024.123068" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39813968/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gong%20Y,%20Cheng%20Y,%20Zeng%20F,%20Liu%20X,%20Yang%20Y,%20Zhang%20F,%20Wen%20C,%20Yang%20F,%20Li%20H,%20He%20Y.%20A%20self-gelling%20hemostatic%20powder%20boosting%20radiotherapy-elicited%20NK%20cell%20immunity%20to%20combat%20postoperative%20hepatocellular%20carcinoma%20relapse.%20Biomaterials.%202025;317:123068." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR137">
<span class="label">137.</span><cite>Zhao H, Jin S, Liu Y, Wang Q, Tan B SN, Wang S, Han K, Niu X, Zhao Y. A second near-infrared window-responsive metal–organic-framework-based photosensitizer for tumor immunotherapy via synergistic ferroptosis and STING activation. J Am Chem Soc. 2025;147:4871–85.
</cite> [<a href="https://doi.org/10.1021/jacs.4c13241" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39854684/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhao%20H,%20Jin%20S,%20Liu%20Y,%20Wang%20Q,%20Tan%20B%20SN,%20Wang%20S,%20Han%20K,%20Niu%20X,%20Zhao%20Y.%20A%20second%20near-infrared%20window-responsive%20metal%E2%80%93organic-framework-based%20photosensitizer%20for%20tumor%20immunotherapy%20via%20synergistic%20ferroptosis%20and%20STING%20activation.%20J%20Am%20Chem%20Soc.%202025;147:4871%E2%80%9385." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR138">
<span class="label">138.</span><cite>Zhao X, Zhang K, Wang Y, Jiang W, Cheng H, Wang Q, Xiang T, Zhang Z, Liu J, Shi J. Intracellular self-assembly driven nucleus‐targeted photo‐immune stimulator with chromatin decompaction function for robust innate and adaptive antitumor immunity. Adv Funct Mater. 2022;32:2108883.</cite> [<a href="https://scholar.google.com/scholar_lookup?Zhao%20X,%20Zhang%20K,%20Wang%20Y,%20Jiang%20W,%20Cheng%20H,%20Wang%20Q,%20Xiang%20T,%20Zhang%20Z,%20Liu%20J,%20Shi%20J.%20Intracellular%20self-assembly%20driven%20nucleus%E2%80%90targeted%20photo%E2%80%90immune%20stimulator%20with%20chromatin%20decompaction%20function%20for%20robust%20innate%20and%20adaptive%20antitumor%20immunity.%20Adv%20Funct%20Mater.%202022;32:2108883." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR139">
<span class="label">139.</span><cite>Lei J, Zhang W, Ma L, He Y, Liang H, Zhang X, Li G, Feng X, Tan L, Yang C. Sonodynamic amplification of cGAS-STING activation by cobalt-based nanoagonist against bone and metastatic tumor. Biomaterials. 2023;302:122295.
</cite> [<a href="https://doi.org/10.1016/j.biomaterials.2023.122295" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37666101/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lei%20J,%20Zhang%20W,%20Ma%20L,%20He%20Y,%20Liang%20H,%20Zhang%20X,%20Li%20G,%20Feng%20X,%20Tan%20L,%20Yang%20C.%20Sonodynamic%20amplification%20of%20cGAS-STING%20activation%20by%20cobalt-based%20nanoagonist%20against%20bone%20and%20metastatic%20tumor.%20Biomaterials.%202023;302:122295." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR140">
<span class="label">140.</span><cite>Xu M, Chen H, Zhu G, Zhu X, Gao R, Xu B, Song X, Han X, Shao T, Sun Q. Spiky metal-organic framework nanosystem for enhanced cuproptosis-mediated cancer immunotherapy. Nano Today. 2024;56:102231.</cite> [<a href="https://scholar.google.com/scholar_lookup?Xu%20M,%20Chen%20H,%20Zhu%20G,%20Zhu%20X,%20Gao%20R,%20Xu%20B,%20Song%20X,%20Han%20X,%20Shao%20T,%20Sun%20Q.%20Spiky%20metal-organic%20framework%20nanosystem%20for%20enhanced%20cuproptosis-mediated%20cancer%20immunotherapy.%20Nano%20Today.%202024;56:102231." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR141">
<span class="label">141.</span><cite>Li LG, Yang XX, Xu HZ, Yu TT, Li QR, Hu J, Peng XC, Han N, Xu X, Chen NN. A dihydroartemisinin-loaded nanoreactor motivates anti‐cancer immunotherapy by synergy‐induced ferroptosis to activate cgas/sting for reprogramming of macrophage. Adv Healthc Mater. 2023;12: 2301561.</cite> [<a href="https://doi.org/10.1002/adhm.202301561" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37567571/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Li%20LG,%20Yang%20XX,%20Xu%20HZ,%20Yu%20TT,%20Li%20QR,%20Hu%20J,%20Peng%20XC,%20Han%20N,%20Xu%20X,%20Chen%20NN.%20A%20dihydroartemisinin-loaded%20nanoreactor%20motivates%20anti%E2%80%90cancer%20immunotherapy%20by%20synergy%E2%80%90induced%20ferroptosis%20to%20activate%20cgas/sting%20for%20reprogramming%20of%20macrophage.%20Adv%20Healthc%20Mater.%202023;12:%202301561." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR142">
<span class="label">142.</span><cite>Liu Y, Zhao H, Niu R, Zhang B, Lim BTG, Song S, Wang Y, Zhang H, Zhao Y. Single-site nanozyme with exposed unsaturated Cu-O<sub>2</sub> sites for tumor therapy by coordinating innate immunity and vasculature normalization. Chem. 2024;11:102297.</cite> [<a href="https://scholar.google.com/scholar_lookup?Liu%20Y,%20Zhao%20H,%20Niu%20R,%20Zhang%20B,%20Lim%20BTG,%20Song%20S,%20Wang%20Y,%20Zhang%20H,%20Zhao%20Y.%20Single-site%20nanozyme%20with%20exposed%20unsaturated%20Cu-O2%20sites%20for%20tumor%20therapy%20by%20coordinating%20innate%20immunity%20and%20vasculature%20normalization.%20Chem.%202024;11:102297." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR143">
<span class="label">143.</span><cite>Wu Q, Tan L, Ren X, Fu C, Chen Z, Ren J, Ma T, Meng X. Metal–organic framework-based nano-activators facilitating microwave combined therapy via a divide-and-conquer tactic for triple-negative breast cancer. ACS Nano. 2023;17:25575–90.
</cite> [<a href="https://doi.org/10.1021/acsnano.3c09734" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38095158/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wu%20Q,%20Tan%20L,%20Ren%20X,%20Fu%20C,%20Chen%20Z,%20Ren%20J,%20Ma%20T,%20Meng%20X.%20Metal%E2%80%93organic%20framework-based%20nano-activators%20facilitating%20microwave%20combined%20therapy%20via%20a%20divide-and-conquer%20tactic%20for%20triple-negative%20breast%20cancer.%20ACS%20Nano.%202023;17:25575%E2%80%9390." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR144">
<span class="label">144.</span><cite>Zhou Q, Dutta D, Cao Y, Ge Z. Oxidation-responsive polymof nanoparticles for combination photodynamic-immunotherapy with enhanced STING activation. ACS Nano. 2023;17:9374–87.
</cite> [<a href="https://doi.org/10.1021/acsnano.3c01333" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37141569/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhou%20Q,%20Dutta%20D,%20Cao%20Y,%20Ge%20Z.%20Oxidation-responsive%20polymof%20nanoparticles%20for%20combination%20photodynamic-immunotherapy%20with%20enhanced%20STING%20activation.%20ACS%20Nano.%202023;17:9374%E2%80%9387." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR145">
<span class="label">145.</span><cite>Li T, Gao M, Wu Z, Yang J, Mo B, Yu S, Gong X, Liu J, Wang W, Luo S. Tantalum–Zirconium co-doped metal–organic frameworks sequentially sensitize radio–radiodynamic–immunotherapy for metastatic osteosarcoma. Adv Sci. 2023;10:2206779.</cite> [<a href="https://doi.org/10.1002/advs.202206779" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10074130/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36739599/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Li%20T,%20Gao%20M,%20Wu%20Z,%20Yang%20J,%20Mo%20B,%20Yu%20S,%20Gong%20X,%20Liu%20J,%20Wang%20W,%20Luo%20S.%20Tantalum%E2%80%93Zirconium%20co-doped%20metal%E2%80%93organic%20frameworks%20sequentially%20sensitize%20radio%E2%80%93radiodynamic%E2%80%93immunotherapy%20for%20metastatic%20osteosarcoma.%20Adv%20Sci.%202023;10:2206779." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR146">
<span class="label">146.</span><cite>Li X, Cheng G, Chen N, Ding Z, Dai Z, Wang W, Li L, Li C, Liu C, Zheng X. MnO<sub>2</sub>-mediated cGAS-STING signaling and photothermal effect amplify chemodynamic therapy induced by Fe-based nanoparticle in tumor therapy. ACS Appl Nano Mater. 2025;8:2986–96.</cite> [<a href="https://scholar.google.com/scholar_lookup?Li%20X,%20Cheng%20G,%20Chen%20N,%20Ding%20Z,%20Dai%20Z,%20Wang%20W,%20Li%20L,%20Li%20C,%20Liu%20C,%20Zheng%20X.%20MnO2-mediated%20cGAS-STING%20signaling%20and%20photothermal%20effect%20amplify%20chemodynamic%20therapy%20induced%20by%20Fe-based%20nanoparticle%20in%20tumor%20therapy.%20ACS%20Appl%20Nano%20Mater.%202025;8:2986%E2%80%9396." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR147">
<span class="label">147.</span><cite>Yang Y, Wang N, Wang Z, Yan F, Shi Z, Feng S. Glutathione-responsive metal–organic-framework-derived Mn<sub>x</sub>O<sub>y</sub>/(A/R)TiO<sub>2</sub> nanoparticles for enhanced synergistic sonodynamic/chemodynamic/immunotherapy. ACS Nano. 2025;19:885–99.
</cite> [<a href="https://doi.org/10.1021/acsnano.4c12304" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39752569/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yang%20Y,%20Wang%20N,%20Wang%20Z,%20Yan%20F,%20Shi%20Z,%20Feng%20S.%20Glutathione-responsive%20metal%E2%80%93organic-framework-derived%20MnxOy/(A/R)TiO2%20nanoparticles%20for%20enhanced%20synergistic%20sonodynamic/chemodynamic/immunotherapy.%20ACS%20Nano.%202025;19:885%E2%80%9399." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR148">
<span class="label">148.</span><cite>Song J, Wang H, Meng X, Li W, Qi J. A hypoxia-activated and microenvironment-remodeling nanoplatform for multifunctional imaging and potentiated immunotherapy of cancer. Nat Commun. 2024;15:10395.
</cite> [<a href="https://doi.org/10.1038/s41467-024-53906-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11607447/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39613774/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Song%20J,%20Wang%20H,%20Meng%20X,%20Li%20W,%20Qi%20J.%20A%20hypoxia-activated%20and%20microenvironment-remodeling%20nanoplatform%20for%20multifunctional%20imaging%20and%20potentiated%20immunotherapy%20of%20cancer.%20Nat%20Commun.%202024;15:10395." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR149">
<span class="label">149.</span><cite>Zhao D-W, Gao Z, Si M, Hu R, Ma X, Liu K, Zhao Y, He Q, Kong X, Jia C. Immune checkpoint-regulatable hydrogel-immobilized nanotherapeutics for post-surgical treatment of osteosarcoma. Chem Eng J. 2024;498: 155072.</cite> [<a href="https://scholar.google.com/scholar_lookup?Zhao%20D-W,%20Gao%20Z,%20Si%20M,%20Hu%20R,%20Ma%20X,%20Liu%20K,%20Zhao%20Y,%20He%20Q,%20Kong%20X,%20Jia%20C.%20Immune%20checkpoint-regulatable%20hydrogel-immobilized%20nanotherapeutics%20for%20post-surgical%20treatment%20of%20osteosarcoma.%20Chem%20Eng%20J.%202024;498:%20155072." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR150">
<span class="label">150.</span><cite>Zhao Y, Song R, Zhang Z, Hu H, Ning W, Duan X, Jiao J, Fu X, Zhang G. Hollow metal–organic framework-based, stimulator of interferon genes pathway-activating nanovaccines for tumor immunotherapy. Nanoscale Adv. 2024;6:72–8.</cite> [<a href="https://doi.org/10.1039/d3na00867c" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10729872/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38125595/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhao%20Y,%20Song%20R,%20Zhang%20Z,%20Hu%20H,%20Ning%20W,%20Duan%20X,%20Jiao%20J,%20Fu%20X,%20Zhang%20G.%20Hollow%20metal%E2%80%93organic%20framework-based,%20stimulator%20of%20interferon%20genes%20pathway-activating%20nanovaccines%20for%20tumor%20immunotherapy.%20Nanoscale%20Adv.%202024;6:72%E2%80%938." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR151">
<span class="label">151.</span><cite>Howlett TS, Kumari S, Ehrman RN, Masson J, Izzo L, Wang T, Gull H, Trashi I, Tang W, Trashi O, Satish N, Wijesundara YH, Herbert FC, Izzo AA, Gassensmith JJ. Mn and Zn-doped multivariate metal-organic framework as a metalloimmunological adjuvant to promote protection against tuberculosis infection. Adv Healthc Mater. 2024;2402358.</cite> [<a href="https://doi.org/10.1002/adhm.202402358" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39648542/" class="usa-link">PubMed</a>]</li>
<li id="CR152">
<span class="label">152.</span><cite>Huang Y, Qin G, Cui T, Zhao C, Ren J, Qu X. A bimetallic nanoplatform for STING activation and crispr/cas mediated depletion of the methionine transporter in cancer cells restores anti-tumor immune responses. Nat Commun. 2023;14:4647.
</cite> [<a href="https://doi.org/10.1038/s41467-023-40345-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10397352/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37532731/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Huang%20Y,%20Qin%20G,%20Cui%20T,%20Zhao%20C,%20Ren%20J,%20Qu%20X.%20A%20bimetallic%20nanoplatform%20for%20STING%20activation%20and%20crispr/cas%20mediated%20depletion%20of%20the%20methionine%20transporter%20in%20cancer%20cells%20restores%20anti-tumor%20immune%20responses.%20Nat%20Commun.%202023;14:4647." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR153">
<span class="label">153.</span><cite>Qian Y, Xie Y, Zhu G, Wang M, Wang J, Sun Q, Lin J, Li C. Internal trouble and outside aggression strategy: energy deprivation synergized with cGAS-STING pathway activation for stimuli‐responsive photodynamic‐metal‐metabolic immunotherapy. Adv Funct Mater. 2024;34:2410142.</cite> [<a href="https://scholar.google.com/scholar_lookup?Qian%20Y,%20Xie%20Y,%20Zhu%20G,%20Wang%20M,%20Wang%20J,%20Sun%20Q,%20Lin%20J,%20Li%20C.%20Internal%20trouble%20and%20outside%20aggression%20strategy:%20energy%20deprivation%20synergized%20with%20cGAS-STING%20pathway%20activation%20for%20stimuli%E2%80%90responsive%20photodynamic%E2%80%90metal%E2%80%90metabolic%20immunotherapy.%20Adv%20Funct%20Mater.%202024;34:2410142." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR154">
<span class="label">154.</span><cite>Zhang X, Tian H, Chen Y, Liang B, Nice EC, Huang C, Xie N, Zheng S. A metal-organic nanoframework for efficient colorectal cancer immunotherapy by the cGAS-STING pathway activation and immune checkpoint blockade. J Nanobiotechnol. 2024;22:592.</cite> [<a href="https://doi.org/10.1186/s12951-024-02836-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11441132/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39343911/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20X,%20Tian%20H,%20Chen%20Y,%20Liang%20B,%20Nice%20EC,%20Huang%20C,%20Xie%20N,%20Zheng%20S.%20A%20metal-organic%20nanoframework%20for%20efficient%20colorectal%20cancer%20immunotherapy%20by%20the%20cGAS-STING%20pathway%20activation%20and%20immune%20checkpoint%20blockade.%20J%20Nanobiotechnol.%202024;22:592." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR155">
<span class="label">155.</span><cite>Zhang W-X, Li L-Y, Shu Y, Wang J-H. Coordination catalysis of metals and polydopamine enables controlled release of CO from MnCO by enhancing oxidative stress and the thermal effect. Inorg Chem Front. 2024;11:5196–209.</cite> [<a href="https://scholar.google.com/scholar_lookup?Zhang%20W-X,%20Li%20L-Y,%20Shu%20Y,%20Wang%20J-H.%20Coordination%20catalysis%20of%20metals%20and%20polydopamine%20enables%20controlled%20release%20of%20CO%20from%20MnCO%20by%20enhancing%20oxidative%20stress%20and%20the%20thermal%20effect.%20Inorg%20Chem%20Front.%202024;11:5196%E2%80%93209." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR156">
<span class="label">156.</span><cite>Zhao X, Cheng H, Wang Q, Nie W, Yang Y, Yang X, Zhang K, Shi J, Liu J. Regulating photosensitizer metabolism with DNAzyme-loaded nanoparticles for amplified mitochondria-targeting photodynamic immunotherapy. ACS Nano. 2023;17:13746–59.
</cite> [<a href="https://doi.org/10.1021/acsnano.3c03308" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37438324/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhao%20X,%20Cheng%20H,%20Wang%20Q,%20Nie%20W,%20Yang%20Y,%20Yang%20X,%20Zhang%20K,%20Shi%20J,%20Liu%20J.%20Regulating%20photosensitizer%20metabolism%20with%20DNAzyme-loaded%20nanoparticles%20for%20amplified%20mitochondria-targeting%20photodynamic%20immunotherapy.%20ACS%20Nano.%202023;17:13746%E2%80%9359." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR157">
<span class="label">157.</span><cite>Ding L, Liang M, Li Y, Zeng M, Liu M, Ma W, Chen F, Li C, Reis RL, Li FR. Zinc-organometallic framework vaccine controlled‐release Zn<sup>2+</sup> regulates tumor extracellular matrix degradation potentiate efficacy of immunotherapy. Adv Sci. 2023;10:2302967.</cite> [<a href="https://doi.org/10.1002/advs.202302967" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10520680/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37439462/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ding%20L,%20Liang%20M,%20Li%20Y,%20Zeng%20M,%20Liu%20M,%20Ma%20W,%20Chen%20F,%20Li%20C,%20Reis%20RL,%20Li%20FR.%20Zinc-organometallic%20framework%20vaccine%20controlled%E2%80%90release%20Zn2+%20regulates%20tumor%20extracellular%20matrix%20degradation%20potentiate%20efficacy%20of%20immunotherapy.%20Adv%20Sci.%202023;10:2302967." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR158">
<span class="label">158.</span><cite>Zhang S, Zhang H, Cao Y, Bai S, Li W, Song P, Wang B, Wang Z, Wang D, Zhang H. Triple-pathway cGAS-STING activation collaborated with ferroptosis-induced immunogenic cell death for boosting systemic colorectal cancer immunotherapy. Nano Today. 2024;59:102484.</cite> [<a href="https://scholar.google.com/scholar_lookup?Zhang%20S,%20Zhang%20H,%20Cao%20Y,%20Bai%20S,%20Li%20W,%20Song%20P,%20Wang%20B,%20Wang%20Z,%20Wang%20D,%20Zhang%20H.%20Triple-pathway%20cGAS-STING%20activation%20collaborated%20with%20ferroptosis-induced%20immunogenic%20cell%20death%20for%20boosting%20systemic%20colorectal%20cancer%20immunotherapy.%20Nano%20Today.%202024;59:102484." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR159">
<span class="label">159.</span><cite>Tian H, Duan J, Li B, Qin S, Nice EC, Zhang W, Lang T, Zhang H, Huang C. Clinical chemotherapeutic agent coordinated copper-based nanoadjuvants for efficiently sensitizing cancer chemo‐immunotherapy by cuproptosis‐mediated mitochondrial metabolic reprogramming. Adv Funct Mater. 2023;33:2306584.</cite> [<a href="https://scholar.google.com/scholar_lookup?Tian%20H,%20Duan%20J,%20Li%20B,%20Qin%20S,%20Nice%20EC,%20Zhang%20W,%20Lang%20T,%20Zhang%20H,%20Huang%20C.%20Clinical%20chemotherapeutic%20agent%20coordinated%20copper-based%20nanoadjuvants%20for%20efficiently%20sensitizing%20cancer%20chemo%E2%80%90immunotherapy%20by%20cuproptosis%E2%80%90mediated%20mitochondrial%20metabolic%20reprogramming.%20Adv%20Funct%20Mater.%202023;33:2306584." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR160">
<span class="label">160.</span><cite>Eddaoudi M, Kim J, Rosi N, Vodak D, Wachter J, O’Keeffe M, Yaghi OM. Systematic design of pore size and functionality in isoreticular MOFs and their application in methane storage. Science. 2002;295:469–72.
</cite> [<a href="https://doi.org/10.1126/science.1067208" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11799235/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Eddaoudi%20M,%20Kim%20J,%20Rosi%20N,%20Vodak%20D,%20Wachter%20J,%20O%E2%80%99Keeffe%20M,%20Yaghi%20OM.%20Systematic%20design%20of%20pore%20size%20and%20functionality%20in%20isoreticular%20MOFs%20and%20their%20application%20in%20methane%20storage.%20Science.%202002;295:469%E2%80%9372." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR161">
<span class="label">161.</span><cite>Cai G, Jiang H-L. A modulator-induced defect-formation strategy to hierarchically porous metal–organic frameworks with high stability. Angew Chem Int Ed Engl. 2017;56:563–7.
</cite> [<a href="https://doi.org/10.1002/anie.201610914" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27930852/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cai%20G,%20Jiang%20H-L.%20A%20modulator-induced%20defect-formation%20strategy%20to%20hierarchically%20porous%20metal%E2%80%93organic%20frameworks%20with%20high%20stability.%20Angew%20Chem%20Int%20Ed%20Engl.%202017;56:563%E2%80%937." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR162">
<span class="label">162.</span><cite>Yuan S, Zou L, Qin J-S, Li J, Huang L, Feng L, Wang X, Bosch M, Alsalme A, Cagin T, Zhou H-C. Construction of hierarchically porous metal–organic frameworks through linker labilization. Nat Commun. 2017;8:15356.
</cite> [<a href="https://doi.org/10.1038/ncomms15356" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5458506/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28541301/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yuan%20S,%20Zou%20L,%20Qin%20J-S,%20Li%20J,%20Huang%20L,%20Feng%20L,%20Wang%20X,%20Bosch%20M,%20Alsalme%20A,%20Cagin%20T,%20Zhou%20H-C.%20Construction%20of%20hierarchically%20porous%20metal%E2%80%93organic%20frameworks%20through%20linker%20labilization.%20Nat%20Commun.%202017;8:15356." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR163">
<span class="label">163.</span><cite>Guo X, Tu P, Wang X, Du C, Jiang W, Qiu X, Wang J, Chen L, Chen Y, Ren J. Decomposable nanoagonists enable NIR-elicited cGAS‐STING activation for tandem‐amplified photodynamic‐metalloimmunotherapy. Adv Mater. 2024;36:2313029. </cite> [<a href="https://doi.org/10.1002/adma.202313029" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38353366/" class="usa-link">PubMed</a>]</li>
<li id="CR164">
<span class="label">164.</span><cite>Zhang P, Zhong D, Yu Y, Wang L, Li Y, Liang Y, Shi Y, Duan M, Li B, Niu H, Xu Y. Integration of STING activation and COX-2 inhibition via steric-hindrance effect tuned nanoreactors for cancer chemoimmunotherapy. Biomaterials. 2024;311:122695.
</cite> [<a href="https://doi.org/10.1016/j.biomaterials.2024.122695" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38954960/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20P,%20Zhong%20D,%20Yu%20Y,%20Wang%20L,%20Li%20Y,%20Liang%20Y,%20Shi%20Y,%20Duan%20M,%20Li%20B,%20Niu%20H,%20Xu%20Y.%20Integration%20of%20STING%20activation%20and%20COX-2%20inhibition%20via%20steric-hindrance%20effect%20tuned%20nanoreactors%20for%20cancer%20chemoimmunotherapy.%20Biomaterials.%202024;311:122695." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR165">
<span class="label">165.</span><cite>Lu K, He C, Lin W. A chlorin-based nanoscale metal–organic framework for photodynamic therapy of colon cancers. J Am Chem Soc. 2015;137:7600–3.
</cite> [<a href="https://doi.org/10.1021/jacs.5b04069" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4691355/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26068094/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lu%20K,%20He%20C,%20Lin%20W.%20A%20chlorin-based%20nanoscale%20metal%E2%80%93organic%20framework%20for%20photodynamic%20therapy%20of%20colon%20cancers.%20J%20Am%20Chem%20Soc.%202015;137:7600%E2%80%933." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR166">
<span class="label">166.</span><cite>Luo T, Ni K, Culbert A, Lan G, Li Z, Jiang X, Kaufmann M, Lin W. Nanoscale metal–organic frameworks stabilize bacteriochlorins for type I and type II photodynamic therapy. J Am Chem Soc. 2020;142:7334–9.
</cite> [<a href="https://doi.org/10.1021/jacs.0c02129" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32248686/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Luo%20T,%20Ni%20K,%20Culbert%20A,%20Lan%20G,%20Li%20Z,%20Jiang%20X,%20Kaufmann%20M,%20Lin%20W.%20Nanoscale%20metal%E2%80%93organic%20frameworks%20stabilize%20bacteriochlorins%20for%20type%20I%20and%20type%20II%20photodynamic%20therapy.%20J%20Am%20Chem%20Soc.%202020;142:7334%E2%80%939." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR167">
<span class="label">167.</span><cite>Lu K, He C, Lin W. Nanoscale metal–organic framework for highly effective photodynamic therapy of resistant head and neck cancer. J Am Chem Soc. 2014;136:16712–5.
</cite> [<a href="https://doi.org/10.1021/ja508679h" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4277757/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25407895/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lu%20K,%20He%20C,%20Lin%20W.%20Nanoscale%20metal%E2%80%93organic%20framework%20for%20highly%20effective%20photodynamic%20therapy%20of%20resistant%20head%20and%20neck%20cancer.%20J%20Am%20Chem%20Soc.%202014;136:16712%E2%80%935." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR168">
<span class="label">168.</span><cite>Lan G, Ni K, Veroneau SS, Feng X, Nash GT, Luo T, Xu Z, Lin W. Titanium-based nanoscale metal–organic framework for type I photodynamic therapy. J Am Chem Soc. 2019;141:4204–8.
</cite> [<a href="https://doi.org/10.1021/jacs.8b13804" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30779556/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lan%20G,%20Ni%20K,%20Veroneau%20SS,%20Feng%20X,%20Nash%20GT,%20Luo%20T,%20Xu%20Z,%20Lin%20W.%20Titanium-based%20nanoscale%20metal%E2%80%93organic%20framework%20for%20type%20I%20photodynamic%20therapy.%20J%20Am%20Chem%20Soc.%202019;141:4204%E2%80%938." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR169">
<span class="label">169.</span><cite>Liu C, Liu B, Zhao J, Di Z, Chen D, Gu Z, Li L, Zhao Y. Nd<sup>3+</sup>-sensitized upconversion metal–organic frameworks for mitochondria‐targeted amplified photodynamic therapy. Angew Chem Int Ed Engl. 2020;59:2634–8.
</cite> [<a href="https://doi.org/10.1002/anie.201911508" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31750975/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Liu%20C,%20Liu%20B,%20Zhao%20J,%20Di%20Z,%20Chen%20D,%20Gu%20Z,%20Li%20L,%20Zhao%20Y.%20Nd3+-sensitized%20upconversion%20metal%E2%80%93organic%20frameworks%20for%20mitochondria%E2%80%90targeted%20amplified%20photodynamic%20therapy.%20Angew%20Chem%20Int%20Ed%20Engl.%202020;59:2634%E2%80%938." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR170">
<span class="label">170.</span><cite>Zhou W, Liu Z, Wang N, Chen X, Sun X, Cheng Y. Hafnium-based metal–organic framework nanoparticles as a radiosensitizer to improve radiotherapy efficacy in esophageal cancer. ACS Omega. 2022;7:12021–29.
</cite> [<a href="https://doi.org/10.1021/acsomega.2c00223" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9016869/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35449918/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhou%20W,%20Liu%20Z,%20Wang%20N,%20Chen%20X,%20Sun%20X,%20Cheng%20Y.%20Hafnium-based%20metal%E2%80%93organic%20framework%20nanoparticles%20as%20a%20radiosensitizer%20to%20improve%20radiotherapy%20efficacy%20in%20esophageal%20cancer.%20ACS%20Omega.%202022;7:12021%E2%80%9329." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR171">
<span class="label">171.</span><cite>Ni K, Lan G, Chan C, Quigley B, Lu K, Aung T, Guo N, La Riviere P, Weichselbaum RR, Lin W. Nanoscale metal-organic frameworks enhance radiotherapy to potentiate checkpoint blockade immunotherapy. Nat Commun. 2018;9:2351.
</cite> [<a href="https://doi.org/10.1038/s41467-018-04703-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6003951/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29907739/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ni%20K,%20Lan%20G,%20Chan%20C,%20Quigley%20B,%20Lu%20K,%20Aung%20T,%20Guo%20N,%20La%20Riviere%20P,%20Weichselbaum%20RR,%20Lin%20W.%20Nanoscale%20metal-organic%20frameworks%20enhance%20radiotherapy%20to%20potentiate%20checkpoint%20blockade%20immunotherapy.%20Nat%20Commun.%202018;9:2351." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR172">
<span class="label">172.</span><cite>Lu K, He C, Guo N, Chan C, Ni K, Lan G, Tang H, Pelizzari C, Fu Y-X, Spiotto MT, Weichselbaum RR, Lin W. Low-dose X-ray radiotherapy–radiodynamic therapy via nanoscale metal–organic frameworks enhances checkpoint blockade immunotherapy. Nat Biomed Eng. 2018;2:600–10.
</cite> [<a href="https://doi.org/10.1038/s41551-018-0203-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31015630/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lu%20K,%20He%20C,%20Guo%20N,%20Chan%20C,%20Ni%20K,%20Lan%20G,%20Tang%20H,%20Pelizzari%20C,%20Fu%20Y-X,%20Spiotto%20MT,%20Weichselbaum%20RR,%20Lin%20W.%20Low-dose%20X-ray%20radiotherapy%E2%80%93radiodynamic%20therapy%20via%20nanoscale%20metal%E2%80%93organic%20frameworks%20enhances%20checkpoint%20blockade%20immunotherapy.%20Nat%20Biomed%20Eng.%202018;2:600%E2%80%9310." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR173">
<span class="label">173.</span><cite>Zhao Y, Liang C, Mei Z, Yang H, Wang B, Xie C, Xu Y, Tian J. Oxygen-enriched MOF-hemoglobin X-ray nanosensitizer for enhanced cancer radio–radiodynamic therapy. ACS Mater Lett. 2023;5:3237–47.</cite> [<a href="https://scholar.google.com/scholar_lookup?Zhao%20Y,%20Liang%20C,%20Mei%20Z,%20Yang%20H,%20Wang%20B,%20Xie%20C,%20Xu%20Y,%20Tian%20J.%20Oxygen-enriched%20MOF-hemoglobin%20X-ray%20nanosensitizer%20for%20enhanced%20cancer%20radio%E2%80%93radiodynamic%20therapy.%20ACS%20Mater%20Lett.%202023;5:3237%E2%80%9347." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR174">
<span class="label">174.</span><cite>Yoshida T, Goto S, Kawakatsu M, Urata Y, Li T-s. Mitochondrial dysfunction, a probable cause of persistent oxidative stress after exposure to ionizing radiation. Free Radic Res. 2012;46:147–53.
</cite> [<a href="https://doi.org/10.3109/10715762.2011.645207" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22126415/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yoshida%20T,%20Goto%20S,%20Kawakatsu%20M,%20Urata%20Y,%20Li%20T-s.%20Mitochondrial%20dysfunction,%20a%20probable%20cause%20of%20persistent%20oxidative%20stress%20after%20exposure%20to%20ionizing%20radiation.%20Free%20Radic%20Res.%202012;46:147%E2%80%9353." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR175">
<span class="label">175.</span><cite>Sabharwal SS, Schumacker PT. Mitochondrial ROS in cancer: initiators, amplifiers or an achilles’ heel? Nat Rev Cancer. 2014;14:709–21.
</cite> [<a href="https://doi.org/10.1038/nrc3803" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4657553/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25342630/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sabharwal%20SS,%20Schumacker%20PT.%20Mitochondrial%20ROS%20in%20cancer:%20initiators,%20amplifiers%20or%20an%20achilles%E2%80%99%20heel?%20Nat%20Rev%20Cancer.%202014;14:709%E2%80%9321." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR176">
<span class="label">176.</span><cite>McArthur K, Whitehead LW, Heddleston JM, Li L, Padman BS, Oorschot V, Geoghegan ND, Chappaz S, Davidson S. San chin H. BAK/BAX macropores facilitate mitochondrial herniation and MtDNA efflux during apoptosis. Science. 2018;359:eaao6047.
</cite> [<a href="https://doi.org/10.1126/science.aao6047" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29472455/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?McArthur%20K,%20Whitehead%20LW,%20Heddleston%20JM,%20Li%20L,%20Padman%20BS,%20Oorschot%20V,%20Geoghegan%20ND,%20Chappaz%20S,%20Davidson%20S.%20San%20chin%20H.%20BAK/BAX%20macropores%20facilitate%20mitochondrial%20herniation%20and%20MtDNA%20efflux%20during%20apoptosis.%20Science.%202018;359:eaao6047." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR177">
<span class="label">177.</span><cite>Fang C, Mo F, Liu L, Du J, Luo M, Men K, Na F, Wang W, Yang H, Wei X. Oxidized mitochondrial DNA sensing by STING signaling promotes the antitumor effect of an irradiated immunogenic cancer cell vaccine. Cell Mol Immunol. 2021;18:2211–23.
</cite> [<a href="https://doi.org/10.1038/s41423-020-0456-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8429462/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32398808/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Fang%20C,%20Mo%20F,%20Liu%20L,%20Du%20J,%20Luo%20M,%20Men%20K,%20Na%20F,%20Wang%20W,%20Yang%20H,%20Wei%20X.%20Oxidized%20mitochondrial%20DNA%20sensing%20by%20STING%20signaling%20promotes%20the%20antitumor%20effect%20of%20an%20irradiated%20immunogenic%20cancer%20cell%20vaccine.%20Cell%20Mol%20Immunol.%202021;18:2211%E2%80%9323." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR178">
<span class="label">178.</span><cite>Du M, Chen ZJ. DNA-induced liquid phase condensation of cGAS activates innate immune signaling. Science. 2018;361:704–09.
</cite> [<a href="https://doi.org/10.1126/science.aat1022" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9417938/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29976794/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Du%20M,%20Chen%20ZJ.%20DNA-induced%20liquid%20phase%20condensation%20of%20cGAS%20activates%20innate%20immune%20signaling.%20Science.%202018;361:704%E2%80%9309." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR179">
<span class="label">179.</span><cite>Xu M, Hu Y, Ding W, Li F, Lin J, Wu M, Wu J, Wen L-P, Qiu B, Wei P-F. Rationally designed rapamycin-encapsulated ZIF-8 nanosystem for overcoming chemotherapy resistance. Biomaterials. 2020;258:120308.
</cite> [<a href="https://doi.org/10.1016/j.biomaterials.2020.120308" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32841911/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Xu%20M,%20Hu%20Y,%20Ding%20W,%20Li%20F,%20Lin%20J,%20Wu%20M,%20Wu%20J,%20Wen%20L-P,%20Qiu%20B,%20Wei%20P-F.%20Rationally%20designed%20rapamycin-encapsulated%20ZIF-8%20nanosystem%20for%20overcoming%20chemotherapy%20resistance.%20Biomaterials.%202020;258:120308." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR180">
<span class="label">180.</span><cite>Lenders V, Koutsoumpou X, Sargsian A, Manshian BB. Biomedical nanomaterials for immunological applications: ongoing research and clinical trials. Nanoscale Adv. 2020;2:5046–89.
</cite> [<a href="https://doi.org/10.1039/d0na00478b" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9418019/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36132021/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lenders%20V,%20Koutsoumpou%20X,%20Sargsian%20A,%20Manshian%20BB.%20Biomedical%20nanomaterials%20for%20immunological%20applications:%20ongoing%20research%20and%20clinical%20trials.%20Nanoscale%20Adv.%202020;2:5046%E2%80%9389." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR181">
<span class="label">181.</span><cite>Ji J, Ding K, Cheng B, Zhang X, Luo T, Huang B, Yu H, Chen Y, Xu X, Lin H. Radiotherapy-induced astrocyte senescence promotes an immunosuppressive microenvironment in glioblastoma to facilitate tumor regrowth. Adv Sci. 2024;11:2304609.</cite> [<a href="https://doi.org/10.1002/advs.202304609" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11022718/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38342629/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ji%20J,%20Ding%20K,%20Cheng%20B,%20Zhang%20X,%20Luo%20T,%20Huang%20B,%20Yu%20H,%20Chen%20Y,%20Xu%20X,%20Lin%20H.%20Radiotherapy-induced%20astrocyte%20senescence%20promotes%20an%20immunosuppressive%20microenvironment%20in%20glioblastoma%20to%20facilitate%20tumor%20regrowth.%20Adv%20Sci.%202024;11:2304609." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR182">
<span class="label">182.</span><cite>Lan G, Ni K, Lin W. Nanoscale metal–organic frameworks for phototherapy of cancer. Coord Chem Rev. 2019;379:65–81.
</cite> [<a href="https://doi.org/10.1016/j.ccr.2017.09.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6366651/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30739946/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lan%20G,%20Ni%20K,%20Lin%20W.%20Nanoscale%20metal%E2%80%93organic%20frameworks%20for%20phototherapy%20of%20cancer.%20Coord%20Chem%20Rev.%202019;379:65%E2%80%9381." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR183">
<span class="label">183.</span><cite>Yang Y, Zhu W, Feng L, Chao Y, Yi X, Dong Z, Yang K, Tan W, Liu Z, Chen M. G-quadruplex-based nanoscale coordination polymers to modulate tumor hypoxia and achieve nuclear-targeted drug delivery for enhanced photodynamic therapy. Nano Lett. 2018;18:6867–75.
</cite> [<a href="https://doi.org/10.1021/acs.nanolett.8b02732" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30303384/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yang%20Y,%20Zhu%20W,%20Feng%20L,%20Chao%20Y,%20Yi%20X,%20Dong%20Z,%20Yang%20K,%20Tan%20W,%20Liu%20Z,%20Chen%20M.%20G-quadruplex-based%20nanoscale%20coordination%20polymers%20to%20modulate%20tumor%20hypoxia%20and%20achieve%20nuclear-targeted%20drug%20delivery%20for%20enhanced%20photodynamic%20therapy.%20Nano%20Lett.%202018;18:6867%E2%80%9375." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR184">
<span class="label">184.</span><cite>Yu Q, Li X, Wang J, Guo L, Huang L, Gao W. Recent advances in reprogramming strategy of tumor microenvironment for rejuvenating photosensitizers-mediated photodynamic therapy. Small. 2024;20: 2305708.</cite> [<a href="https://doi.org/10.1002/smll.202305708" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38018311/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yu%20Q,%20Li%20X,%20Wang%20J,%20Guo%20L,%20Huang%20L,%20Gao%20W.%20Recent%20advances%20in%20reprogramming%20strategy%20of%20tumor%20microenvironment%20for%20rejuvenating%20photosensitizers-mediated%20photodynamic%20therapy.%20Small.%202024;20:%202305708." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR185">
<span class="label">185.</span><cite>Xie J, Wang Y, Choi W, Jangili P, Ge Y, Xu Y, Kang J, Liu L, Zhang B, Xie Z. Overcoming barriers in photodynamic therapy harnessing nano-formulation strategies. Chem Soc Rev. 2021;50:9152–201.
</cite> [<a href="https://doi.org/10.1039/d0cs01370f" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34223847/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Xie%20J,%20Wang%20Y,%20Choi%20W,%20Jangili%20P,%20Ge%20Y,%20Xu%20Y,%20Kang%20J,%20Liu%20L,%20Zhang%20B,%20Xie%20Z.%20Overcoming%20barriers%20in%20photodynamic%20therapy%20harnessing%20nano-formulation%20strategies.%20Chem%20Soc%20Rev.%202021;50:9152%E2%80%93201." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR186">
<span class="label">186.</span><cite>Hong G, Antaris AL, Dai H. Near-infrared fluorophores for biomedical imaging. Nat Biomed Eng. 2017;1:0010.</cite> [<a href="https://scholar.google.com/scholar_lookup?Hong%20G,%20Antaris%20AL,%20Dai%20H.%20Near-infrared%20fluorophores%20for%20biomedical%20imaging.%20Nat%20Biomed%20Eng.%202017;1:0010." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR187">
<span class="label">187.</span><cite>Li X, Lovell JF, Yoon J, Chen X. Clinical development and potential of photothermal and photodynamic therapies for cancer. Nat Rev Clin Oncol. 2020;17:657–74.
</cite> [<a href="https://doi.org/10.1038/s41571-020-0410-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32699309/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Li%20X,%20Lovell%20JF,%20Yoon%20J,%20Chen%20X.%20Clinical%20development%20and%20potential%20of%20photothermal%20and%20photodynamic%20therapies%20for%20cancer.%20Nat%20Rev%20Clin%20Oncol.%202020;17:657%E2%80%9374." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR188">
<span class="label">188.</span><cite>Xu C, Jiang Y, Han Y, Pu K, Zhang R. A polymer multicellular Nanoengager for synergistic NIR-II photothermal immunotherapy. Adv Mater. 2021;33:2008061.</cite> [<a href="https://doi.org/10.1002/adma.202008061" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33634897/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Xu%20C,%20Jiang%20Y,%20Han%20Y,%20Pu%20K,%20Zhang%20R.%20A%20polymer%20multicellular%20Nanoengager%20for%20synergistic%20NIR-II%20photothermal%20immunotherapy.%20Adv%20Mater.%202021;33:2008061." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR189">
<span class="label">189.</span><cite>Wan Y, Fu LH, Li C, Lin J, Huang P. Conquering the hypoxia limitation for photodynamic therapy. Adv Mater. 2021;33: e2103978.
</cite> [<a href="https://doi.org/10.1002/adma.202103978" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34580926/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wan%20Y,%20Fu%20LH,%20Li%20C,%20Lin%20J,%20Huang%20P.%20Conquering%20the%20hypoxia%20limitation%20for%20photodynamic%20therapy.%20Adv%20Mater.%202021;33:%20e2103978." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR190">
<span class="label">190.</span><cite>Li X, Kwon N, Guo T, Liu Z, Yoon J. Innovative strategies for hypoxic-tumor photodynamic therapy. Angew Chem Int Ed Engl. 2018;57:11522–31.
</cite> [<a href="https://doi.org/10.1002/anie.201805138" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29808948/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Li%20X,%20Kwon%20N,%20Guo%20T,%20Liu%20Z,%20Yoon%20J.%20Innovative%20strategies%20for%20hypoxic-tumor%20photodynamic%20therapy.%20Angew%20Chem%20Int%20Ed%20Engl.%202018;57:11522%E2%80%9331." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR191">
<span class="label">191.</span><cite>Chen H, Tian J, He W, Guo Z. H<sub>2</sub>O<sub>2</sub>-activatable and O<sub>2</sub>-evolving nanoparticles for highly efficient and selective photodynamic therapy against hypoxic tumor cells. J Am Chem Soc. 2015;137:1539–47.
</cite> [<a href="https://doi.org/10.1021/ja511420n" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25574812/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chen%20H,%20Tian%20J,%20He%20W,%20Guo%20Z.%20H2O2-activatable%20and%20O2-evolving%20nanoparticles%20for%20highly%20efficient%20and%20selective%20photodynamic%20therapy%20against%20hypoxic%20tumor%20cells.%20J%20Am%20Chem%20Soc.%202015;137:1539%E2%80%9347." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR192">
<span class="label">192.</span><cite>Cui M, Tang D, Wang B, Zhang H, Liang G, Xiao H. Bioorthogonal guided activation of cGAS-STING by AIE photosensitizer nanoparticles for targeted tumor therapy and imaging. Adv Mater. 2023;35:e2305668.
</cite> [<a href="https://doi.org/10.1002/adma.202305668" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37668998/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cui%20M,%20Tang%20D,%20Wang%20B,%20Zhang%20H,%20Liang%20G,%20Xiao%20H.%20Bioorthogonal%20guided%20activation%20of%20cGAS-STING%20by%20AIE%20photosensitizer%20nanoparticles%20for%20targeted%20tumor%20therapy%20and%20imaging.%20Adv%20Mater.%202023;35:e2305668." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR193">
<span class="label">193.</span><cite>Xiao Q, Zheng X, Bu W, Ge W, Zhang S, Chen F, Xing H, Ren Q, Fan W, Zhao K, Hua Y, Shi J. A core/satellite multifunctional nanotheranostic for in vivo imaging and tumor eradication by radiation/photothermal synergistic therapy. J Am Chem Soc. 2013;135:13041–8.
</cite> [<a href="https://doi.org/10.1021/ja404985w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23924214/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Xiao%20Q,%20Zheng%20X,%20Bu%20W,%20Ge%20W,%20Zhang%20S,%20Chen%20F,%20Xing%20H,%20Ren%20Q,%20Fan%20W,%20Zhao%20K,%20Hua%20Y,%20Shi%20J.%20A%20core/satellite%20multifunctional%20nanotheranostic%20for%20in%20vivo%20imaging%20and%20tumor%20eradication%20by%20radiation/photothermal%20synergistic%20therapy.%20J%20Am%20Chem%20Soc.%202013;135:13041%E2%80%938." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR194">
<span class="label">194.</span><cite>Tang Z, Zhao P, Ni D, Liu Y, Zhang M, Wang H, Zhang H, Gao H, Yao Z, Bu W. Pyroelectric nanoplatform for NIR-II-triggered photothermal therapy with simultaneous pyroelectric dynamic therapy. Mater Horiz. 2018;5:946–52.</cite> [<a href="https://scholar.google.com/scholar_lookup?Tang%20Z,%20Zhao%20P,%20Ni%20D,%20Liu%20Y,%20Zhang%20M,%20Wang%20H,%20Zhang%20H,%20Gao%20H,%20Yao%20Z,%20Bu%20W.%20Pyroelectric%20nanoplatform%20for%20NIR-II-triggered%20photothermal%20therapy%20with%20simultaneous%20pyroelectric%20dynamic%20therapy.%20Mater%20Horiz.%202018;5:946%E2%80%9352." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR195">
<span class="label">195.</span><cite>Zeng S, Chen J, Gao R, Chen R, Xue Q, Ren Y, Liu L, Tang C, Hu H, Zeng N, Wen S, Zhang H, Liu C, Fang C. NIR-II photoacoustic imaging-guided oxygen delivery and controlled release improves photodynamic therapy for hepatocellular carcinoma. Adv Mater. 2024;36:e2308780.
</cite> [<a href="https://doi.org/10.1002/adma.202308780" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37983859/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zeng%20S,%20Chen%20J,%20Gao%20R,%20Chen%20R,%20Xue%20Q,%20Ren%20Y,%20Liu%20L,%20Tang%20C,%20Hu%20H,%20Zeng%20N,%20Wen%20S,%20Zhang%20H,%20Liu%20C,%20Fang%20C.%20NIR-II%20photoacoustic%20imaging-guided%20oxygen%20delivery%20and%20controlled%20release%20improves%20photodynamic%20therapy%20for%20hepatocellular%20carcinoma.%20Adv%20Mater.%202024;36:e2308780." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR196">
<span class="label">196.</span><cite>Huang J, He B, Zhang Z, Li Y, Kang M, Wang Y, Li K, Wang D, Tang BZ. Aggregation-induced emission luminogens married to 2D black phosphorus nanosheets for highly efficient multimodal theranostics. Adv Mater. 2020;32:e2003382.
</cite> [<a href="https://doi.org/10.1002/adma.202003382" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32761671/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Huang%20J,%20He%20B,%20Zhang%20Z,%20Li%20Y,%20Kang%20M,%20Wang%20Y,%20Li%20K,%20Wang%20D,%20Tang%20BZ.%20Aggregation-induced%20emission%20luminogens%20married%20to%202D%20black%20phosphorus%20nanosheets%20for%20highly%20efficient%20multimodal%20theranostics.%20Adv%20Mater.%202020;32:e2003382." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR197">
<span class="label">197.</span><cite>Wang X, Zhong X, Gong F, Chao Y, Cheng L. Newly developed strategies for improving sonodynamic therapy. Mater Horiz. 2020;7:2028–46.</cite> [<a href="https://scholar.google.com/scholar_lookup?Wang%20X,%20Zhong%20X,%20Gong%20F,%20Chao%20Y,%20Cheng%20L.%20Newly%20developed%20strategies%20for%20improving%20sonodynamic%20therapy.%20Mater%20Horiz.%202020;7:2028%E2%80%9346." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR198">
<span class="label">198.</span><cite>Zhu C, Li J, Sun W, Li D, Wang Y, Shen XC. Signaling mechanism of Cuproptosis activating cGAS-STING immune pathway. JACS Au. 2024;4:3988–99.
</cite> [<a href="https://doi.org/10.1021/jacsau.4c00712" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11522904/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39483232/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhu%20C,%20Li%20J,%20Sun%20W,%20Li%20D,%20Wang%20Y,%20Shen%20XC.%20Signaling%20mechanism%20of%20Cuproptosis%20activating%20cGAS-STING%20immune%20pathway.%20JACS%20Au.%202024;4:3988%E2%80%9399." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR199">
<span class="label">199.</span><cite>Yu X, Li B, Yan J, Li W, Tian H, Wang G, Zhou S, Dai Y. Cuproptotic nanoinducer-driven proteotoxic stress potentiates cancer immunotherapy by activating the mtDNA-cGAS-STING signaling. Biomaterials. 2024;307:122512.
</cite> [<a href="https://doi.org/10.1016/j.biomaterials.2024.122512" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38430646/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yu%20X,%20Li%20B,%20Yan%20J,%20Li%20W,%20Tian%20H,%20Wang%20G,%20Zhou%20S,%20Dai%20Y.%20Cuproptotic%20nanoinducer-driven%20proteotoxic%20stress%20potentiates%20cancer%20immunotherapy%20by%20activating%20the%20mtDNA-cGAS-STING%20signaling.%20Biomaterials.%202024;307:122512." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR200">
<span class="label">200.</span><cite>Bai J, Zhang X, Zhao Z, Sun S, Cheng W, Yu H, Chang X, Wang B. CuO nanozymes catalyze cysteine and glutathione depletion induced ferroptosis and cuproptosis for synergistic tumor therapy. Small. 2024;20:e2400326.
</cite> [<a href="https://doi.org/10.1002/smll.202400326" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38813723/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Bai%20J,%20Zhang%20X,%20Zhao%20Z,%20Sun%20S,%20Cheng%20W,%20Yu%20H,%20Chang%20X,%20Wang%20B.%20CuO%20nanozymes%20catalyze%20cysteine%20and%20glutathione%20depletion%20induced%20ferroptosis%20and%20cuproptosis%20for%20synergistic%20tumor%20therapy.%20Small.%202024;20:e2400326." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR201">
<span class="label">201.</span><cite>Li Y, Liu B, Zheng Y, Hu M, Liu LY, Li CR, Zhang W, Lai YX, Mao ZW. Photoinduction of ferroptosis and cGAS-STING activation by a H<sub>2</sub>S-responsive iridium(III) complex for cancer-specific therapy. J Med Chem. 2024;67:16235–47.
</cite> [<a href="https://doi.org/10.1021/acs.jmedchem.4c01065" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39250558/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Li%20Y,%20Liu%20B,%20Zheng%20Y,%20Hu%20M,%20Liu%20LY,%20Li%20CR,%20Zhang%20W,%20Lai%20YX,%20Mao%20ZW.%20Photoinduction%20of%20ferroptosis%20and%20cGAS-STING%20activation%20by%20a%20H2S-responsive%20iridium(III)%20complex%20for%20cancer-specific%20therapy.%20J%20Med%20Chem.%202024;67:16235%E2%80%9347." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR202">
<span class="label">202.</span><cite>Wei X, Sun L, Deng J, Yang Q, Zhao J, Zhou S. A multifunctional exosome with dual homeostasis disruption augments cGAS-STING-mediated tumor immunotherapy by boosting ferroptosis. Nano Lett. 2024;24:14263–72.
</cite> [<a href="https://doi.org/10.1021/acs.nanolett.4c03862" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39475013/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wei%20X,%20Sun%20L,%20Deng%20J,%20Yang%20Q,%20Zhao%20J,%20Zhou%20S.%20A%20multifunctional%20exosome%20with%20dual%20homeostasis%20disruption%20augments%20cGAS-STING-mediated%20tumor%20immunotherapy%20by%20boosting%20ferroptosis.%20Nano%20Lett.%202024;24:14263%E2%80%9372." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR203">
<span class="label">203.</span><cite>Vitale I, Manic G, Coussens LM, Kroemer G, Galluzzi L. Macrophages and metabolism in the tumor microenvironment. Cell Metab. 2019;30:36–50.
</cite> [<a href="https://doi.org/10.1016/j.cmet.2019.06.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31269428/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Vitale%20I,%20Manic%20G,%20Coussens%20LM,%20Kroemer%20G,%20Galluzzi%20L.%20Macrophages%20and%20metabolism%20in%20the%20tumor%20microenvironment.%20Cell%20Metab.%202019;30:36%E2%80%9350." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR204">
<span class="label">204.</span><cite>Poggio M, Hu T, Pai C-C, Chu B, Belair CD, Chang A, Montabana E, Lang UE, Fu Q, Fong L. Suppression of Exosomal PD-L1 induces systemic anti-tumor immunity and memory. Cell. 2019;177:414–27. e13.
</cite> [<a href="https://doi.org/10.1016/j.cell.2019.02.016" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6499401/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30951669/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Poggio%20M,%20Hu%20T,%20Pai%20C-C,%20Chu%20B,%20Belair%20CD,%20Chang%20A,%20Montabana%20E,%20Lang%20UE,%20Fu%20Q,%20Fong%20L.%20Suppression%20of%20Exosomal%20PD-L1%20induces%20systemic%20anti-tumor%20immunity%20and%20memory.%20Cell.%202019;177:414%E2%80%9327.%20e13." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR205">
<span class="label">205.</span><cite>Wang W, Lu K, Jiang X, Wei Q, Zhu L, Wang X, Jin H, Feng L. Ferroptosis inducers enhanced cuproptosis induced by copper ionophores in primary liver cancer. J Exp Clin Cancer Res. 2023;42:142.
</cite> [<a href="https://doi.org/10.1186/s13046-023-02720-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10242978/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37277863/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang%20W,%20Lu%20K,%20Jiang%20X,%20Wei%20Q,%20Zhu%20L,%20Wang%20X,%20Jin%20H,%20Feng%20L.%20Ferroptosis%20inducers%20enhanced%20cuproptosis%20induced%20by%20copper%20ionophores%20in%20primary%20liver%20cancer.%20J%20Exp%20Clin%20Cancer%20Res.%202023;42:142." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR206">
<span class="label">206.</span><cite>Chen K, Zhou A, Zhou X, He J, Xu Y, Ning X. Cellular trojan horse initiates bimetallic Fe-Cu MOF-mediated synergistic cuproptosis and ferroptosis against malignancies. Sci Adv. 2024;10: eadk3201.
</cite> [<a href="https://doi.org/10.1126/sciadv.adk3201" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11006215/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38598629/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chen%20K,%20Zhou%20A,%20Zhou%20X,%20He%20J,%20Xu%20Y,%20Ning%20X.%20Cellular%20trojan%20horse%20initiates%20bimetallic%20Fe-Cu%20MOF-mediated%20synergistic%20cuproptosis%20and%20ferroptosis%20against%20malignancies.%20Sci%20Adv.%202024;10:%20eadk3201." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR207">
<span class="label">207.</span><cite>Ishida N, Hori Y, Okumura S, Murakami M. Synthesis of 2-aryloxy-1, 3-dienes from phenols and propargyl carbonates. J Am Chem Soc. 2018;141:84–8.
</cite> [<a href="https://doi.org/10.1021/jacs.8b11159" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30563331/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ishida%20N,%20Hori%20Y,%20Okumura%20S,%20Murakami%20M.%20Synthesis%20of%202-aryloxy-1,%203-dienes%20from%20phenols%20and%20propargyl%20carbonates.%20J%20Am%20Chem%20Soc.%202018;141:84%E2%80%938." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR208">
<span class="label">208.</span><cite>Xu Y, Liu SY, Zeng L, Ma H, Zhang Y, Yang H, Liu Y, Fang S, Zhao J, Xu Y. An enzyme-engineered nonporous copper(I) coordination polymer nanoplatform for cuproptosis‐based synergistic cancer therapy. Adv Mater. 2022;34:2204733.</cite> [<a href="https://doi.org/10.1002/adma.202204733" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36054475/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Xu%20Y,%20Liu%20SY,%20Zeng%20L,%20Ma%20H,%20Zhang%20Y,%20Yang%20H,%20Liu%20Y,%20Fang%20S,%20Zhao%20J,%20Xu%20Y.%20An%20enzyme-engineered%20nonporous%20copper(I)%20coordination%20polymer%20nanoplatform%20for%20cuproptosis%E2%80%90based%20synergistic%20cancer%20therapy.%20Adv%20Mater.%202022;34:2204733." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR209">
<span class="label">209.</span><cite>Li K, Xu K, He Y, Yang Y, Tan M, Mao Y, Zou Y, Feng Q, Luo Z, Cai K. Oxygen self-generating nanoreactor mediated ferroptosis activation and immunotherapy in triple-negative breast cancer. ACS Nano. 2023;17:4667–87.
</cite> [<a href="https://doi.org/10.1021/acsnano.2c10893" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36861638/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Li%20K,%20Xu%20K,%20He%20Y,%20Yang%20Y,%20Tan%20M,%20Mao%20Y,%20Zou%20Y,%20Feng%20Q,%20Luo%20Z,%20Cai%20K.%20Oxygen%20self-generating%20nanoreactor%20mediated%20ferroptosis%20activation%20and%20immunotherapy%20in%20triple-negative%20breast%20cancer.%20ACS%20Nano.%202023;17:4667%E2%80%9387." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR210">
<span class="label">210.</span><cite>Brancaccio D, Gallo A, Piccioli M, Novellino E, Ciofi-Baffoni S, Banci L. [4Fe-4S] cluster assembly in mitochondria and its impairment by copper. J Am Chem Soc. 2017;139:719–30.
</cite> [<a href="https://doi.org/10.1021/jacs.6b09567" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27989128/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Brancaccio%20D,%20Gallo%20A,%20Piccioli%20M,%20Novellino%20E,%20Ciofi-Baffoni%20S,%20Banci%20L.%20%5B4Fe-4S%5D%20cluster%20assembly%20in%20mitochondria%20and%20its%20impairment%20by%20copper.%20J%20Am%20Chem%20Soc.%202017;139:719%E2%80%9330." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR211">
<span class="label">211.</span><cite>Wang Z, Zhou P, Li Y, Zhang D, Chu F, Yuan F, Pan B, Gao F. A bimetallic polymerization network for effective increase in labile iron pool and robust activation of cGAS/STING induces ferroptosis-based tumor immunotherapy. Small. 2023;20:2308397.</cite> [<a href="https://doi.org/10.1002/smll.202308397" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38072786/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang%20Z,%20Zhou%20P,%20Li%20Y,%20Zhang%20D,%20Chu%20F,%20Yuan%20F,%20Pan%20B,%20Gao%20F.%20A%20bimetallic%20polymerization%20network%20for%20effective%20increase%20in%20labile%20iron%20pool%20and%20robust%20activation%20of%20cGAS/STING%20induces%20ferroptosis-based%20tumor%20immunotherapy.%20Small.%202023;20:2308397." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>No datasets were generated or analysed during the current study.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Journal of Nanobiotechnology are provided here courtesy of <strong>BMC</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1186/s12951-025-03669-4"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/12951_2025_Article_3669.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (4.3 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12369232/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12369232/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12369232%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12369232/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12369232/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12369232/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40841898/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12369232/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40841898/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12369232/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12369232/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="9ty3LNXC7re0dMGmlj9P9zFJVtVy2YoiG0QEsdyxiRk6VCoSsH9WtujhH9IruuG0">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
